{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:17:28Z","timestamp":1792192648325,"version":"4.4.0"},"publisher-location":"Basel","reference-count":810,"publisher":"Birkh\u00e4user Basel","isbn-type":[{"value":"9783034871433","type":"print"},{"value":"9783034871419","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1992]]},"DOI":"10.1007\/978-3-0348-7141-9_3","type":"book-chapter","created":{"date-parts":[[2012,1,16]],"date-time":"2012-01-16T09:47:57Z","timestamp":1326707277000},"page":"171-297","source":"Crossref","is-referenced-by-count":20,"title":["The new generation of monoamine oxidase inhibitors"],"prefix":"10.1007","author":[{"given":"Andrea M.","family":"Cesura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Pletscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/BF02041242","volume":"47","author":"A Pletscher","year":"1991","unstructured":"A. Pletscher: The discovery of antidepressants: a winding path. Experientia 47: 4\u20138, 1991.","journal-title":"Experientia"},{"key":"3_CR2","first-page":"593","volume-title":"Handbook of Experimental Pharmacology, Vol. XIX: 5-Hydroxytryptamine and Related Indolealkylamines","author":"A Pletscher","year":"1965","unstructured":"A. Pletscher, K. F. Gey, W. P. Burkard: Inhibitors of monoamine oxidase and decarboxylase of aromatic amino acids. In: O. Eichler, A. Farah, eds. Handbook of Experimental Pharmacology, Vol. XIX: 5-Hydroxytryptamine and Related Indolealkylamines. Berlin: Springer Verlag, pp. 593\u2013735, 1965."},{"key":"3_CR3","first-page":"313","volume-title":"The Enzymes, Vol.8","author":"EA Zeller","year":"1963","unstructured":"E. A. Zeller: Diamine oxidase. In: P. D. Boyer, H. Lardy, K. Myrb\u00e4ck, eds. The Enzymes, Vol.8, 2nd. edn. London: Academic Press, pp. 313\u2013335, 1963.","edition":"2"},{"key":"3_CR4","first-page":"531","volume-title":"Monoamine Oxidases: Structure, Function, and Altered Functions","author":"EA Zeller","year":"1979","unstructured":"E. A. Zeller: Classification and nomenclature of monoamine oxidases and other amine oxidases. In: T. P. Singer, R. W. von Korff, D. L. Murphy, eds. Monoamine Oxidases: Structure, Function, and Altered Functions. London: Academic Press, pp. 531\u2013537, 1979."},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/BFb0034294","volume":"70","author":"H Blaschko","year":"1974","unstructured":"H. Blaschko: The natural history of amine oxidases. Rev Physiol Biochem Pharmacol 70: 83\u2013148, 1974.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"3_CR6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0031-6997(25)07174-1","volume":"18","author":"F Buffoni","year":"1966","unstructured":"F. Buffoni: Histaminase and related amine oxidases. Pharmacol Rev 18: 1163\u20131199, 1966.","journal-title":"Pharmacol Rev"},{"key":"3_CR7","doi-asserted-by":"crossref","unstructured":"L. Oreland, B. Callingham, eds.: Monoamine Oxidase Enzymes. J Neural Transm, [Suppl] 23, 1987.","DOI":"10.1007\/978-3-7091-8901-6"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1254\/jjp.26.493","volume":"26","author":"T Egashira","year":"1976","unstructured":"T. Egashira: Studies on monoamine oxidase. XVIII. Enzymic properties of placental monoamine oxidase. Jap J Pharmac 26: 493\u2013500, 1976.","journal-title":"Jap J Pharmac"},{"key":"3_CR9","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1016\/S0021-9258(17)38856-7","volume":"260","author":"W Weyler","year":"1985","unstructured":"W. Weyler, J. I. Salach: Purification and properties of mitochondrial monoamine oxidase type A from human placenta. J Biol Chem 260: 13199\u201313207, 1985.","journal-title":"J Biol Chem"},{"key":"3_CR10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0026-895X(25)09109-6","volume":"36","author":"LA Riley","year":"1989","unstructured":"L. A. Riley, M. A. Waguespack, R. M. Denney: Characterization and quantification of monoamine oxidases A and B in mitochondria from human placenta. Molec Pharmacol 36: 544\u2013560, 1989.","journal-title":"Molec Pharmacol"},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/0006-2952(77)90398-7","volume":"26","author":"CH Donnelly","year":"1977","unstructured":"C. H. Donnelly, D. L. Murphy: Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26: 852\u2013858, 1977.","journal-title":"Biochem Pharmacol"},{"key":"3_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0009-8981(77)90039-0","volume":"80","author":"PA Bond","year":"1977","unstructured":"P. A. Bond, R. L. Cundall: Properties of monoamine oxidase (MAO) in human blood platelets, plasma, lymphocytes and granulocytes. Clin Chim Acta 80: 317\u2013326, 1977.","journal-title":"Clin Chim Acta"},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0006-2952(91)90471-G","volume":"41","author":"MBH Youdim","year":"1991","unstructured":"M. B. H. Youdim, J. P. M. Finberg: New directions in monoamine oxidase A and B selective inhibitors and substrates. Biochem Pharmacol 41: 155\u2013162, 1991.","journal-title":"Biochem Pharmacol"},{"key":"3_CR14","first-page":"428","volume-title":"Flavins and Flavoproteins","author":"DH Gurne","year":"1982","unstructured":"D. H. Gurne, E. A. Zeller: Monoamine oxidase type A from human placental mitochondria: isolation procedure and properties. In: V. Massey, C. H. Williams, eds. Flavins and Flavoproteins. New York: Elsevier-North Holland, pp. 428\u2013432, 1982."},{"key":"3_CR15","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/01483918308064861","volume":"6","author":"GAS Ansari","year":"1983","unstructured":"G. A. S. Ansari, N. T. Patel, R. R. Fritz, C. W. Abell: Purification of human platelet monoamine oxidase B by high performance liquid chromatography. J Liq Chromat 6: 1407\u20131419, 1983.","journal-title":"J Liq Chromat"},{"key":"3_CR16","first-page":"216","volume":"39","author":"AM Cesura","year":"1990","unstructured":"A. M. Cesura, R. Imhof, D. Muggli-Maniglio, G. B. Picotti, M. Da Prada: Characterization of [3H]Ro 16\u20136491 binding to digitonin solubilized monoamine oxidase-B and purification of the enzyme from human platelets by affinity chromatography. Biochem. Pharmacol 39: 216\u2013220, 1990.","journal-title":"Pharmacol"},{"key":"3_CR17","first-page":"2874","volume":"5","author":"LM Kochersperger","year":"1985","unstructured":"L. M. Kochersperger, L. A. Waguespack, J. C. Patterson, C. C. W. Hsieh, W. Weyler, I. I. Salach, R. M. Denney: Immunological uniqueness of human monoamine oxidase A and B. New evidence from studies with monoclonal antibodies to human monoamine oxidase A. J Neurochem 5: 2874\u20132881, 1985.","journal-title":"J Neurochem"},{"key":"3_CR18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0026-895X(25)15125-0","volume":"22","author":"RM Denney","year":"1982","unstructured":"R. M. Denney, N. T. Patel, R. R. Fritz, C. W. Abell: A monoclonal antibody elicited to human platelet monoamine oxidase. Isolation and specificity for human monoamine oxidase B but not A. Molec Pharmac 22: 500\u2013508, 1982.","journal-title":"Molec Pharmac"},{"key":"3_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0163-7258(85)90050-6","volume":"30","author":"RM Denney","year":"1985","unstructured":"R. M. Denney, C. B. Denney: An update on the identity crisis of monoamine oxidase: new and old evidence for the independence of MAO A and B. Pharmac Ther 30: 227\u2013259, 1985.","journal-title":"Pharmac Ther"},{"key":"3_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/BF00500765","volume":"322","author":"AM O\u2019Carroll","year":"1983","unstructured":"A. M. O\u2019Carroll, C. J. Fowler, J. O. Phillips, I. Tobbia, K. F. Tipton: The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiede-berg\u2019s Arch Pharmacol 322: 198\u2013202, 1983.","journal-title":"Naunyn-Schmiede-berg\u2019s Arch Pharmacol"},{"key":"3_CR21","first-page":"246","volume-title":"Monoamine Oxidase and its Selective Inhibitors","author":"L Oreland","year":"1983","unstructured":"L. Oreland, Y. Arai, A. Stenstr\u00f6m, C. J. Fowler: Monoamine oxidase activity and localization in the brain and the activity in relation to psychiatric disorders. In: H. Beckmann, P. Riederer, eds. Monoamine Oxidase and its Selective Inhibitors. Basel: Karger, pp. 246\u2013254, 1983."},{"key":"3_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0404.1983.tb01518.x","volume":"95","author":"L Oreland","year":"1983","unstructured":"L. Oreland, Y. Arai, A. Stenstr\u00f6m: The activity of deprenyl (selegiline) on intra- and extraneuronal dopamine oxidation. Acta Neurol Scand 95: 81\u201385, 1983.","journal-title":"Acta Neurol Scand"},{"key":"3_CR23","first-page":"55","volume":"23","author":"PC Waldmeier","year":"1987","unstructured":"P. C. Waldmeier: Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). J Neural Transm [Suppl] 23: 55\u201372, 1987.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR24","first-page":"103","volume-title":"Progress in Catecholamine Research, Part A: Basic Aspects and Peripheral Mechanisms","author":"CW Abell","year":"1988","unstructured":"C. W. Abell, R. M. Denney, K. N. Westlund: Localization and function of monoamine oxidases A and B. In: Progress in Catecholamine Research, Part A: Basic Aspects and Peripheral Mechanisms. New York: Alan R. Liss, pp. 103\u2013108, 1988."},{"key":"3_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0163-7258(90)90064-9","volume":"47","author":"W Weyler","year":"1990","unstructured":"W. Weyler, Y.-P. P. Hsu, X. O. Breakefield: Biochemistry and genetics of monoamine oxidase. Pharmac Ther 47: 391\u2013417, 1990.","journal-title":"Pharmac Ther"},{"key":"3_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/13.7.604","volume":"13","author":"RC Graham","year":"1965","unstructured":"R. C. Graham, M.J. Karnovsky: The histochemical demonstration of monoamine oxidase by coupled peroxidatic oxidation. J Histochem Cytochem 13: 604\u2013605, 1965.","journal-title":"J Histochem Cytochem"},{"key":"3_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0306-4522(86)90307-6","volume":"19","author":"Y Arai","year":"1986","unstructured":"Y. Arai, H. Kimura, T. Maeda: Topographic atlas of monoamine oxidase-containing neurons in the rat brain studied by an improved histochemical method. Neurosci 19: 905\u2013925, 1986.","journal-title":"Neurosci"},{"key":"3_CR28","first-page":"61","volume":"29","author":"S Kishimoto","year":"1983","unstructured":"S. Kishimoto, H. Kimura, T. Maeda: Histochemical demonstration for monoamine oxidase (MAO) by a new coupled peroxidation method. Cellular & Molecular Biology 29: 61\u201369, 1983.","journal-title":"Cellular & Molecular Biology"},{"key":"3_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1267\/ahc.17.179","volume":"17","author":"T Maeda","year":"1984","unstructured":"T. Maeda, H. Kimura, T. Nagai, H. Imai, R. Arai, T. Sakumoto, K. Sakai, K. Kitahama, M. Jouvet: Histochemistry of the magnocellular neurons in the posterior hypothalamus, with special reference to MAO activity and ability of 5 HTP uptake and decarboxylation. Acta Histochem Cytochem 17: 179\u2013193, 1984.","journal-title":"Acta Histochem Cytochem"},{"key":"3_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0304-3940(86)90250-8","volume":"71","author":"K Kitahama","year":"1986","unstructured":"K. Kitahama, R. Arai, T. Maeda, M. Jouvet: Demonstration of MAO-B in serotoninergic and MAO-A in noradrenergic neurons in the cat dorsal pontine tegmentum by an improved histochemical technique. Neurosci Lett 71: 19\u201324, 1986.","journal-title":"Neurosci Lett"},{"key":"3_CR31","first-page":"1","volume":"33","author":"T Maeda","year":"1987","unstructured":"T. Maeda, H. Imai, R. Arai, H. Tago, T. Nagai, T. Sakumoto, K. Kitahama, B. Onteniente, H. Imura: An improved coupled peroxidatic oxidation method of MAO histochemistry for neuroanatomical research at light and electron microscopic levels. Cellular & Molecular Biology 33: 1\u201311, 1987.","journal-title":"Cellular & Molecular Biology"},{"key":"3_CR32","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/0306-4522(87)90257-0","volume":"20","author":"K Kitahama","year":"1987","unstructured":"K. Kitahama, H. Kimura, T. Maeda, M. Jouvet: Distribution of two types of monoamine oxidase-containing neurons in the cat medulla oblongata demonstrated by an improved histochemical method. Neurosci 20: 991\u2013999, 1987.","journal-title":"Neurosci"},{"key":"3_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/cne.902850205","volume":"285","author":"K Kitahama","year":"1989","unstructured":"K. Kitahama, M. Sallanon, J.-S. Lin, T. Maeda, M. Jouvet: Type B monoamine oxidase-containing cells and fibers in the cat hypothalamus demonstrated by an improved enzyme histochemical method. J Compar Neurol 285: 218\u2013230, 1989.","journal-title":"J Compar Neurol"},{"key":"3_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0306-4522(89)90218-2","volume":"33","author":"C Konradi","year":"1989","unstructured":"C. Konradi, J. Kornhuber, L. Froelich, J. Fritze, H. Heinsen, H. Beckmann, E. Schulz, P. Riederer: Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique. Neurosci 33: 383\u2013400, 1989.","journal-title":"Neurosci"},{"key":"3_CR35","first-page":"243","volume-title":"Early Diagnosis and Preventive Therapy in Parkinson\u2019s Disease","author":"C Konradi","year":"1990","unstructured":"C. Konradi, P. Riederer, H. Hensen: Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson\u2019s disease? In: Przuntek, P. Riederer, eds. Early Diagnosis and Preventive Therapy in Parkinson\u2019s Disease. Wien: Springer Verlag, pp. 243\u2013248, 1990."},{"key":"3_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF01243573","volume":"74","author":"J Willoughby","year":"1988","unstructured":"J. Willoughby, V. Glover, M. Sandler: Histochemical localisation of MAO-A and -B in rat brain. J Neural Transm 74: 29\u201342, 1988.","journal-title":"J Neural Transm"},{"key":"3_CR37","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1073\/pnas.79.20.6385","volume":"79","author":"P Levitt","year":"1982","unstructured":"P. Levitt, J. E. Pintar, X. O. Breakefield: Immunocytochemical demonstration of MAO-B in brain astrocytes and serotoninergic neurons. Proc Natl Acad Sci USA 79: 6385\u20136389, 1982.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.3875898","volume":"230","author":"KN Westlund","year":"1985","unstructured":"K. N. Westlund, R. M. Denney, L. M. Kochersperger, R. M. Rose, C. W. Abell: Distinct MAO A and MAO B populations in the primate brain. Science 230: 181\u2013183, 1985.","journal-title":"Science"},{"key":"3_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1177\/35.1.3025289","volume":"35","author":"LW Thorpe","year":"1987","unstructured":"L. W. Thorpe, K. N. Westlund, L. M. Kochersperger, C. W. Abell, R. M. Denney: Immunocytochemical localization of MAO-A and -B in human peripheral tissues and brain. J Histochem Cytochem 35: 23\u201332, 1987.","journal-title":"J Histochem Cytochem"},{"key":"3_CR40","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0306-4522(88)90250-3","volume":"25","author":"KN Westlund","year":"1988","unstructured":"K. N. Westlund, R. M. Denney, R. M. Rose, C. W. Abell: Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neurosci 25: 439\u2013456, 1988.","journal-title":"Neurosci"},{"key":"3_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0306-4522(88)90099-1","volume":"26","author":"C Konradi","year":"1988","unstructured":"C. Konradi, K. Jellinger, P. Riederer, P. Denney, J.Thibault: Topographic immunocyto-chemical mapping of MAO-A, MAO-B and tyrosine hydroxylase in human post mortem brain stem. Neurosci 26: 791\u2013802, 1988.","journal-title":"Neurosci"},{"key":"3_CR42","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1073\/pnas.81.14.4591","volume":"81","author":"JA Javitch","year":"1984","unstructured":"J. A. Javitch, G. R. Uhl, S. H. Snyder: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci USA 81: 4591\u20134595, 1984.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR43","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0014-2999(84)90274-7","volume":"102","author":"B Parsons","year":"1984","unstructured":"B. Parsons, T. C. Rainbow: High-affinity binding sites for 3H-MPTP may correspond to MAO. Eur J Pharmacol 102: 375\u2013377, 1984.","journal-title":"Eur J Pharmacol"},{"key":"3_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0006-8993(85)90694-8","volume":"330","author":"TC Rainbow","year":"1985","unstructured":"T. C. Rainbow, B. Parsons, C. M. Wieczorek, S. Manaker: Localization in rat brain of binding sites for Parkinsonian toxin MPTP: similarities with 3H-pargyline binding to MAO. Brain Res 330: 337\u2013343, 1985.","journal-title":"Brain Res"},{"issue":"IV","key":"3_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0031-6989(88)80557-5","volume":"20","author":"JG Richards","year":"1988","unstructured":"J. G. Richards, J. Saura Marti, A. M. Cesura, M. Da Prada: Quantitative enzyme radioautography with [3H]Ro 19\u20136327: localization of MAO-B in rat CNS, peripheral organs und human brain. Pharmacol Res Commun 20, (Suppl IV): 91\u201392, 1988.","journal-title":"Pharmacol Res Commun"},{"key":"3_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF02246228","volume":"106","author":"JG Richards","year":"1992","unstructured":"J. G. Richards, J. Saura, J. Ulrich, M. Da Prada: Molecular neuroanatomy of monoamine oxidases. Psychopharmacology 106 [Suppl]: 21\u201323, 1992.","journal-title":"Psychopharmacology"},{"key":"3_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0006-8993(91)90575-G","volume":"547","author":"SS Jossan","year":"1991","unstructured":"S. S. Jossan, P. G. Gillberg, R. d\u2019Argy, S. M. Aquilonius, B. Langstrom, C. Halldin, L. Oreland: Quantitative localization of human brain monoamine oxidase by large section autoradiography using L- (3H)deprenyl. Brain Res 547: 69\u201376, 1991.","journal-title":"Brain Res"},{"key":"3_CR48","first-page":"49","volume":"32","author":"JS Marti","year":"1990","unstructured":"J. Saura Marti, R. Kettler, M. Da Prada, J. G. Richards: Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm. [Suppl] 32: 49\u201353, 1990.","journal-title":"J Neural Transm. [Suppl]"},{"key":"3_CR49","doi-asserted-by":"crossref","unstructured":"J. Saura, R. Kettler, M. Da Prada, J. G. Richards: Quantitative enzyme radioautography with (3H)Ro 41\u20131049 and (3H)Ro 19\u20136327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs and human brain. J Neurosci, 1992, in press.","DOI":"10.1523\/JNEUROSCI.12-05-01977.1992"},{"key":"3_CR50","volume-title":"Monoamine Oxidase: Basic and Clinical Aspects","author":"AM Cesura","year":"1992","unstructured":"A. M. Cesura, J. G. Richards, G. B. Picotti, R. Kettler, R. Imhof, M. Da Prada: Reversible monoamine oxidase inhibitors: from laboratory to clinic. In: H. Yasuhara, S. Parvez, M. Sandler, K. Oguchi, T. Nagatsu, eds. Monoamine Oxidase: Basic and Clinical Aspects. The Netherlands: VSP Press, 1992, in press."},{"key":"3_CR51","first-page":"67","volume":"32","author":"G Moll","year":"1990","unstructured":"G. Moll, R. Moll, P. Riederer, W. Gsell, H. Heinsen, R. M. Denney: Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study. J Neural Transm [Suppl] 32: 67\u201377, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0306-4522(91)90069-Z","volume":"44","author":"S Nakamura","year":"1991","unstructured":"S. Nakamura, T. Kawamata, O. Yasuhara, I. Akiguchi, J. Kimura, H. Kimura, T. Kimura: The histochemical demonstration of monoamine oxidase-containing neurons in the human hypothalamus. Neurosci 44: 457\u2013463, 1991.","journal-title":"Neurosci"},{"key":"3_CR53","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0304-3940(91)90760-Q","volume":"128","author":"JS Lin","year":"1991","unstructured":"J. S. Lin, P. Fort, K. Kitahama, P. Panula, R. M. Denney, M. Jouvet: Immunohistochemical evidence for the presence of type B monoamine oxidase in histamine-containing neurons in the posterior hypothalamus of cats. Neurosci Lett 128: 61\u201365, 1991.","journal-title":"Neurosci Lett"},{"key":"3_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0306-4522(91)90260-U","volume":"44","author":"K Kitahama","year":"1991","unstructured":"K. Kitahama, R. M. Denney, T. Maeda, J. Jouvet: Distribution of type B monoamine oxidase immunoreactivity in the cat brain with reference to enzyme histochemistry. Neurosci 44: 185\u2013204, 1991.","journal-title":"Neurosci"},{"key":"3_CR55","first-page":"126","volume-title":"Handbook of Chemical Neuroanatomy, Vol.2: Classical Transmitters in the CNS, Part I","author":"HWM Steinbusch","year":"1984","unstructured":"H. W. M. Steinbusch, A. H. Mulder: Immunohistochemical localization of histamine in neurons and mast cells in the rat brain. In: Bj\u00f6rklund, H\u00f6kfelt, eds. Handbook of Chemical Neuroanatomy, Vol.2: Classical Transmitters in the CNS, Part I. Amsterdam: Elsevier Science Publishers, pp. 126\u2013140, 1984."},{"key":"3_CR56","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0026-895X(25)10827-4","volume":"37","author":"AM Cesura","year":"1990","unstructured":"A. M. Cesura, M. B\u00f6s, M. D. Galva, R. Imhof, M. Da Prada: Characterization of the binding of [3H]Ro 41\u20131049 to the active site of human monoamine oxidase-A. Molec Pharmacol 37: 358\u2013366, 1990.","journal-title":"Molec Pharmacol"},{"key":"3_CR57","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/0014-2999(89)90336-1","volume":"162","author":"AM Cesura","year":"1989","unstructured":"A. M. Cesura, M. D. Galva, R. Imhof, E. Kyburz, G. B. Picotti, M. Da Prada: [3H]Ro 19\u20136327: a reversible ligand and affinity labelling probe for monoamine oxidase-B. Eur J Pharmacol 162: 457\u2013465, 1989.","journal-title":"Eur J Pharmacol"},{"key":"3_CR58","first-page":"279","volume":"29","author":"M Prada Da","year":"1990","unstructured":"M. Da Prada, R. Kettler, H. H. Keller, A. M. Cesura, J. G. Richards, J. Saura Marti, D. Muggli Maniglio, P.-C. Wyss, E. Kyburz, R. Imhof: From moclobemide to Ro 19\u20136327 and Ro 41\u20141049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29: 279\u2013292, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR59","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3099392","volume":"23","author":"CJ Fowler","year":"1987","unstructured":"C. J. Fowler, R. R. MacGregor, A. P. Wolf, C. F. Arnett, S. L. Dewey, D. Scyler, D. Christman, J. Logan, M. Smith, H. Sachs, S. M. Aquilonius, P. Njurling, C. Halldin, P. Hartvig, K. L. Leenders, H. Lundqvist, L. Ore-land, C. G. St\u00e5lnacke, B. Langstrom: Mapping human brain MAO-A and -B with 11C-labeled suicide inactivators and PET. Science 23: 481\u2013485, 1987.","journal-title":"Science"},{"key":"3_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF01255819","volume":"77","author":"SS Jossan","year":"1989","unstructured":"S. S. Jossan, R. d\u2019Argy, P. G. Gillberg, S. M. Aquilonius, B. L\u00e5ngstr\u00f6m, C. Halldin, P. Bjurling, C. G. St\u00e5lnacke, J. C. Fowler, R. MacGregor, L. Oreland: Localization of monoamine oxidase B in human brain by au-toradiographical use of 11C-labelled L-deprenyl. J Neural Transm 77: 55\u201364, 1989.","journal-title":"J Neural Transm"},{"key":"3_CR61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1471-4159.1987.tb02895.x","volume":"49","author":"CD Arnett","year":"1987","unstructured":"C. D. Arnett, J. S. Fowler, R. R. MacGregor, D.J. Schlyer, A. P. Wolf, B. L\u00e5ngstr\u00f6m, C. Alldin: Turnover of brain monoamine oxidase in vivo by positron emission tomography using L-[11C]deprenly. J Neurochem 49: 522\u2013527, 1987.","journal-title":"J Neurochem"},{"key":"3_CR62","first-page":"55","volume":"32","author":"L Oreland","year":"1990","unstructured":"L. Oreland, S.S. Jossan, P. Hartvig, S. M. Aquilonius, B. L\u00e5ngstr\u00f6m: Turnover of monoamine oxidase B (MAO-B) in pig brain by positron emission tomography using 11C-L-deprenyl. J Neural Transm [Suppl] 32: 55\u201359, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01249185","volume":"49","author":"CJ Fowler","year":"1980","unstructured":"C. J. Fowler, A. Wiberg, L. Oreland, J. Marcusson, B. Winblad: The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49: 1\u201320, 1980.","journal-title":"J Neural Transm"},{"key":"3_CR64","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/j.1471-4159.1980.tb07856.x","volume":"35","author":"MS Benedetti","year":"1980","unstructured":"M. Strolin Benedetti, P. E. Keane: Differential changes in MAO-A and -B activity in the aging rat brain. J Neurochem 35: 1026\u20131032, 1980.","journal-title":"J Neurochem"},{"key":"3_CR65","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01250233","volume":"72","author":"Y Arai","year":"1988","unstructured":"Y. Arai, H. Kinemuchi: Differences between MAO concentrations in striatum and forebrain of aged and young rats. J Neural Transm 72: 99\u2013105, 1988.","journal-title":"J Neural Transm"},{"key":"3_CR66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0006-2952(89)90198-6","volume":"38","author":"MS Benedetti","year":"1989","unstructured":"M. Strolin Benedetti, P. Dostert: Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38: 555\u2013561, 1989.","journal-title":"Biochem Pharmacol"},{"key":"3_CR67","first-page":"119","volume":"45","author":"G Cohen","year":"1986","unstructured":"G. Cohen: Monoamine oxidase, hydrogen peroxide, and Parkinson\u2019s disease. Adv Neurol 45: 119\u2013125, 1986.","journal-title":"Adv Neurol"},{"key":"3_CR68","first-page":"299","volume":"32","author":"G Cohen","year":"1990","unstructured":"G. Cohen: Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm [Suppl] 32: 299\u2013238, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR69","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1073\/pnas.86.4.1398","volume":"86","author":"MB Spina","year":"1989","unstructured":"M. B. Spina, G. Cohen: Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 86: 1398\u20131400, 1989.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0014-5793(91)80200-M","volume":"280","author":"R Werner","year":"1991","unstructured":"R. Werner, G. Cohen: Intramitochondrial formation of oxidized glutathione during the oxidation of benzylamine by monoamine oxidase. FEBS Lett 280: 44\u201346, 1991.","journal-title":"FEBS Lett"},{"key":"3_CR71","first-page":"239","volume":"32","author":"MBH Youdim","year":"1990","unstructured":"M. B. H. Youdim, D. Ben-Shachar, P. Riederer: The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson\u2019s disease. J Neural Transm [Suppl] 32: 239\u2013248, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR72","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/0278-5846(86)90023-0","volume":"10","author":"L Oreland","year":"1986","unstructured":"L. Oreland, C. G. Gottfries: Brain and brain monoamine oxidase in aging and dementia of the Alzheimer\u2019s type. Prog Neuro-Psychopharmacol Biol Psychiat 10: 533\u2013540, 1986","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"3_CR73","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0197-4580(88)80061-7","volume":"9","author":"KJ Reinikanen","year":"1988","unstructured":"K. J. Reinikanen, L. Palj\u00e4rvi, T. Halonen, O. Malminen, V.-M. Kosma, M. Laakso, P.J. Riekkinen: Dopaminergic system and monoamine oxi-dase-B activity in Alzheimer\u2019s disease. Neurobiology of Ageing 9: 245\u2013252, 1988.","journal-title":"Neurobiology of Ageing"},{"key":"3_CR74","first-page":"61","volume":"32","author":"SS Jossan","year":"1990","unstructured":"S. S. Jossan, P.-G. Gillberg, I. Karlsson, C. G. Gottfries, L. Oreland: Visualization of brain monoamine oxidase B (MAO-B) in dementia of Alzheimer\u2019s type by means of large cryosection autoradiography: a pilot study. J Neural Transm [Suppl] 32: 61\u201365, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR75","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF00307697","volume":"80","author":"S Nakamura","year":"1990","unstructured":"S. Nakamura, T. Kawamata, I. Akiguchi, M. Kameyama, N. Nakamura, H. Kimura: Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80: 319\u2013325, 1990.","journal-title":"Acta Neuropathol"},{"key":"3_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/BF02246225","volume":"106","author":"WE Haefely","year":"1992","unstructured":"W. E. Haefely, W. P. Burkard, A. M. Cesura, R. Kettler, H. P. Lorez, J. R. Martin, J. G. Richards, R. Scherschlicht, M. Da Prada: Biochemistry and pharmacology of moclobemide, a prototype R. I.M.A. Psychopharmacology 106 [Suppl]: 6\u201314, 1992.","journal-title":"Psychopharmacology"},{"key":"3_CR77","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/j.1471-4159.1987.tb00973.x","volume":"49","author":"RN Kalaria","year":"1987","unstructured":"R. N. Kalaria, S. I. Harik: Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J Neurochem 49: 856\u2013864, 1987.","journal-title":"J Neurochem"},{"key":"3_CR78","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/j.1471-4159.1977.tb10719.x","volume":"29","author":"PC Waldmeier","year":"1977","unstructured":"P.C. Waldmeier, J.J. Feldtrauer, L. Ma\u00eetre: Methylhistamine: evidence for selective deamination by MAO-B in the rat brain in vivo. J Neurochem 29: 785\u2013790, 1977.","journal-title":"J Neurochem"},{"key":"3_CR79","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/med.2610090104","volume":"9","author":"P Dostert","year":"1989","unstructured":"P. Dostert, M. Strolin Benedetti, K. F. Tipton: Interactions of monoamine oxidase with substates and inhibitors. Med Res Rev 9: 45\u201389, 1989.","journal-title":"Med Res Rev"},{"key":"3_CR80","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/265080a0","volume":"265","author":"V Glover","year":"1977","unstructured":"V. Glover, M. Sandler, F. Owen, G. Riley: Dopamine is a monoamine oxidase B substrate in man. Nature 265: 80\u201381, 1977.","journal-title":"Nature"},{"key":"3_CR81","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-3565(25)32321-9","volume":"215","author":"KT Demarest","year":"1980","unstructured":"K. T. Demarest, D. J. Smith, A. J. Azzaro: The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmac Exp Ther 215: 461\u2013468, 1980.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR82","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/0006-2952(68)90066-X","volume":"17","author":"JP Johnston","year":"1968","unstructured":"J. P. Johnston: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285\u20131297, 1968.","journal-title":"Biochem Pharmacol"},{"key":"3_CR83","first-page":"32","volume":"174","author":"RW Fuller","year":"1968","unstructured":"R. W. Fuller: Influence of substrate in the inhibition of rat liver and brain monoamine oxidase. Arch Int Pharmacodyn Ther 174: 32\u201337, 1968.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"3_CR84","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/0006-2952(68)90184-6","volume":"17","author":"RW Fuller","year":"1968","unstructured":"R. W. Fuller: Kinetic studies and effects in vivo of a new monoamine oxidase inhibitor, N-[2-(o-chlorophenoxy)-ethyl]-cycloprophylamine. Biochem Pharmacol 17: 2097\u20132107, 1968.","journal-title":"Biochem Pharmacol"},{"key":"3_CR85","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/223626a0","volume":"223","author":"MBH Youdim","year":"1969","unstructured":"M. B. H. Youdim, G. G. S. Collins, M. Sandler: Multiple forms of rat brain monoamine oxidase. Nature 223: 626\u2013628, 1969.","journal-title":"Nature"},{"key":"3_CR86","first-page":"393","volume":"5","author":"J Knoll","year":"1972","unstructured":"J. Knoll, K. Magyar: Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharm 5: 393\u2013408, 1972.","journal-title":"Adv Biochem Psychopharm"},{"key":"3_CR87","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1073\/pnas.85.13.4934","volume":"85","author":"AJW Bach","year":"1988","unstructured":"A. J. W. Bach, N. C. Lan, D. L. Johnson, C. W. Abell, M. E. Bembenek, S. W. Kwan, P. Seeburg, J. C. Shih: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85: 4934\u20134938, 1988.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR88","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/j.1471-4159.1988.tb03105.x","volume":"51","author":"Y-PP Hsu","year":"1988","unstructured":"Y.-P. P. Hsu, W. Weyler, S. Chen. K. B. Sims, W. B. Rinehart, M. Utter-back, J. F. Powell, X. O. Breakefield: Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem 51: 1321\u20131324, 1988.","journal-title":"J Neurochem"},{"key":"3_CR89","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/bj2590407","volume":"259","author":"JF Powell","year":"1989","unstructured":"J. F. Powell, Y.-P. P. Hsu, W. Weyler, S. Chen, J. Salach, K. Andrikopoulos, J. Mallet, X. O. Breakefield: The primary structure of bovine monoamine oxidase type A: comparison with peptide sequences of bovine monoamine oxidase type B and other flavoenzymes. Biochem J 259: 407\u2013413, 1989.","journal-title":"Biochem J"},{"key":"3_CR90","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S0006-291X(88)80969-0","volume":"157","author":"A Ito","year":"1988","unstructured":"A. Ito, T. Kuwahara, S. Inadome, Y. Sagara: Molecular cloning of a cDNA for rat liver monoamine oxidase B. Biochem Biophys Res Commun 157: 970\u2013976, 1988.","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR91","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1271\/bbb1961.54.253","volume":"54","author":"T Kuwahara","year":"1990","unstructured":"T. Kuwahara, S. Takamoto, A. Ito: Primary structure of rat monoamine oxidase A deduced from cDNA and its expression in rat tissues. Agric Biol Chem 54: 253\u2013257, 1990.","journal-title":"Agric Biol Chem"},{"key":"3_CR92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bst0190199","volume":"19","author":"JF Powell","year":"1991","unstructured":"J. F. Powell: Molecular biological studies of monoamine oxidase: structure and function. Biochem Soc Trans 19: 199\u2013201, 1991.","journal-title":"Biochem Soc Trans"},{"key":"3_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02246224","volume":"106","author":"S-W Kwan","year":"1992","unstructured":"S.-W. Kwan, J. M. Bergeron, C. W. Abell: Molecular properties of monoamine oxidase A and B. Psychopharmacology 106 [Suppl]: 1\u20135, 1992.","journal-title":"Psychopharmacology"},{"key":"3_CR94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0022-2836(86)90409-2","volume":"187","author":"RK Wierenga","year":"1986","unstructured":"R. K. Wierenga, P. Terpsta, W. G. J. Hol: Prediction of the occurrence of the ADP-binding beta-alpha-beta-fold in proteins, using an amino acid sequence fingerprint. J Molec Biol 187: 101\u2013107, 1986.","journal-title":"J Molec Biol"},{"key":"3_CR95","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1021\/bi00355a036","volume":"25","author":"TD Porter","year":"1986","unstructured":"T. D. Porter, C. B. Kasper: NADPH-Cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins. Biochemistry 25: 1682\u20131687, 1986.","journal-title":"Biochemistry"},{"key":"3_CR96","first-page":"44","volume-title":"Flavins and Flavoproteins","author":"LD Arscott","year":"1982","unstructured":"L. D. Arscott, C. H. Williams, G. E. Schulz: Pig hearts lipoamide dehydrogenase and human erythrocyte glutathione reductase-homology in each of the three domains. In: V. Massey, C. H. Williams, eds. Flavins and Flavoproteins. New York: Elsevier-North Holland, pp. 44\u201388, 1982."},{"key":"3_CR97","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1432-1033.1971.tb19689.x","volume":"24","author":"EB Kearney","year":"1971","unstructured":"E. B. Kearney, J. I. Salach, W. H. Walker, R. L. Seng, W. Kenney, E. Zes-zotek, T. P. Singer: The covalently-bound flavin of hepatic monoamine oxidase. Isolation and sequence of a flavin peptide and evidence for binding at the 8-alpha position. Eur J Biochem 24: 321\u2013327, 1971.","journal-title":"Eur J Biochem"},{"key":"3_CR98","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/S0021-9258(19)42741-5","volume":"249","author":"HYK Chuang","year":"1974","unstructured":"H. Y. K. Chuang, D. R. Patek, L. Hellerman: Mitochondrial monoamine oxidase. Inactivation by pargyline. Adduct formation. J Biol Chem 249: 2381\u20132384, 1974.","journal-title":"J Biol Chem"},{"key":"3_CR99","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0003-9861(78)90237-0","volume":"189","author":"N Minamura","year":"1978","unstructured":"N. Minamura, K. T. Yasunobu: Bovine liver monoamine oxidase: a modified purification procedure and preliminary evidence for two subunits and one FAD. Archs Biochem Biophys 189: 481\u2013489, 1978.","journal-title":"Archs Biochem Biophys"},{"key":"3_CR100","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0003-9861(73)90527-4","volume":"159","author":"L Oreland","year":"1973","unstructured":"L. Oreland, H. Kinemuchi, T. Stigbrand: Pig liver monoamine oxidase: studies on the subunit structure. Archs Biochem Biophys 159: 851\u2013860, 1973.","journal-title":"Archs Biochem Biophys"},{"key":"3_CR101","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1471-4159.1981.tb00464.x","volume":"37","author":"RM Cawthon","year":"1981","unstructured":"R. M. Cawthon, J. E. Pintar, F. P. Haseltine, X. O. Breakefield: Differences in the structure of A and B forms of human monoamine oxidase. J Neurochem 37: 363\u2013372, 1981.","journal-title":"J Neurochem"},{"key":"3_CR102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1042\/bj2600725","volume":"260","author":"W Weyler","year":"1989","unstructured":"W. Weyler: Monoamine oxidase A from human placenta and monoamine oxidase from bovine liver both have one FAD per subunit. An important revision. Biochem J 260: 726\u2013729, 1989.","journal-title":"Biochem J"},{"key":"3_CR103","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/j.1471-4159.1982.tb07922.x","volume":"38","author":"HL White","year":"1982","unstructured":"H. L. White, D. K. Stine: Monoamine oxidase A and B as components of a membrane complex. J Neurochem 38: 1429\u20131436, 1982.","journal-title":"J Neurochem"},{"key":"3_CR104","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/j.1471-4159.1984.tb12766.x","volume":"42","author":"HL White","year":"1984","unstructured":"H. L. White, D. K. Stine: Selective effects of proteases and phospholipase A 2 on monoamine oxidase A and B of human brain and liver. J Neurochem 42: 1743\u20131751, 1984.","journal-title":"J Neurochem"},{"key":"3_CR105","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1471-4159.1989.tb09223.x","volume":"52","author":"NC Lan","year":"1989","unstructured":"N. C. Lan, C. H. Chen, J. C. Shih: Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells. J Neurochem 52: 1652\u20131654, 1989.","journal-title":"J Neurochem"},{"key":"3_CR106","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0006-291X(05)80914-3","volume":"173","author":"W Weyler","year":"1990","unstructured":"W. Weyler, C. C. Titlow, J. I. Salach: Catalytically active monoamine oxidase type A from human liver expressed in Saccharomyces cerevisiae contains covalent FAD. Biochem Biophys Res Commun 173: 1205\u20131211, 1990.","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR107","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/978-1-349-06276-8_55","volume-title":"Function and Regulation of Monoamine Enzymes","author":"D Smith","year":"1981","unstructured":"D. Smith, R. McCauley: The processing and assembly of rat liver MAO. In: E. Usdin, N. Weiner, M. B. H. Youdim, eds. Function and Regulation of Monoamine Enzymes. London: McMillan, pp. 503\u2013508, 1981."},{"key":"3_CR108","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/BF00716270","volume":"4","author":"V Bonnefil","year":"1981","unstructured":"V. Bonnefil, C. M. Castiglione, R. M. Cawthon, X. O. Breakefield: Effect of riboflavin on monoamine oxidase activity in cultured neuroblastoma cells. Cell Molec Neurobiol 4: 351\u2013359, 1981.","journal-title":"Cell Molec Neurobiol"},{"key":"3_CR109","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0014-5793(88)80253-9","volume":"328","author":"Z Zhuang","year":"1988","unstructured":"Z. Zhuang, M. Hogan, R. McCauley: The in vitro insertion of monoamine oxidase B into mitochondrial outer membranes. FEBS Lett 328: 185\u2013190, 1988.","journal-title":"FEBS Lett"},{"key":"3_CR110","doi-asserted-by":"crossref","first-page":"14594","DOI":"10.1016\/S0021-9258(18)63734-2","volume":"264","author":"Z Zhaung","year":"1989","unstructured":"Z. Zhaung, R. McCauley: Ubiquitin is involved in the in vitro insertion of monoamine oxidase B into mitochondrial outer membanes. J Biol Chem 264: 14594\u201314596, 1989.","journal-title":"J Biol Chem"},{"key":"3_CR111","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1002\/j.1460-2075.1984.tb02274.x","volume":"3","author":"T Hase","year":"1984","unstructured":"T. Hase, U. Muller, H. Riezman, G. Schatz: A 70-kd protein of the yeast mitochondrial outer membrane is targeted and anchored via its extreme amino terminus. EMBO J 3: 3157\u20133164, 1984.","journal-title":"EMBO J"},{"key":"3_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-4157(89)90002-6","volume":"988","author":"F-U Hartl","year":"1989","unstructured":"F.-U. Hartl, N. Pfanner, D.W. Nicholson, W. Neupert: Mitochondrial protein import. Biochim Biophys Acta 988: 1\u201345, 1989.","journal-title":"Biochim Biophys Acta"},{"key":"3_CR113","first-page":"253","volume":"15","author":"RE Dalbey","year":"1990","unstructured":"R. E. Dalbey: Positively charged residues are important determinants of membrane protein topology. TIBS 15: 253\u2013257, 1990.","journal-title":"TIBS"},{"key":"3_CR114","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/bj1810007","volume":"181","author":"SM Russell","year":"1979","unstructured":"S. M. Russell, J. Davey, R. J. Mayer: The vectorial orientation of human monoamine oxidase in the mitochondrial outer membrane. Biochem J 181: 7\u201314, 1979.","journal-title":"Biochem J"},{"key":"3_CR115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0026-895X(25)15001-3","volume":"25","author":"TD Buckman","year":"1984","unstructured":"T. D. Buckman, M. S. Sutphin, S. Eiduson: Proteases as probes of mitochondrial monoamine oxidase topography in situ. Molec Pharmacol 25: 165\u2013170, 1984.","journal-title":"Molec Pharmacol"},{"key":"3_CR116","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev.bi.55.070186.001341","volume":"55","author":"A Tzagoloff","year":"1986","unstructured":"A. Tzagoloff, A. M. Myers: Genetics of mitochondrial biogenesis. A Rev Biochem 55: 249\u2013285, 1986.","journal-title":"A Rev Biochem"},{"key":"3_CR117","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1126\/science.2842866","volume":"241","author":"K Verner","year":"1988","unstructured":"K. Verner, G. Schatz: Protein translocation across membranes. Science 241: 1307\u20131313, 1988.","journal-title":"Science"},{"key":"3_CR118","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/0006-291X(82)91890-3","volume":"109","author":"Y Sagara","year":"1982","unstructured":"Y. Sagara, A. Ito: In vitro synthesis of monoamine oxidase of rat liver outer mitochondrial membrane. Biochem Biophys Res Commun 109: 1102\u20131107, 1982.","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR119","first-page":"1","volume":"4","author":"JC Shih","year":"1991","unstructured":"J. C. Shih: Molecular basis of human MAO A and B. Neuropsychopharmacol 4: 1\u20137, 1991.","journal-title":"Neuropsychopharmacol"},{"key":"3_CR120","first-page":"353","volume":"78 C","author":"A Nicotra","year":"1984","unstructured":"A. Nicotra, O. Senatori: Occurrence of type A and type B monoamine oxidase activities in toad egg mitochondria. Comp Biochem Physiol 78 C: 353\u2013356, 1984.","journal-title":"Comp Biochem Physiol"},{"key":"3_CR121","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1523\/JNEUROSCI.01-02-00166.1981","volume":"1","author":"JE Pintar","year":"1981","unstructured":"J. E. Pintar, J. Barbosa, U. Francke, C. M. Castiglione, M. Hawkins Jr., X. O. Breakefield: Gene for monoamine oxidase type A assigned to the human X chromosome. J Neurosci 1: 166\u2013175, 1981.","journal-title":"J Neurosci"},{"key":"3_CR122","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jnr.490160403","volume":"16","author":"LM Kochersperger","year":"1986","unstructured":"L. M. Kochersperger, E. L. Parker, M. Siciliano, G.J. Darlington, R. M. Denney: Assignment of genes for human monoamine oxidase A and B to the X chromosome. J Neurosci Res 16: 601\u2013619, 1986.","journal-title":"J Neurosci Res"},{"key":"3_CR123","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0888-7543(88)90159-0","volume":"3","author":"L Ozelius","year":"1988","unstructured":"L. Ozelius, Y.-P. Hsu, G. Bruns, J. F. Powell, S. Chen, W. Weyler, M. Ut-terback, D. Zucker, J. Haines, J. A. Trofatter, P. M. Conneally, J. F. Gusella, X. O. Breakefield: Human monoamine oxidase gene (MAOA): chromosome position (Xp21\u2013p11) and DNA polymorphism. Genomics 3: 53\u201358, 1988.","journal-title":"Genomics"},{"key":"3_CR124","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/0888-7543(89)90072-4","volume":"5","author":"ER Levy","year":"1989","unstructured":"E. R. Levy, J. F. Powell, V.J. Buckle, H.-P. P. Hsu, X. O. Breakefield, I. W. Craig: Localization of human monoamine oxidase-A gene to Xp 11.23\u201311.4 by in situ hybridization: implications for Norrie disease. Genomics 5: 368\u2013370, 1989.","journal-title":"Genomics"},{"key":"3_CR125","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/0888-7543(89)90279-6","volume":"4","author":"NC Lan","year":"1989","unstructured":"N. C. Lan, C. Heinzmann, A. Gal, I. Klisak, U. Orth, E. Lai, J. Grimsby, R. S. Sparkes, T. Mohandas, J. C. Shih: Human monoamine oxidase A and B genes map to Xp 11.23 and are deleted in a patient with Norrie disease. Genomics 4: 552\u2013559, 1989.","journal-title":"Genomics"},{"key":"3_CR126","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000132282","volume":"42","author":"A Gal","year":"1986","unstructured":"A. Gal, B. Wieringa, D. F. Smeets, L. M. Bleeker-Wagemakers, H. H. Ropers: Submicroscopic interstitial deletion of the X chromosome explains a complex genetic syndrome dominated by Norrie disease. Cytogenet Cell Genet 42: 219\u2013224, 1986.","journal-title":"Cytogenet Cell Genet"},{"key":"3_CR127","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/0896-6273(89)90231-6","volume":"2","author":"KB Sims","year":"1989","unstructured":"K. B. Sims, A. DEla Chapelle, R. Norio, D. M. Sankila, Y.-P. P. Hsu, W. B. Rinehart, T. J. Corey, L. Ozelius, J. F. Powell, G. Bruns, J. F. Gusella, D. L. Murphy, X. O. Breakefield: Monoamine oxidase deficiency in males with an X chromosome deletion. Neuron 2: 1069\u20131076, 1989.","journal-title":"Neuron"},{"key":"3_CR128","first-page":"424","volume":"45","author":"KB Sims","year":"1989","unstructured":"K. B. Sims, L. Ozelius, T. Corey, W. B. Rinehart, R. Liberfarb, J. Haines, W. J. Chen, R. Norio, E. Sankila, A. DEla Chapelle, D. Murphy, J. Gusella, X. O. Braekefield: The Norrie disease gene is distinct from the monoamine oxidase genes. Am I Hum Genet 45: 424\u2013434, 1989.","journal-title":"Am I Hum Genet"},{"key":"3_CR129","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1073\/pnas.88.9.3637","volume":"88","author":"J Grimsby","year":"1991","unstructured":"J. Grimsby, K. Chen, L.-J. Wang, N. C. Lan, J. C. Shih: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci USA 88: 3637\u20133641, 1991.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR130","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1093\/nar\/19.16.4537","volume":"19","author":"Z-Y Chen","year":"1991","unstructured":"Z.-Y. Chen, G. S. Hotamisligil, J.-K. Huang, L. Weng, D. Ezzedine, N. Aydin-Muderrisoglu, J. F. Powell, R. H. Huang, X. O. Breakefield, I. Craig, Y.-P. P. Hsu: Structure of the human gene for monoamine oxidase type A. Nucl Acids Res 19: 4537\u20134541, 1991.","journal-title":"Nucl Acids Res"},{"key":"3_CR131","first-page":"41","volume":"32","author":"JC Shih","year":"1990","unstructured":"J. C. Shih, J. Grimsby, K. Chen: The expression of human MAO-A and B genes. J Neural Transm [Suppl] 32: 41\u201347, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR132","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0024-3205(84)90407-7","volume":"35","author":"HL White","year":"1984","unstructured":"H. L. White, D. K. Stine: Species differences in monoamine oxidase-A and -B as revealed by sensitivity to trypsin. Life Sci 35: 827\u2013833, 1984.","journal-title":"Life Sci"},{"key":"3_CR133","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0024-3205(83)90146-7","volume":"32","author":"H Kinemuchi","year":"1983","unstructured":"H. Kinemuchi, M. Sudo, M. Yoshino, T. Kawaguchi, Y. Sunami, K. Kamijo: A new type of mitochondrial monoamine oxidase distinct from type-A and type-B. Life Sci 32: 517\u2013524, 1983.","journal-title":"Life Sci"},{"key":"3_CR134","first-page":"321","volume-title":"Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors","author":"DL Murphy","year":"1984","unstructured":"D. L. Murphy: Are there diseases attributable to monoamine oxidase abnormalities? In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 321\u2013332, 1984."},{"key":"3_CR135","first-page":"379","volume-title":"Monoamine Oxidase: Structure, Function and Altered Functions","author":"L Oreland","year":"1979","unstructured":"L. Oreland: The activity of human brain and thrombocyte monoamine oxidase (MAO) in relation to various psychiatric disorders. I. MAO activity in some disease states. In: T. P. Singer, R. W. von Korff, D. L. Murphy, eds. Monoamine Oxidase: Structure, Function and Altered Functions. New York: Academic Press, pp. 379\u2013388, 1979."},{"key":"3_CR136","first-page":"339","volume":"8","author":"L Oreland","year":"1983","unstructured":"L. Oreland, E.G. Shaskan: Monoamine oxidase activity as a biological marker. TIPS 8: 339\u2013341, 1983.","journal-title":"TIPS"},{"key":"3_CR137","first-page":"111","volume-title":"Biological Markers in Psychiatry and Neurology","author":"E Jr","year":"1982","unstructured":"E. Jr. Giller, C. Castiglione, J. Wojciechowski, X. O. Breakefield: Molecular properties of platelet MAO in psychiatric patients and controls. In: E. Usdin, E. Hanin, eds. Biological Markers in Psychiatry and Neurology. New York: Pergamon Press, pp. 111\u2013121, 1982."},{"key":"3_CR138","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0165-1781(86)90069-7","volume":"17","author":"RM Rose","year":"1986","unstructured":"R. M. Rose, S. Castellani, J. A. Boeringa, P. Malek-Ahmadi, D. A. Lank-ford, J. D. Bessman, R. R. Fritz, C. B. Denney, R. M. Denney, C. W. Abell: Platelet MAO concentration and molecular activity: II. Comparison of normal and schizophrenic populations. Psychiat Res 17: 141\u2013151, 1986.","journal-title":"Psychiat Res"},{"key":"3_CR139","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0006-291X(88)80861-1","volume":"156","author":"S Chen","year":"1988","unstructured":"S. Chen, W. Weyler: Partial amino acid sequence analysis of human placenta monoamine oxidase A and bovine liver monoamine oxidase B. Biochem Biophys Res Commun 156: 445\u2013450, 1988.","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR140","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1471-4159.1989.tb07289.x","volume":"53","author":"Y-PP Hsu","year":"1989","unstructured":"Y.-P. P. Hsu, J. F. Powell, K. B. Sims, X. O. Breakefield: Molecular genetics of the monoamine oxidases. J Neurochem 53: 12\u201318, 1989.","journal-title":"J Neurochem"},{"key":"3_CR141","unstructured":"a M. Strolin Benedetti, P. Dostert: Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Advance Drug Research, 1992, in press."},{"key":"3_CR142","first-page":"74","volume-title":"Monoamine Oxidase: Basic and Clinical Frontiers","author":"O Suzuki","year":"1982","unstructured":"O. Suzuki, Y. Katsumata, O. Masakazu: Substrate specificity of type A and type B monoamine oxidase. In: K. Kamijo, E. Usdin, T. Nagatsu, eds. Monoamine Oxidase: Basic and Clinical Frontiers. Amsterdam: Excerpta Medica, pp. 74\u201386, 1982."},{"key":"3_CR143","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.2042-7158.1984.tb03004.x","volume":"36","author":"CJ Fowler","year":"1984","unstructured":"C. J. Fowler, K. F. Tipton: On the substrate specificities of the two forms of monoamine oxidase. J Pharm Pharmacol 36: 111\u2013115, 1984.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR144","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1471-4159.1980.tb12495.x","volume":"35","author":"H Kinemuchi","year":"1980","unstructured":"H. Kinemuchi, Y. Wakui, K. Kamijo: Substrate selectivity of type A and type B monoamine oxidase in rat brain. J Neurochem 35: 109\u2013115, 1980.","journal-title":"J Neurochem"},{"key":"3_CR145","first-page":"87","volume-title":"Monoamine Oxidase: Basic and Clinical Frontiers","author":"KF Tipton","year":"1982","unstructured":"K. F. Tipton, C. J. Fowler, M. D. Houslay: Specificities of the two forms of monoamine oxidase. In: K. Kamijo, E. Usdin, T. Nagatsu, eds. Monoamine Oxidase: Basic and Clinical Frontiers. Amsterdam: Excerpta Me-dica, pp. 87\u201399, 1982."},{"key":"3_CR146","first-page":"53","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"H Kinemuchi","year":"1984","unstructured":"H. Kinemuchi, C. J. Fowler, K. F. Tipton: Substrate specificities of the two forms of monoamine oxidase. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 53\u201362, 1984."},{"key":"3_CR147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/bst0190207","volume":"19","author":"P Dostert","year":"1991","unstructured":"P. Dostert, M. Strolin Benedetti: Structure-modulated recognition of substrates and inhibitors by monoamine oxidases A and B. Biochem Soc Trans 19: 207\u2013211, 1991.","journal-title":"Biochem Soc Trans"},{"key":"3_CR148","first-page":"25","volume":"23","author":"KF Tipton","year":"1987","unstructured":"K. F. Tipton, A.-M. O\u2019Carroll, J. M. McCrodden: The catalytic behaviour of monoamine oxidase. J Neural Transm [Suppl] 23: 25\u201335, 1987.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR149","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/BF00510258","volume":"311","author":"R Ortmann","year":"1980","unstructured":"R. Ortmann, P. C. Waldmeier, E. Radeke, A. Feiner, A. Delini Stula: The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 311: 185\u2013192, 1980.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/bj1390645","volume":"139","author":"MD Houslay","year":"1974","unstructured":"M. D. Houslay, K. F. Tipton: A kinetic evaluation of monoamine oxidase activity in rat liver mitochondrial outer membranes. Biochem J 139: 645\u2013652, 1974.","journal-title":"Biochem J"},{"key":"3_CR151","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1476-5381.1971.tb07217.x","volume":"43","author":"C Gordidis","year":"1971","unstructured":"C. Gordidis, N. H. Neff: Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type. Br J Pharmacol 43: 814\u2013818, 1971.","journal-title":"Br J Pharmacol"},{"key":"3_CR152","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0022-3565(25)29881-0","volume":"189","author":"NY Yang","year":"1974","unstructured":"N. Y. Yang, N. H. Neff: The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmac Exp Ther 189: 733\u2013740, 1974.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR153","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1471-4159.1977.tb06502.x","volume":"29","author":"HL White","year":"1977","unstructured":"H. L. White, A. T. Glassman: Multiple binding sites of human brain and liver monoamine oxidase: substrate specificities, selective inhibition, and attempts to separate enzyme forms. J. Neurochem 29: 987\u2013997, 1977.","journal-title":"J. Neurochem"},{"key":"3_CR154","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1016\/0006-2952(82)90656-6","volume":"31","author":"NA Garrick","year":"1982","unstructured":"N. A. Garrick, D. L. Murphy: Monoamine oxidase type A: differences in selectivity towards 1-norepinephrine compared to serotonin. Biochem Pharmacol 31: 4061\u20134066, 1982.","journal-title":"Biochem Pharmacol"},{"key":"3_CR155","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/0006-2952(84)90408-8","volume":"33","author":"NA Garrick","year":"1984","unstructured":"N. A. Garrick, M. Scheinin, W. H. Chand, M. Linnoila, D. L. Murphy: Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Biochem Pharmacol 33: 1423\u20131427, 1984.","journal-title":"Biochem Pharmacol"},{"key":"3_CR156","first-page":"593","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"AM O\u2019Carroll","year":"1984","unstructured":"A. M. O\u2019Carroll: The oxidation of noradrenaline by the two forms of human brain monoamine oxidase. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 593\u2013594, 1984."},{"key":"3_CR157","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/0006-2952(81)90312-9","volume":"30","author":"RW Fuller","year":"1981","unstructured":"R. W. Fuller, S. K. Hemrick-Luecke, K. W. Perry: Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats. Biochem Pharmacol 30: 1295\u20131298, 1981.","journal-title":"Biochem Pharmacol"},{"key":"3_CR158","first-page":"207","volume":"32","author":"RW Fuller","year":"1981","unstructured":"R. W. Fuller, S. K. Hemrick-Luecke: Elevation of epinephrine concentration in rat brain by LY 51641, a selective inhibitor of type A monoamine oxidase. Res Commun Chem Pathol 32: 207\u2013221, 1981.","journal-title":"Res Commun Chem Pathol"},{"key":"3_CR159","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/0006-8993(85)90101-5","volume":"399","author":"IN Mefford","year":"1985","unstructured":"I. N. Mefford, K. A. Roth, S. M. Jurik, V. Collman, S. McIntire: Epinephrine accumulation in rat brain after chronic administration of pargyline and LY 51641 \u2014 comparison with other brain amines. Brain Res 399: 342\u2013345, 1985.","journal-title":"Brain Res"},{"key":"3_CR160","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1600-0773.1985.tb02502.x","volume":"56","author":"OJ Rafaelsen","year":"1985","unstructured":"O. J. Rafaelsen, N. H. Christensen, A. Gjerris: Adrenaline and MAO-inhibitionin CSF and brain. Acta Pharmacol Toxicol 56: 98\u2013104, 1985.","journal-title":"Acta Pharmacol Toxicol"},{"key":"3_CR161","first-page":"393","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"CJ Fowler","year":"1984","unstructured":"C. J. Fowler, A. M. O\u2019Carroll, K. F. Tipton: Deamination of dopamine by monoamine oxidase A and B in the rat and in man. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 393\u2013402, 1984."},{"key":"3_CR162","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF00506483","volume":"292","author":"PC Waldmeier","year":"1976","unstructured":"P. C. Waldmeier, A. Delini-Stula, L. Ma\u00eetre: Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 292: 9\u201314, 1976.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR163","first-page":"79","volume":"32","author":"A Colzi","year":"1990","unstructured":"A. Colzi, F. d\u2019Agostini, R. Kettler, E. Borroni, M. Da Prada: Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. J Neural Transm [Suppl] 32: 79\u201384, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR164","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00433804","volume":"72","author":"NA Garrick","year":"1980","unstructured":"N. A. Garrick, D. L. Murphy: Species differences in the deamination of dopamine and other substrates for mono-amine oxidase in brain. Psychopharmacology 72: 27\u201333, 1980.","journal-title":"Psychopharmacology"},{"key":"3_CR165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00432211","volume":"86","author":"NA Garrick","year":"1985","unstructured":"N. A. Garrick, T. Seppala, M. Linnoila, D. L. Murphy: Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone. Psycho-pharmacology 86: 265\u2013269, 1985.","journal-title":"Psycho-pharmacology"},{"key":"3_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(85)90022-6","volume":"119","author":"NA Garrick","year":"1985","unstructured":"N. A. Garrick, T. Seppala, M. Linnoila, D. L. Murphy: The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey. Eur J Pharmacol 119: 1\u20139, 1985.","journal-title":"Eur J Pharmacol"},{"key":"3_CR167","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/246213a0","volume":"246","author":"KF Tipton","year":"1973","unstructured":"K. F. Tipton, M. D. Houslay, N. J. Garrett: Allotopic properties of human brain monoamine oxidase. Nature 246: 213\u2013214, 1973.","journal-title":"Nature"},{"key":"3_CR168","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/0006-2952(78)90493-8","volume":"27","author":"JA Roth","year":"1978","unstructured":"J. A. Roth, K. Feor: Deamination of dopamine and its 3-O-methylated derivative by human brain monoamine oxidase. Biochem. Pharmacol 27: 1606\u20131608, 1978.","journal-title":"Biochem. Pharmacol"},{"key":"3_CR169","first-page":"75","volume":"22","author":"J Knoll","year":"1986","unstructured":"J. Knoll: The pharmacology of (-)deprenyl. J. Neural Transm [Suppl] 22: 75\u201389, 1986.","journal-title":"J. Neural Transm [Suppl]"},{"key":"3_CR170","first-page":"15","volume":"25","author":"C Konradi","year":"1987","unstructured":"C. Konradi, P. Riederer, K. Jellinger, R. Denney: Cellular action of MAO inhibitors. J Neural Transm [Suppl] 25: 15\u201325, 1987.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR171","first-page":"37","volume":"45","author":"DL Murphy","year":"1984","unstructured":"D. L. Murphy, N. A. Garrick, C. S. Aulakh, R. M. Cohen: New contribution from basic science of understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psychiat 45: 37\u201343, 1984.","journal-title":"J Clin Psychiat"},{"key":"3_CR172","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-642-71288-3_16","volume-title":"Clinical Pharmacology in Psychiatry","author":"DL Murphy","year":"1987","unstructured":"D. L. Murphy, T. Sunderland, N. A. Garrick, C. S. Aulakh, R. M. Cohen: Selective amine oxidase inhibitors: basic to clinical studies and back. In: Dahl, Gram, Potter, eds. Clinical Pharmacology in Psychiatry. Berlin: Springer Verlag, pp. 135\u2013146, 1987."},{"key":"3_CR173","first-page":"479","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"JPM Finberg","year":"1984","unstructured":"J. P. M. Finberg, M. B. H. Youdim: Reversible monoamine oxidase inhibitors and the cheese effect. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 479\u2013485, 1984."},{"key":"3_CR174","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/9780470720059.ch4","volume-title":"Aromatic Amino Acids in the Brain, Ciba Foundation Symposium 2 (New Series)","author":"J Axelrod","year":"1974","unstructured":"J. Axelrod, J. M. Saavedra: Octopamine, phenylethanolamine, phenyle-thylamine and tryptamine in the brain. In: Aromatic Amino Acids in the Brain, Ciba Foundation Symposium 2 (New Series). Amsterdam: Elsevier-Excerpta Medica, pp. 51\u201359, 1974."},{"key":"3_CR175","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-642-73551-6_5","volume":"90\/II","author":"JM Saavedra","year":"1989","unstructured":"J. M. Saavedra: \u03b2-Phenylethylamine, phenylethanolamine, tyramine and octopamine. Handbk Exp Pharmacol 90\/II: 181\u2013210, 1989.","journal-title":"Handbk Exp Pharmacol"},{"key":"3_CR176","first-page":"57","volume":"15","author":"AA Boulton","year":"1976","unstructured":"A. A. Boulton: Identification, distribution, metabolism and function of meta- and para-tyramine, phenylethylamine and tryptamine in brain. Adv Biochem Psychopharmacol 15: 57\u201367, 1976.","journal-title":"Adv Biochem Psychopharmacol"},{"key":"3_CR177","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0278-5846(91)90076-D","volume":"15","author":"AA Boulton","year":"1991","unstructured":"A.A. Boulton: Phenylethylaminergic modulation of catecholaminergic neurotransmission. Prog Neuro-Psychopharm Biol Psychiat 15: 139\u2013156, 1991.","journal-title":"Prog Neuro-Psychopharm Biol Psychiat"},{"key":"3_CR178","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1471-4159.1990.tb13307.x","volume":"54","author":"DL Murphy","year":"1990","unstructured":"D. L. Murphy, K. B. Sims, F. Karoum, A. De la Chapelle, R. Norio, E. M. Sankila, X. O. Breakefield: Marked amine and amine metabolite changes in Norrie disease patients with an X chromosome deletion affecting monoamine oxidase. J Neurochem 54: 242\u2013247, 1990.","journal-title":"J Neurochem"},{"key":"3_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF01244447","volume":"83","author":"DL Murphy","year":"1991","unstructured":"D. L. Murphy, K. B. Sims, F. Karoum, N. A. Garrick, A. De la Chapelle, E. M. Sankila, R. Norio, X. O. Breakefield: Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neural Transm [Gen Sect] 83: 1\u201312, 1991.","journal-title":"J Neural Transm [Gen Sect]"},{"key":"3_CR180","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/0006-2952(91)90647-N","volume":"41","author":"JM Lizcano","year":"1991","unstructured":"J. M. Lizcano, D. Balsa, K. F. Tipton, M. Unzeta: The oxidation of dopamine by the semicarbazide-sensitive amine oxidase (SSAO) from rat vas deferens. Biochem Pharmacol 41: 1107\u20131110, 1991.","journal-title":"Biochem Pharmacol"},{"key":"3_CR181","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","volume":"80","author":"RS Burns","year":"1983","unstructured":"R. S. Burns, C. C. Chiueh, S.P. Markey, M. H. Ebert, D. M. Jacobowitz, I. J. Kopin: A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-me-thyl-4-phenyl-l, 2, 3, 5-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546\u20134550, 1983.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR182","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJM198505303122203","volume":"312","author":"RS Burns","year":"1985","unstructured":"R. S. Burns, P. A. LeWitt, M. H. Ebert, H. Pakkenberg, I. J. Kopin: The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). N Engl J Med 312: 1418\u20131421, 1985.","journal-title":"N Engl J Med"},{"key":"3_CR183","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"J. W. Langston, P. Ballard, J. W. Tetrud, I. Irwin: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979\u2013980, 1983.","journal-title":"Science"},{"key":"3_CR184","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.6332378","volume":"225","author":"JW Langston","year":"1984","unstructured":"J. W. Langston, I. Irwin, E. B. Langston, L. S. Forno: Pargyline prevents MPTP-induced Parkinsonism in primates. Science 225: 1480\u20131482, 1984.","journal-title":"Science"},{"key":"3_CR185","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/311467a0","volume":"311","author":"RE Heikkila","year":"1984","unstructured":"R. E. Heikkila, L. Manzino, F. S. Cabbat, R. C. Duvoisin: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetra-hydropyridine by monoamine oxidase inhibitors. Nature 311: 467\u2013469, 1984.","journal-title":"Nature"},{"key":"3_CR186","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0014-2999(85)90168-2","volume":"116","author":"RE Heikkila","year":"1985","unstructured":"R. E. Heikkila, R. C. Duvoisin, J. P. M. Finberg, M. B. H. Youdim: The prevention of MPTP neurotoxicity by AGN 1135, a selective MAO type B inhibitor without the cheese effect. Eur J Pharmacol 116: 313\u2013317, 1985.","journal-title":"Eur J Pharmacol"},{"key":"3_CR187","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/0024-3205(86)90558-8","volume":"38","author":"MY Kindt","year":"1986","unstructured":"M. Y. Kindt, R. E. Heikkila: Prevention of 1-methyl-4-phenyl-1, 2, 3, 6-tet-rahydropyridine-induced dopaminergic toxicity in mice by MDL 72, 145, a selective inhibitor of MAO-B. Life Sci 38: 1459\u20131467, 1986.","journal-title":"Life Sci"},{"key":"3_CR188","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/311464a0","volume":"311","author":"SP Markey","year":"1984","unstructured":"S. P. Markey, J. N. Johannessen, C. C. Chiueh, R. S. Burns, M. A. Herkenham: Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464\u2013467, 1984.","journal-title":"Nature"},{"key":"3_CR189","first-page":"175","volume":"45","author":"M Prada Da","year":"1986","unstructured":"M. Da Prada, R. Kettler, H.H. Keller, E. P. Bonetti, R. Imhof: Ro 16\u20136491, a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv Neurol 45: 175\u2013178, 1986.","journal-title":"Adv Neurol"},{"key":"3_CR190","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0024-3205(85)90063-3","volume":"36","author":"N Castagnoli Jr.","year":"1985","unstructured":"N. Castagnoli Jr., K. Chiba, A. J. Trevor: Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Life Sci 36: 225\u2013230, 1985.","journal-title":"Life Sci"},{"key":"3_CR191","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1073\/pnas.85.16.6172","volume":"85","author":"RE Heikkila","year":"1988","unstructured":"R. E. Heikkila, M. V. Kindt, P. K. Sonsalla, A. Giovanni, S. K. Youngster, K. A. McKeown, T. P. Singer: Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahy-dropyridine. Proc Natl Acad Sci USA 85: 6172\u20136186, 1988.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR192","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0014-5793(85)80807-3","volume":"183","author":"W Gessner","year":"1985","unstructured":"W. Gessner, A. Brossi, R.-S. Shen, C. W. Abell: Further insight into the mode of action of the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydro-pyridine (MPTP), FEBS Lett 183: 345\u2013348, 1985.","journal-title":"FEBS Lett"},{"key":"3_CR193","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1021\/bi00385a015","volume":"26","author":"RR Ramsay","year":"1987","unstructured":"R. R. Ramsay, S. C. Koerber, T. P. Singer: Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase B. Biochemistry 26: 3045\u20133050, 1987.","journal-title":"Biochemistry"},{"key":"3_CR194","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/bj2680219","volume":"268","author":"MJ Krueger","year":"1990","unstructured":"M. J. Krueger, K. McKeown, R. R. Ramsay, S. K. Youngster, T. P. Singer: Mechanism-based inactivation of monoamine oxidases A and B by tetra-hydropyridines and dihydropyridines. Biochem J 268: 219\u2013214, 1990.","journal-title":"Biochem J"},{"key":"3_CR195","first-page":"147","volume-title":"Molecular Neuroscience: Expression of Neural Genes","author":"CW Abell","year":"1987","unstructured":"C. W. Abell, M. A. Bembenek, R. R. Fritz: Studies on the bioactivation and neurotoxicity of the Parkinsonian-inducing compound MPTP. In: Molecular Neuroscience: Expression of Neural Genes. New York: Alan R. Liss, pp. 147\u2013158, 1987."},{"key":"3_CR196","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","volume":"82","author":"JA Javitch","year":"1985","unstructured":"J. A. Javitch, R. J. D\u2019Amato, S. M. Strittmatter, S. H. Snyder: Parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82: 2173\u20132177, 1985.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR197","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/0006-291X(85)91071-X","volume":"128","author":"K Chiba","year":"1985","unstructured":"K. Chiba, A. Trevor, N. Castagnoli Jr.: Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128: 1228\u20131232, 1985.","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR198","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1471-4159.1987.tb03405.x","volume":"49","author":"AM Cesura","year":"1987","unstructured":"A. M. Cesura, A. Ritter, G. B. Picotti, M. Da Prada: Uptake, release, and subcellular localization of l-methyl-4-phenylpyridinium in blood platelets. J Neurochem 49: 138\u2013145, 1987.","journal-title":"J Neurochem"},{"key":"3_CR199","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0006-291X(86)80483-1","volume":"134","author":"RR Ramsay","year":"1986","unstructured":"R. R. Ramsay, J. I. Salach, T. P. Singer: Uptake of the neurotoxin 1-me-thyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem. Biophys Res Commun 134: 743\u2013748, 1986.","journal-title":"Biochem. Biophys Res Commun"},{"key":"3_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.1987.tb03384.x","volume":"49","author":"TP Singer","year":"1987","unstructured":"T. P. Singer, N. Catagnoli Jr., R. R. Ramsay, A. J. Trevor: Biochemical events in the development of Parkinsonism induced by l-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J Neurochem 49: 1\u20138, 1987.","journal-title":"J Neurochem"},{"key":"3_CR201","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0006-8993(90)90308-X","volume":"509","author":"M Takada","year":"1991","unstructured":"M. Takada, Z. K. Li, T. Hattori: Astroglial ablation prevents MPTP-in-duced nigrostriatal neuronal death. Brain Res 509: 55\u201361, 1991.","journal-title":"Brain Res"},{"key":"3_CR202","unstructured":"D. Calne, J. Langston: Parkinson\u2019s disease: hypothesis. Lancet ii: 1457\u20131461, 1983."},{"key":"3_CR203","first-page":"49","volume":"12","author":"CM Tanner","year":"1989","unstructured":"C. M. Tanner: The role of environmental toxins in the etiology of Parkinson\u2019s disease. TINS 12: 49\u201354, 1989.","journal-title":"TINS"},{"key":"3_CR204","first-page":"217","volume":"32","author":"RE Heikkila","year":"1990","unstructured":"R. E. Heikkila, I. Terleckyj, B. A. Sieber: Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. J Neural Transm [Suppl] 32: 217\u2013227, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR205","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0304-3940(87)90422-8","volume":"76","author":"C Gibb","year":"1987","unstructured":"C. Gibb, J. Willoughby, V. Glover, M. Sandler, B. Testa, P. Jenner, C. D. Marsden: Analogues of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine as monoamine oxidase substrates: a second ring is not necessary. Neurosci Lett 76: 316\u2013322, 1987.","journal-title":"Neurosci Lett"},{"key":"3_CR206","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/j.1471-4159.1988.tb10566.x","volume":"50","author":"PJ Varebeke de","year":"1988","unstructured":"P. J. de Varebeke, R. Cavalier, M. David-Remacle, M. B. H. Youdim: Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B. J Neurochem 50: 1011\u20131016, 1988.","journal-title":"J Neurochem"},{"key":"3_CR207","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/j.1471-4159.1989.tb07403.x","volume":"53","author":"PJ Varebeke de","year":"1989","unstructured":"P. J. de Varebeke, G. Pauwels, C. Buyse, M. David-Remacle, J. DEMey, J. Roba, M. B. H. Youdim: The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B. J Neurochem 53: 1109\u20131116, 1989.","journal-title":"J Neurochem"},{"key":"3_CR208","first-page":"169","volume-title":"New Anticonvulsant Drugs","author":"J Roba","year":"1986","unstructured":"J. Roba, R. Cavalier, A. Cordi, H. Gorissen, M. Herin, P. Janssens Varbeke, C. Onkelinx, M. Remade, W. van Dorsser: Milacemide. In: B. S. Meldrum, R. R. Porter, eds. New Anticonvulsant Drugs, London: Libbey &Co., pp. 169\u2013180, 1986."},{"key":"3_CR209","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1476-5381.1990.tb12062.x","volume":"100","author":"JM Godfraind","year":"1990","unstructured":"J. M. Godfraind, Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells. Br J Pharmacol 100: 119\u2013125, 1990.","journal-title":"Br J Pharmacol"},{"key":"3_CR210","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/0006-2952(91)90177-7","volume":"41","author":"EM O\u2019Brien","year":"1991","unstructured":"E. M. O\u2019Brien, K. F. Tipton, M. Strolin Benedetti, A. Bonsignori, P. Marrari, P. Dostert: Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions? Biochem Pharmacol 41: 1731\u20131737, 1991.","journal-title":"Biochem Pharmacol"},{"key":"3_CR211","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1042\/bst0190224","volume":"19","author":"MBH Youdim","year":"1991","unstructured":"M. B. H. Youdim, N. Narshak, M. Yoshioka, H. Araki, Y. Mukai, G. Gotto: Novel substrates and products of amine oxidase-catalysed reactions. Biochem Soc Trans 19: 224\u2013228, 1991.","journal-title":"Biochem Soc Trans"},{"key":"3_CR212","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1432-1033.1968.tb00372.x","volume":"5","author":"KF Tipton","year":"1968","unstructured":"K. F. Tipton: The reaction pathway of pig brain mitochondrial monoamine oxidase. Eur J Biochem 5: 316\u2013320, 1968.","journal-title":"Eur J Biochem"},{"key":"3_CR213","first-page":"699","volume-title":"Flavins and Flavoproteins","author":"MC Walker","year":"1987","unstructured":"M. C. Walker, D. E. Edmondson: Kinetic probes of the proposed radical mechanism of monoamine oxidase. In: Edmondson, D. B. McCormick, eds. Flavins and Flavoproteins. Berlin: Walter DeGruyter, pp. 699\u2013703, 1987."},{"key":"3_CR214","first-page":"410","volume":"146","author":"S Oi","year":"1970","unstructured":"S. Oi, K. Shimada, M. Inamasu, K. T. Yasunobu: Mechanistic studies of beef liver mitochondrial monoamine oxidase. Archs Biochem Biophys 146: 410\u2013421, 1970.","journal-title":"Archs Biochem Biophys"},{"key":"3_CR215","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/0006-2952(79)90614-2","volume":"28","author":"CJ Fowler","year":"1979","unstructured":"C. J. Fowler, B. Ekstedt, T. Egasira, H. Kinemuchi, L. Oreland: The interaction between human platelet monoamine oxidase, its monoamine substrates and oxygen. Biochem Pharmacol 28: 3063\u20133068, 1979.","journal-title":"Biochem Pharmacol"},{"key":"3_CR216","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1021\/bi00532a028","volume":"21","author":"M Husain","year":"1982","unstructured":"M. Husain, D. E. Edmondson, T. P. Singer: Kinetic studies on the catalytic mechanism of liver monoamine oxidase. Biochemistry 21: 595\u2013600, 1982.","journal-title":"Biochemistry"},{"key":"3_CR217","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1021\/bi00329a003","volume":"24","author":"LB Pearce","year":"1985","unstructured":"L. B. Pearce, J. A. Roth: Human brain monoamine oxidase type B: mechanism of deamination as probed by steady-state methods. Biochemistry 24: 1821\u20131826, 1985.","journal-title":"Biochemistry"},{"key":"3_CR218","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/bst0190219","volume":"19","author":"RR Ramsay","year":"1991","unstructured":"R. R. Ramsay, T. P. Singer: The kinetic mechanisms of monoamine oxidases A and B. Biochem Soc Trans 19: 219\u2013223, 1991.","journal-title":"Biochem Soc Trans"},{"key":"3_CR219","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bst0190211","volume":"19","author":"TP Singer","year":"1991","unstructured":"T. P. Singer, R. R. Ramsay: The interaction of monoamine oxidases with tertiary amines. Biochem Soc Trans 19: 211\u2013215, 1991.","journal-title":"Biochem Soc Trans"},{"key":"3_CR220","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1021\/ja00543a052","volume":"102","author":"RB Silverman","year":"1980","unstructured":"R. B. Silverman, S. J. Hoffman, W. B. Catus III: A mechanism for mitochondrial monoamine oxidase catalyzed amine oxidation. J Am Chem Soc 102: 7126\u20137128, 1980.","journal-title":"J Am Chem Soc"},{"key":"3_CR221","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1021\/ja00389a044","volume":"104","author":"JT Simpson","year":"1982","unstructured":"J. T. Simpson, A. Krantz, F. D. Lewis, B. Kokel: Photochemical and photophysical studies of amines with excited flavins. Relevance to the mechanism of action of the flavin-dependent monoamine oxidase. J Am Chem Soc 104: 7155\u20137161, 1982.","journal-title":"J Am Chem Soc"},{"key":"3_CR222","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1021\/jo00016a026","volume":"56","author":"J-M Kim","year":"1991","unstructured":"J.-M. Kim, I.-S. Cho, P. S. Mariano: Amine-flavin electron transfer photochemistry. Potential models for monoamine oxidase catalysis and inhibition. J Org Chem 56: 4943\u20134955, 1991","journal-title":"J Org Chem"},{"key":"3_CR223","doi-asserted-by":"publisher","first-page":"9364","DOI":"10.1021\/ja00181a044","volume":"112","author":"KS Gates","year":"1990","unstructured":"K. S. Gates, R. B. Silverman: 5-(Aminomethyl)-3-aryl-2-oxazolidinones. A novel class of mechanism-based inactivators of monoamine oxidase B. J Am Chem Soc 112: 9364\u20139372, 1990.","journal-title":"J Am Chem Soc"},{"key":"3_CR224","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1042\/bst0190201","volume":"19","author":"RB Silverman","year":"1991","unstructured":"R. B. Silverman: The use of mechanism-based inactivators to probe the mechanism of monoamine oxidase. Biochem Soc Trans 19: 201\u2013206, 1991.","journal-title":"Biochem Soc Trans"},{"key":"3_CR225","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1021\/bi00301a046","volume":"23","author":"RB Silverman","year":"1984","unstructured":"R. B. Silverman, R. B. Yamasaki: Mechanism-based inactivation of mitochondrial monoamine oxidase by N-(1-methylcyclopropyl) benzylamine. Biochemistry 23: 1322\u20131332, 1984.","journal-title":"Biochemistry"},{"key":"3_CR226","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1021\/bi00330a005","volume":"24","author":"RB Silverman","year":"1985","unstructured":"R. B. Silverman, P. A. Zieske: Mechanism of inactivation of monoamine oxidase by 1-phenylcyclopropylamine. Biochemistry 24: 2128\u20132138, 1985.","journal-title":"Biochemistry"},{"key":"3_CR227","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1021\/bi00350a010","volume":"25","author":"RB Silverman","year":"1986","unstructured":"R. B. Silverman, P. A. Zieske: 1-Phenylcyclobutylamine, the first in a new class of monoamine oxidase inactivators. Further evidence for a radical intermediate. Biochemistry 25: 341\u2013346, 1986.","journal-title":"Biochemistry"},{"key":"3_CR228","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/0006-291X(86)90955-1","volume":"135","author":"RB Silverman","year":"1986","unstructured":"R. B. Silverman, P. A. Zieske: Identification of the amino acid bound to the labile adduct formed during inactivation of monoamine oxidase by 1-phenylcyclopropylamine. Biochem Biophys Res Commun 135: 154\u2013159, 1986.","journal-title":"Biochem Biophys Res Commun"},{"key":"3_CR229","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1021\/ja00167a057","volume":"112","author":"GM Banik","year":"1990","unstructured":"G. M. Banik, R. B. Silverman: Mechanism of inactivation of monoamine oxidase B by (arninomethyl)trimethylsilane. J Am Chem Soc 112: 4499\u20134507, 1990.","journal-title":"J Am Chem Soc"},{"key":"3_CR230","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1021\/ja00241a070","volume":"109","author":"RB Silverman","year":"1987","unstructured":"R. B. Silverman, G. M. Banik: (Aminoalkyl)trimethylsilanes. A new class of monoamine oxidase inactivators. J Am Chem Soc 109: 2219\u20132220, 1987.","journal-title":"J Am Chem Soc"},{"key":"3_CR231","doi-asserted-by":"publisher","first-page":"8448","DOI":"10.1021\/bi00422a023","volume":"27","author":"RB Silverman","year":"1988","unstructured":"R. B. Silverman, C. K. Hiebert: Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1-phenylcyclopropylamine, 1-benzyl-cyclopropylamine, and N-cyclopropyl\u03b1-methylbenzylamine. Biochemistry 27: 8448\u20138453, 1988.","journal-title":"Biochemistry"},{"key":"3_CR232","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/ja00185a059","volume":"111","author":"K Yelekci","year":"1989","unstructured":"K. Yelekci, X. Lu, R. B. Silverman: Electron spin resonance studies of monoamine oxidase B. First direct evidence for a substrate radical intermediate. J Am Chem Soc 111: 1138\u20131140, 1989.","journal-title":"J Am Chem Soc"},{"key":"3_CR233","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/j.1749-6632.1963.tb13326.x","volume":"107","author":"B Belleau","year":"1963","unstructured":"B. Belleau, J. Moran: Deuterium isotope effects in relation to the chemical mechanism of monoamine oxidase. Ann N Y Acad Sci 107: 822\u2013839, 1963.","journal-title":"Ann N Y Acad Sci"},{"key":"3_CR234","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1039\/p19790002550","volume":"10","author":"AR Battersby","year":"1979","unstructured":"A. R. Battersby, D. G. Buckley, J. Staunton, P. J. Williams: Studies of enzyme-mediated reactions. Part 10. Stereochemical course of the dehydrogenation of stereospecifically labelled 1-aminoheptanes by the amine oxidase from rat liver mitochondria (E. C. I.4.3.4.). J Chem Soc [Perkin I] 10: 2550\u20132558, 1979.","journal-title":". J Chem Soc [Perkin I]"},{"key":"3_CR235","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1016\/0006-2952(81)90497-4","volume":"30","author":"PH Yu","year":"1981","unstructured":"P. H. Yu, S. Barclay, B. Davis, A. A. Boulton: Deuterium isotope effects on the enzymatic oxidative deamination of trace amines. Biochem Pharmacol 30: 3089\u20133094, 1981.","journal-title":"Biochem Pharmacol"},{"key":"3_CR236","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0006-2952(86)90094-8","volume":"35","author":"PH Yu","year":"1986","unstructured":"P. H. Yu, B. A. Bailey, D. A. Durden, A. A. Boulton: Stereospecific deuterium substitution at the \u03b1-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO A and MAO B from different tissues. Biochem Pharmac 35: 1027\u20131036, 1986.","journal-title":"Biochem Pharmac"},{"key":"3_CR237","first-page":"249","volume":"6","author":"MS Benedetti","year":"1985","unstructured":"M. Strolin Benedetti, P. Dostert: Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. TIPS 6: 249\u2013251, 1985.","journal-title":"TIPS"},{"key":"3_CR238","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1432-1033.1975.tb02334.x","volume":"57","author":"A Hiramatsu","year":"1975","unstructured":"A. Hiramatsu, S. Tsurushiin, K. T. Yasunobu: Evidence for essential histi-dine residues in bovine liver mitochondrial monoamine oxidase. Eur J Biochem 57: 587\u2013593, 1975.","journal-title":"Eur J Biochem"},{"key":"3_CR239","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0006-2952(74)90626-1","volume":"23","author":"CH Williams","year":"1974","unstructured":"C. H. Williams: Monoamine oxidase-I. Specificity of some substrates and inhibitors. Biochem Pharmacol 23: 615\u2013228, 1974.","journal-title":"Biochem Pharmacol"},{"key":"3_CR240","first-page":"209","volume-title":"Structure and Functions of Amine Oxidases","author":"KT Yasunobu","year":"1985","unstructured":"K. T. Yasunobu, A. Tan: Advances in monoamine oxidase enzymology. In: B. Mondovi, ed. Structure and Functions of Amine Oxidases. Boca Raton, Florida: CRC Press, pp. 209\u2013217, 1985."},{"key":"3_CR241","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1016\/S0021-9258(18)91942-3","volume":"243","author":"L Hellerman","year":"1968","unstructured":"L. Hellerman, V. G. Erwin: Mitochondrial monoamine oxidase. J Biol Chem 243: 5234\u20135243, 1968.","journal-title":"J Biol Chem"},{"key":"3_CR242","first-page":"101","volume-title":"Monoamine Oxidase: Structure, Function, and Altered Functions","author":"EA Zeller","year":"1979","unstructured":"E. A. Zeller, K. L. Arora, D. H. Gurne, S. V. Huprikar: On the topography of the active site of monoamine oxidase types A and B. In: T. P. Singer, R. W. von Korff, D. L. Murphy, eds. Monoamine Oxidase: Structure, Function, and Altered Functions. New York: Academic Press, p. 101, 1979."},{"key":"3_CR243","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1021\/jm00380a007","volume":"28","author":"IA McDonald","year":"1985","unstructured":"I. A. McDonald, J. M. Lacoste, P. Bey, M. G. Palfreyman, M. Zreika: Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallyl-amine structure-activity relationships. J Med Chem 28: 186\u2013193, 1985.","journal-title":"J Med Chem"},{"key":"3_CR244","first-page":"41","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"CH Williams","year":"1984","unstructured":"C. H. Williams, B. Walker: What does the binding of inhibitors reveal about the active site of monoamine oxidase? In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 41\u201352, 1984."},{"key":"3_CR245","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1042\/bst0140410","volume":"14","author":"MG Palfreyman","year":"1986","unstructured":"M. G. Palfreyman, I. A. McDonald, P. Bey, C. Danzin, M. Zreika, G. A. Lyles, J. R. Fozard: The rational design of suicide substrates of amine oxidases. Biochem Soc Trans 14: 410\u2013413, 1986.","journal-title":"Biochem Soc Trans"},{"key":"3_CR246","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1146\/annurev.bi.53.070184.002425","volume":"53","author":"CT Walsh","year":"1984","unstructured":"C. T. Walsh: Suicide substrates, mechanism-based enzyme inactivators: recent developments. A Rev Biochem 53: 493\u2013535, 1984.","journal-title":"A Rev Biochem"},{"key":"3_CR247","first-page":"28","volume":"23","author":"MG Palfreyman","year":"1987","unstructured":"M. G. Palfreyman, P. Bey, A. Sjoerdsma: Enzyme-activated\/mechanism-based inhibitors. Essay in Biochemistry 23: 28\u201381, 1987.","journal-title":"Essay in Biochemistry"},{"key":"3_CR248","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0021-9258(18)50153-8","volume":"237","author":"R Kitz","year":"1962","unstructured":"R. Kitz, I. B. Wilson: Esters of methane sulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237: 3245\u20133249, 1962.","journal-title":"J Biol Chem"},{"key":"3_CR249","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/bj1850771","volume":"185","author":"SG Waley","year":"1980","unstructured":"S. G. Waley: Kinetics of suicide substrates. Biochem J 185: 771\u2013773, 1980.","journal-title":"Biochem J"},{"key":"3_CR250","first-page":"17","volume-title":"Monoamine Oxidase Inhibitors \u2014 The State of the Art","author":"TP Singer","year":"1981","unstructured":"T. P. Singer, J. I. Salach, Interaction of suicide inhibitors with the active site of monoamine oxidase. In: M. B. H. Youdim, E. S. Paykel, eds. Monoamine Oxidase Inhibitors \u2014 The State of the Art. New York: Wiley, pp. 17\u201329, 1981."},{"key":"3_CR251","first-page":"7","volume-title":"Monoamine Oxidase: Structure, Function and Altered Functions","author":"TP Singer","year":"1979","unstructured":"T. P. Singer: Active site-directed, irreversible inhibitors of monoamine oxidase. In: T. P. Singer, R. W. Von Korff, D. L. Murphy, eds. Monoamine Oxidase: Structure, Function and Altered Functions. London: Academic Press, pp. 7\u201324, 1979."},{"key":"3_CR252","first-page":"389","volume-title":"Flavins and Flavoproteins","author":"TP Singer","year":"1982","unstructured":"T. P. Singer, M. Husain: Monoamine oxidase and its reaction with suicide substrates. In: V. Massay, C. H. Williams, eds. Flavins and Flavoproteins. Amsterdam: Elsevier, pp. 389\u2013401, 1982."},{"key":"3_CR253","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000407501","volume":"19","author":"KF Tipton","year":"1983","unstructured":"K. F. Tipton, A.-M. O\u2019Carroll, T. J. Mantle, C. J. Fowler: Factors involved in the selective inhibition of monoamine oxidase. Mod Probl Pharmacopsychiat 19: 15\u201330, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"3_CR254","first-page":"27","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"KF Tipton","year":"1984","unstructured":"K. F. Tipton, C. J. Fowler: The kinetics of monoamine oxidase inhibitors in relation to their clinical behaviours. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 27\u201340, 1984."},{"key":"3_CR255","first-page":"501","volume":"12","author":"CJ Fowler","year":"1982","unstructured":"C. J. Fowler: Selective inhibitors of monoamine oxidase types A and B and their clinical usefulness. Drugs Future 12: 501\u2013517, 1982.","journal-title":"Drugs Future"},{"key":"3_CR256","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00508078","volume":"273","author":"G Planz","year":"1972","unstructured":"G. Planz, K. Quiring, D. Palm: Rates of recovery of irreversibly inhibited monoamine oxidase: a measure of enzyme protein turnover. Naunyn Schmiedeberg\u2019s Arch Pharmacol 273: 27\u201342, 1972.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR257","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/j.1471-4159.1971.tb03740.x","volume":"18","author":"C Goridis","year":"1971","unstructured":"C. Goridis, N. H. Neff: Monoamine oxidase: an approximation of turnover rates. J Neurochem 18: 1673\u20131682, 1971.","journal-title":"J Neurochem"},{"key":"3_CR258","first-page":"167","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"DS Davies","year":"1984","unstructured":"D. S. Davies: Pharmacokinetic and concentration-effect relationships of reversible and irreversible inhibitors. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. London: Academic Press, pp. 167\u2013172, 1984."},{"key":"3_CR259","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/0006-2952(79)90293-4","volume":"28","author":"AE Feiner","year":"1979","unstructured":"A. E. Feiner, P. C. Waldmeier: Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28: 995\u20131002, 1979.","journal-title":"Biochem Pharmacol"},{"key":"3_CR260","unstructured":"A. Pletscher, K. F. Gey, P. Zeller: Monoamineoxydase-Hemmer. Biochemie, Chemie, Pharmakologie, Klinik. Progress in Drug Research II: 417\u2013590, 1960."},{"key":"3_CR261","first-page":"205","volume":"30","author":"LE Richards","year":"1986","unstructured":"L. E. Richards, A. Burger: Mechanism-based inhibitors of monoamine oxidase. Progress in Drug Research 30: 205\u2013219, 1986.","journal-title":"Progress in Drug Research"},{"key":"3_CR262","first-page":"103","volume":"23","author":"MS Benedetti","year":"1987","unstructured":"M. Strolin Benedetti, P. Dostert: Overview of the present state of MAO inhibitors. J Neural Transm [Suppl] 23: 103\u2013119, 1987.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR263","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/0006-2952(82)90327-6","volume":"31","author":"H Kinemuchi","year":"1982","unstructured":"H. Kinemuchi, Y. Arai, L. Oreland, K. F. Tipton, C. J. Fowler: Time-dependent inhibition of monoamine oxidase by \u03b2-phenethylamine. Biochem Pharmacol 31: 959\u2013964, 1982.","journal-title":"Biochem Pharmacol"},{"key":"3_CR264","first-page":"427","volume":"106","author":"EA Zeller","year":"1952","unstructured":"E. A. Zeller, J. Barsky, E. R. Berman, J. R. Fouts: Action of isonicotinic acid hydrazide and related compounds on enzymes involved in the autonomic nervous system. J Pharmac Exp Ther 106: 427\u2013428, 1952.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR265","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3181\/00379727-81-19910","volume":"81","author":"EA Zeller","year":"1952","unstructured":"E. A. Zeller, J. Barsky: In vivo inhibition of liver and brain monoamine oxidase by 1-isonicotinyl-2-isopropyl hydrazine. Proc Soc Exp Biol NY 81: 459\u2013461, 1952.","journal-title":"Proc Soc Exp Biol NY"},{"key":"3_CR266","unstructured":"H. P. Loomer, J. C. Saunders, N. S. Kline: Iproniazid, an amine oxidase inhibitor, as an example of a psychic energizer. Congr Rec: 1382\u20131390, 1957."},{"key":"3_CR267","first-page":"121","volume":"8","author":"HP Loomer","year":"1958","unstructured":"H. P. Loomer, J. C. Saunders, N. S. Kline: A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiat Res Rep Am Psychiat Ass 8: 121\u2013141, 1958.","journal-title":"Psychiat Res Rep Am Psychiat Ass"},{"key":"3_CR268","first-page":"9","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"P Dostert","year":"1984","unstructured":"P. Dostert: Myth and reality of the classical MAO inhibitors, reasons for seeking a new generation. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 9\u201324, 1984."},{"key":"3_CR269","first-page":"25","volume-title":"Monoamine Oxidase: Structure, Function and Altered Functions","author":"WC Kenney","year":"1979","unstructured":"W. C. Kenney, J. Nagy, J. I. Salach, T. P. Singer: Structure of the covalent Phenylhydrazine adduct of monoamine oxidase. In: T. P. Singer, R. W. Von Korff, D. L. Murphy, eds. Monoamine Oxidase: Structure, Function and Altered Functions. London: Academic Press, pp. 25\u201337, 1979."},{"key":"3_CR270","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1016\/0006-2952(89)90522-4","volume":"38","author":"PH Yu","year":"1989","unstructured":"P. H. Yu, K. F. Tipton: Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem Pharmacol 38: 4245\u20134251, 1989.","journal-title":"Biochem Pharmacol"},{"key":"3_CR271","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1017\/S0033291700030890","volume":"9","author":"MBH Youdim","year":"1979","unstructured":"M. B. H. Youdim, J. K. Aronson, K. Blau, D. G. Grahame-Smith: Tranylcypromine (Parnate) overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med 9: 377\u2013382, 1979.","journal-title":"Psychol Med"},{"key":"3_CR272","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1988.tb06293.x","volume":"78","author":"SC Dilsaver","year":"1988","unstructured":"S. C. Dilsaver: Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology. Acta Psychiatr Scand 78: 1\u20137, 1988.","journal-title":"Acta Psychiatr Scand"},{"key":"3_CR273","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/0006-2952(78)90554-3","volume":"27","author":"DL Murphy","year":"1978","unstructured":"D. L. Murphy, C. H. Donnelly, E. Richelson, R. W. Fuller: N-Substituted cyclopropylamines as inhibitors of MAO A and B forms. Biochem Pharmacol 27: 1767\u20131769, 1978.","journal-title":"Biochem Pharmacol"},{"key":"3_CR274","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/0006-2952(78)90001-1","volume":"27","author":"DL Murphy","year":"1978","unstructured":"D. L. Murphy: Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem Pharmacol 27: 1889\u20131893, 1978.","journal-title":"Biochem Pharmacol"},{"key":"3_CR275","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/med.2610040303","volume":"4","author":"CJ Fowler","year":"1984","unstructured":"C. J. Fowler, S. B. Ross: Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological and clinical properties. Med Res Rev 4: 323\u2013358, 1984.","journal-title":"Med Res Rev"},{"key":"3_CR276","first-page":"523","volume-title":"Trends in Medicinal Chemistry","author":"E Kyburz","year":"1988","unstructured":"E. Kyburz: New developments in the field of monoamine oxidase inhibitors (MAO-I). In: H. Van der Goot, G. Domany, L. Pallos, H. Timmerman, eds. Trends in Medicinal Chemistry. Amsterdam: Elsevier, pp. 523\u2013542, 1988."},{"key":"3_CR277","first-page":"71","volume-title":"Monoamine Oxidase: Structure, Function, and Altered Functions","author":"RB Silverman","year":"1979","unstructured":"R. B. Silverman, S. J. Hoffman: Mechanism of inactivation of monoamine oxidase by N-cyclopropyl-N-arylalkyl amines. In: T. P. Singer, R. W. Von Korff, D. L. Murphy, eds. Monoamine Oxidase: Structure, Function, and Altered Functions. London: Academic Press, pp. 71\u201379, 1979."},{"key":"3_CR278","doi-asserted-by":"crossref","first-page":"14766","DOI":"10.1016\/S0021-9258(17)43725-2","volume":"258","author":"RB Silverman","year":"1983","unstructured":"R. B. Silverman: Mechanism of inactivation of monoamine oxidase by trans-2-phenylcyclopropylamine and the structure of the enzyme-inactivator adduct. J Biol Chem 258: 14766\u201314769, 1983.","journal-title":"J Biol Chem"},{"key":"3_CR279","first-page":"39","volume-title":"Monoamine Oxidase: Structure, Function and Altered Functions","author":"C Paech","year":"1979","unstructured":"C. Paech, J. I. Salach, T. P. Singer: Suicide inactivation of monoamine oxidase by trans-phenylcyclopropylamine. In: T. P. Singer, R. W. Von Korff, D. L. Murphy, eds. Monoamine Oxidase: Structure, Function and Altered Functions. London: Academic Press, pp. 39\u201350, 1979."},{"key":"3_CR280","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/S0021-9258(19)85793-9","volume":"255","author":"C Paech","year":"1980","unstructured":"C. Paech, J. I. Salach, T. P. Singer: Suicide inactivation of monoamine oxidase by trans-phenylcyclopropylamine. J Biol Chem 255: 2700\u20132704, 1980.","journal-title":"J Biol Chem"},{"key":"3_CR281","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1016\/0006-2952(82)90575-5","volume":"31","author":"CJ Fowler","year":"1982","unstructured":"C. J. Fowler, T. J. Mantle, K. F. Tipton: The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, 1-deprenyl and pargyline. Biochem Pharmacol 31: 3555\u20133561, 1982.","journal-title":"Biochem Pharmacol"},{"key":"3_CR282","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00427124","volume":"62","author":"S Lipper","year":"1979","unstructured":"S. Lipper, D. L. Murphy, S. Slater, M. S. Buchsbaum: Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology 62: 123\u2013128, 1979.","journal-title":"Psychopharmacology"},{"key":"3_CR283","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1476-5381.1981.tb16771.x","volume":"73","author":"A Kalir","year":"1981","unstructured":"A. Kalir, A. Sabbagh, M. B. H. Youdim: Selective acetylenic \u201csuicide\u201d and reversible inhibitors of monoamine oxidase type A and B. Br J Pharmacol 73: 55\u201364, 1981.","journal-title":"Br J Pharmacol"},{"key":"3_CR284","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1021\/bi00646a018","volume":"15","author":"AL Maycock","year":"1976","unstructured":"A. L. Maycock, R. H. Abeles, J. I. Salach, T. P. Singer: The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavin of mitochondrial amine oxidase. Biochemistry 15: 114\u2013125, 1976.","journal-title":"Biochemistry"},{"key":"3_CR285","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0026-895X(25)11390-4","volume":"16","author":"JI Salach","year":"1979","unstructured":"J. I. Salach, K. Detmer, M. B. H. Youdim: The reaction of bovine and rat liver monoamine oxidase with [l4C] clorgyline and [14C] deprenyl. Molec Pharmacol 16: 234\u2013241, 1979.","journal-title":"Molec Pharmacol"},{"key":"3_CR286","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00569406","volume":"311","author":"CJ Fowler","year":"1980","unstructured":"C. J. Fowler, L. Oreland, J. Marcusson, R. Winblad: Titration of human brain monoamine oxidase-A and -B by clorgyline and L-deprenyl. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 311: 263, 1980.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR287","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1016\/0006-2952(86)90765-3","volume":"35","author":"N Gomez","year":"1986","unstructured":"N. Gomez, M. Unzeta, K. F. Tipton, M. C. Anderson, A. M. O\u2019Carroll: Determination of monoamine oxidase concentrations in rat liver by inhibitor binding. Biochem Pharmacol 35: 4467\u20134472, 1986.","journal-title":"Biochem Pharmacol"},{"key":"3_CR288","first-page":"103","volume":"32","author":"D Balsa","year":"1990","unstructured":"D. Balsa, E. Fernandez-Alvarez, K. F. Tipton, M. Unzeta: Inhibition of MAO by substituted tryptamine analogues. J Neural Transm [Suppl] 32: 103\u2013105, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR289","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/0006-2952(90)90553-W","volume":"40","author":"MA Cruces","year":"1990","unstructured":"M. A. Cruces, C. Elorriaga, E. Fernandez-Alvarez: The kinetics of monoamine oxidase inhibition by three 2-indolylmethylamine derivatives. Biochem Pharmacol 40: 535\u2013543, 1990.","journal-title":"Biochem Pharmacol"},{"key":"3_CR290","first-page":"127","volume":"45","author":"MBH Youdim","year":"1986","unstructured":"M. B. H. Youdim, J. P. M. Finberg: MAO type B inhibitors as adjunct to L-DOPA therapy. Adv Neurol 45: 127\u2013136, 1986.","journal-title":"Adv Neurol"},{"key":"3_CR291","first-page":"31","volume-title":"Monoamine Oxidase Inhibitors-The State of the Art","author":"JPM Finberg","year":"1981","unstructured":"J. P. M. Finberg, M. Tenne, M. B. H. Youdim: Selective irreversible pro-pargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: M. B. H. Youdim, E. S. Paykel, eds. Monoamine Oxidase Inhibitors-The State of the Art. Chichester: Wiley, pp. 31\u201344, 1981."},{"key":"3_CR292","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1476-5381.1981.tb16772.x","volume":"73","author":"JPM Finberg","year":"1981","unstructured":"J. P. M. Finberg, M. Tenne, M. B. H. Youdim: Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 73: 65\u201374, 1981.","journal-title":"Br J Pharmacol"},{"key":"3_CR293","first-page":"505","volume":"53","author":"WE Haefely","year":"1990","unstructured":"W. E. Haefely, R. Kettler, H. H. Keller, M. Da Prada: Ro 19\u20136327, a reversible and highly selective monoamine oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. Adv Neurol 53: 505\u2013512, 1990.","journal-title":"Adv Neurol"},{"key":"3_CR294","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/BF00402391","volume":"18","author":"MH Lader","year":"1970","unstructured":"M. H. Lader, G. Sakalis, M. Tansella: Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor. Psychopharmacology 18: 118\u2013123, 1970.","journal-title":"Psychopharmacology"},{"key":"3_CR295","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0022-3565(25)23665-5","volume":"248","author":"M Prada Da","year":"1989","unstructured":"M. Da Prada, R. Kettler, H. H. Keller, W. P. Burkard, D. Muggli-Maniglio, W. E. Haefely: Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharma Exp Ther 248: 400\u2013414, 1989.","journal-title":"J Pharma Exp Ther"},{"key":"3_CR296","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1471-4159.1979.tb04508.x","volume":"32","author":"IC Campbell","year":"1979","unstructured":"I. C. Campbell, D. S. Robinson, W. Lovenberg, D. L. Murphy: The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem 32: 49\u201355, 1979.","journal-title":"J Neurochem"},{"key":"3_CR297","first-page":"87","volume-title":"Monoamine Oxidase Inhibitors \u2014 The State of the Art","author":"PC Waldmeier","year":"1981","unstructured":"P. C. Waldmeier, A. E. Feiner, L. Ma\u00eetre: Long-term effects of selective MAO inhibitors on MAO activity and amine metabolism. In: M. B. H. Youdim, E. S. Paykel, eds. Monoamine Oxidase Inhibitors \u2014 The State of the Art. Chichester: Wiley, pp. 87\u2013102, 1981."},{"key":"3_CR298","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF00512062","volume":"328","author":"FJE Stefano","year":"1984","unstructured":"F. J. E. Stefano, U. Trendelenburg: Saturation of monoamine oxidase by intraneuronal noradrenaline accumulation. Naunyn Schmiedeberg\u2019s Arch Pharmacol 328: 135\u2013141, 1984.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR299","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/0006-2952(89)90318-3","volume":"38","author":"NT Buu","year":"1989","unstructured":"N.T. Buu: Modification of vesicular dopamine and norepinephrine by monoamine oxidase inhibitors. Biochem Pharmacol 38: 1685\u20131892, 1989.","journal-title":"Biochem Pharmacol"},{"key":"3_CR300","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0006-8993(91)90371-2","volume":"538","author":"JD Newman","year":"1990","unstructured":"J. D. Newman, J. T. Winslow, D. L. Murphy: Modulation of vocal and nonvocal behavior in adult squirrel monkeys by selective MAO-A and MAO-B inhibition. Brain Res 538: 24\u201328, 1990.","journal-title":"Brain Res"},{"key":"3_CR301","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0091-3057(91)90033-X","volume":"38","author":"M Cox","year":"1991","unstructured":"M. Cox, N. Garrick, M. Reite, M. Gennaro: Minipump clorgyline administration and CSF amine metabolites in unrestrained monkeys. Pharmacol Biochem Behav 38: 677\u2013679, 1991.","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR302","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0014-2999(91)90422-M","volume":"196","author":"EC Twist","year":"1991","unstructured":"E. C. Twist, S. N. Mitchell, T. H. Corn, I. C. Campbell: Effects of chronic ritanserin or clrogyline on amine and metabolite levels in rat frontal cortex. Eur J Pharmacol 196: 157\u2013160, 1991.","journal-title":"Eur J Pharmacol"},{"key":"3_CR303","first-page":"247","volume":"39","author":"L Ma\u00eetre","year":"1976","unstructured":"L. Ma\u00eetre, A. Delini-Stula, P. C. Waldmeier: Relations between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors in rats. Ciba Found Symp 39: 247\u2013270, 1976.","journal-title":"Ciba Found Symp"},{"key":"3_CR304","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1476-5381.1984.tb16228.x","volume":"83","author":"LG H\u00e5rsing Jr","year":"1984","unstructured":"L. G. Jr. H\u00e5rsing, E. S. Vizi: Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (\u2014)-deprenyl. Br J Pharmacol 83: 741\u2013749, 1984.","journal-title":"Br J Pharmacol"},{"key":"3_CR305","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1523\/JNEUROSCI.04-04-00966.1984","volume":"4","author":"A Imperato","year":"1984","unstructured":"A. Imperato, G. Di Chiara: Trans-striatal dialysis coupled to reverse phase high pressure liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J Neurosci 4: 966\u2013977, 1984.","journal-title":"J Neurosci"},{"key":"3_CR306","first-page":"116","volume":"11","author":"G Chiara","year":"1990","unstructured":"G. Di Chiara: In vivo brain dialysis of neurotransmitters. TIPS 11: 116\u2013121, 1990.","journal-title":"TIPS"},{"key":"3_CR307","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1471-4159.1990.tb04587.x","volume":"55","author":"SP Butcher","year":"1990","unstructured":"S. P. Butcher, I. S. Fairbrother, J. S. Kelly, G. W. Arbuthnott: Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981\u2013988, 1990.","journal-title":"J Neurochem"},{"key":"3_CR308","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0028-3908(79)90152-7","volume":"18","author":"P Lerner","year":"1979","unstructured":"P. Lerner, L. F. Major, D. L. Murphy, S. Upper, C. R. Lake, W. Lovenberg: Dopamine-\u03b2-hydroxylase and norepinephrine in human cerebrospinal fluid: effects of monoamine oxidase inhibitors. Neuropharmacology 18: 423\u2013426, 1979.","journal-title":"Neuropharmacology"},{"key":"3_CR309","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/0028-3908(80)90087-8","volume":"19","author":"P Lerner","year":"1980","unstructured":"P. Lerner, L. F. Major, P. S. Dendel, I. C. Campbell, D. L. Murphy: Central and peripheral dopamine beta-hydroxylase: responses to long term-treatment with monoamine oxidase inhibitors. Neuropharmacology 19: 877\u2013881, 1980.","journal-title":"Neuropharmacology"},{"key":"3_CR310","doi-asserted-by":"publisher","first-page":"7522","DOI":"10.1073\/pnas.87.19.7522","volume":"87","author":"EJ Nestler","year":"1990","unstructured":"E. J. Nestler, A. McMahon, E. L. Sabban, J. F. Tallman, R. S. Duman: Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci USA 87: 7522\u20137526, 1990.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR311","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1523\/JNEUROSCI.02-11-01588.1982","volume":"2","author":"RM Cohen","year":"1982","unstructured":"R. M. Cohen, R. P. Ebstein, J. W. Daly, D. L. Murphy: Chronic effects of monoamine oxidase-inhibiting antidepressant: decreases in functional alpha-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3\u2032, 5\u2032-monophosphate systems in rat brain. J Neurosci 2: 1588\u20131595, 1982.","journal-title":"J Neurosci"},{"key":"3_CR312","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0028-3908(82)90091-0","volume":"21","author":"RM Cohen","year":"1982","unstructured":"R. M. Cohen, I. C. Campbell, M. Dauphin, J. F. Tallmann, D. L. Murphy: Changes in \u03b1- and \u03b2-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants. Neuropharmacology 21: 293\u2013298, 1982.","journal-title":"Neuropharmacology"},{"key":"3_CR313","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1016\/0006-2952(87)90002-5","volume":"36","author":"JPM Finberg","year":"1987","unstructured":"J. P. M. Finberg: Antidepressant drugs and down-regulation of presynaptic receptors. Biochem Pharmacol 36: 3557\u20133562, 1987.","journal-title":"Biochem Pharmacol"},{"key":"3_CR314","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0014-2999(87)90342-6","volume":"138","author":"JPM Finberg","year":"1987","unstructured":"J. P. M. Finberg, I. J. Kopin: Chronic Clonidine treatment produces desensitisation of post- but not presynaptic \u03b1 2-adrenoceptors. Eur J Pharmacol. 138: 95\u2013100, 1987.","journal-title":"Eur J Pharmacol"},{"key":"3_CR315","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00428420","volume":"85","author":"RJ Ross","year":"1985","unstructured":"R.J. Ross, M. Scheinin, P. Lesieur, M. V. Rudorfer, R. L. Hauger, L. J. Siever, M. Linnoila, W. Z. Potter: The effect of clorgyline on noradrenergic function. Psychopharmacology 85: 227\u2013230, 1985.","journal-title":"Psychopharmacology"},{"key":"3_CR316","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0165-1781(82)90019-1","volume":"6","author":"LJ Siever","year":"1981","unstructured":"L.J. Siever, T. W. Uhde, D. L. Murphy: Possible subsensitization of alpha2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients. Psychiat Res 6: 293\u2013302, 1981.","journal-title":"Psychiat Res"},{"key":"3_CR317","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1476-5381.1983.tb11042.x","volume":"80","author":"CS Aulakh","year":"1983","unstructured":"C. S. Aulakh, R. M. Cohen, C. McLellan, D. L. Murphy: Correlation of changes in \u03b1 2-adrenoceptor number and locomotor responses to Clonidine following clorgyline discontinuation. Br J Pharmacol 80: 10\u201312, 1983.","journal-title":"Br J Pharmacol"},{"key":"3_CR318","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0022-3565(25)31948-8","volume":"212","author":"DD Savage","year":"1980","unstructured":"D. D. Savage, J. Mendels, A. Frazer: Monoamine oxidase inhibitors and serotonin uptake inhibitors: differential effects on [3H]serotonin binding sites in rat brain. J Pharmac Exp Ther 212: 259\u2013263, 1980.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR319","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/0028-3908(80)90102-1","volume":"19","author":"DD Savage","year":"1980","unstructured":"D. D. Savage, J. Mendels, A. Frazer: Decrease in [3H]-serotonin binding in rat brain produced by the repeated administration of either monoamine oxidase inhibitors or centrally acting serotonin agonists. Neuropharmacology 19: 1063\u20131070, 1980.","journal-title":"Neuropharmacology"},{"key":"3_CR320","first-page":"405","volume":"32","author":"JPM Finberg","year":"1990","unstructured":"J. P. M. Finberg, G. Ari, G. Lavian, D. Hovevey-Sion: Modification of alpha-2 presynaptic receptor activity and catecholamine release following chronic MAO inhibition. J Neural Transm [Suppl] 32: 405\u2013412, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR321","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/BF00504860","volume":"332","author":"JPM Finberg","year":"1986","unstructured":"J. P. M. Finberg, I. J. Kopin: Chronic clorgyline treatment enhances release of norepinephrine following sympathetic stimulation in the rat. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 332: 236\u2013242, 1986.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR322","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF00177753","volume":"336","author":"D Hovevey-Sion","year":"1987","unstructured":"D. Hovevey-Sion, J. P. M. Finberg: Chronic inhibition of monoamine oxidase reduces noradrenaline release in rat vas deferens and anococcygeus muscle. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 336: 70\u201376, 1987.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR323","first-page":"125","volume-title":"Progress in Catecholamine Research, Part A: Basis Aspects and Peripheral Mechanisms","author":"JPM Finberg","year":"1988","unstructured":"J. P. M. Finberg, D. Hovevey-Sion: Monoamine oxidase inhibitors and catecholamine release. In: Progress in Catecholamine Research, Part A: Basis Aspects and Peripheral Mechanisms. New York: Alan R. Liss, pp. 125\u2013129, 1988."},{"key":"3_CR324","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/0024-3205(90)90165-N","volume":"47","author":"Y Itzhak","year":"1990","unstructured":"Y. Itzhak, I. Stein: Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci 47: 1073\u20131081, 1990.","journal-title":"Life Sci"},{"key":"3_CR325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0026-895X(25)10975-9","volume":"39","author":"Y Itzhak","year":"1991","unstructured":"Y. Itzhak, D. Mash, S. H. Zhang, I. Stein: Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL\/6J mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites. Molec Pharmacol 39: 385\u2013393, 1991.","journal-title":"Molec Pharmacol"},{"key":"3_CR326","first-page":"121","volume-title":"Progress in Catecholamine Research, Part A: Basic Aspects and Peripheral Mechanisms","author":"PC Waldmeier","year":"1988","unstructured":"P. C. Waldmeier: MAO inhibition and its consequences for metabolism and function of endogenous substrates. In: Progress in Catecholamine Research, Part A: Basic Aspects and Peripheral Mechanisms. New York: Alan R. Liss, pp. 121\u2013124, 1988."},{"key":"3_CR327","first-page":"147","volume":"5","author":"A Delini-Stula","year":"1988","unstructured":"A. Delini-Stula, E. Radeke, P. C. Waldmeier: Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol Ser 5: 147\u2013158, 1988.","journal-title":"Psychopharmacol Ser"},{"key":"3_CR328","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0074-7742(08)60024-0","volume":"4","author":"A Pletscher","year":"1962","unstructured":"A. Pletscher, A. Brossi, K. F. Gey: Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol 4: 275\u2013305, 1962.","journal-title":"Int Rev Neurobiol"},{"key":"3_CR329","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1476-5381.1975.tb06946.x","volume":"55","author":"AR Green","year":"1975","unstructured":"A. R. Green, M. B. Youdim: Effect of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-HT concentration in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol 55: 415\u2013422, 1975.","journal-title":"Br J Pharmacol"},{"key":"3_CR330","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-4612-5010-4_11","volume-title":"Neuropsychopharmacology of the Trace Amines","author":"A Delini-Stula","year":"1985","unstructured":"A. Delini-Stula, E. Radeke: Behavioral and pharmacological characterisation of tryptamine-induced excitation syndrome in rats. In: A. A. Boulton, L. Ma\u00eetre, P. R. Bieck, P. Riederer, eds. Neuropsychopharmacology of the Trace Amines. Clifton: Humana, pp. 125\u2013140, 1985."},{"key":"3_CR331","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0091-3057(82)90447-6","volume":"16","author":"WB Mendelson","year":"1982","unstructured":"W. B. Mendelson, R. M. Cohen, I. C. Campbell, D. L. Murphy, C. Gillin, R. J. Wyatt: Lifetime monoamine oxidase inhibition and sleep. Pharmacol Biochem Beh 16: 429\u2013431, 1982.","journal-title":"Pharmacol Biochem Beh"},{"key":"3_CR332","first-page":"31","volume":"77","author":"JPM Finberg","year":"1982","unstructured":"J. P. M. Finberg, M. Tenne: Relationship between tyramine potentiation and selective inhibition of MAO types A and B in the rat vas deferens. Br J Pharmacol 77: 31, 1982.","journal-title":"Br J Pharmacol"},{"key":"3_CR333","first-page":"11","volume":"26","author":"JPM Finberg","year":"1988","unstructured":"J. P. M. Finberg, M. B. H. Youdim: Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J Neural Transm [Suppl] 26, 11\u201316, 1988.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR334","series-title":"J Neural Transm","volume-title":"The cheese effect and new reversible MAO-A inhibitors","year":"1988","unstructured":"M. B. H. Youdim, M. Da Prada, R. Amrein, eds. The cheese effect and new reversible MAO-A inhibitors. J Neural Transm [Suppl] 26, 1988."},{"key":"3_CR335","first-page":"449","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"BA Callingham","year":"1984","unstructured":"B. A. Callingham, W. J. McCarry: Pharmacological effects of MAO inhibitors on the anococcygeus muscle and perfused mesenteric arteries of the rat. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 449\u2013458, 1984."},{"key":"3_CR336","first-page":"31","volume":"26","author":"M Prada Da","year":"1988","unstructured":"M. Da Prada, G. Z\u00fcrcher, I. W\u00fctrich, W. E. Haefely: On Tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm [Suppl] 26: 31\u201356, 1988.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR337","first-page":"177","volume-title":"Noncatecholic Phenylethylamines, part 2","author":"F Karoum","year":"1980","unstructured":"F. Karoum, S. G. Potkin, D. L. Murphy, R. J. Wyatt: Quantitation and metabolism of phenylethylamine and tyramine\u2019s three isomers in humans. In: A. D. Mosnaim, M. E. Wolf, eds. Noncatecholic Phenylethylamines, part 2. New York: Marcel Dekker, pp. 177\u2013191, 1980."},{"key":"3_CR338","first-page":"1","volume":"26","author":"F Hasan","year":"1988","unstructured":"F. Hasan, J. M. McCrodden, N. P. Kennedy, K. F. Tipton: The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm [Suppl] 26: 1\u20139, 1988.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR339","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/B978-0-08-021536-5.50021-6","volume-title":"The Release of Catecholamines from Adrenergic Neurones","author":"U Trendelenberg","year":"1979","unstructured":"U. Trendelenberg: Release induced by phenylethylamines. In: D.N. Paton, ed. The Release of Catecholamines from Adrenergic Neurones. New York: Pergamon Press, pp. 333\u2013354, 1979."},{"key":"3_CR340","first-page":"261","volume":"24","author":"U Tredendelenberg","year":"1987","unstructured":"U. Tredendelenberg, A. Langeloh, H. B\u00f6nisch: Mechanism of indirectly acting sympathomimetic amines. Blood Vessels 24: 261\u2013270, 1987.","journal-title":"Blood Vessels"},{"key":"3_CR341","first-page":"323","volume":"41","author":"T Yakoyama","year":"1989","unstructured":"T. Yakoyama, T. Karube, N. Iwata: Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in vitro and in vivo in mouse brain. J Pharm Pharmacol 41: 323\u2013326, 1989.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR342","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1254\/jjp.55.121","volume":"55","author":"Y Kumagae","year":"1991","unstructured":"Y. Kumagae, Y. Matsui, N. Iwate: Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359. Jpn J Pharmacol 55: 121\u2013128, 1991.","journal-title":"Jpn J Pharmacol"},{"key":"3_CR343","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0304-3940(91)90547-7","volume":"126","author":"Y Matsui","year":"1991","unstructured":"Y. Matsui, Y. Kumagae: Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci Lett 126: 175\u2013178, 1991.","journal-title":"Neurosci Lett"},{"key":"3_CR344","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1471-4159.1981.tb01631.x","volume":"36","author":"HS Maker","year":"1981","unstructured":"H. S. Maker, C. Weiss, D. J. Silides, G. Cohen: Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36: 589\u2013593, 1981.","journal-title":"J Neurochem"},{"key":"3_CR345","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/j.1471-4159.1990.tb02322.x","volume":"54","author":"G Damsma","year":"1990","unstructured":"G. Damsma, D. P. Boisvert, L. A. Mudrick, D. Wenkstern, H. C. Fibiger: Effects of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin, and their metabolites in the rat striatum as determined by in vivo microdialysis. J Neurochem 54: 801\u2013808, 1990.","journal-title":"J Neurochem"},{"key":"3_CR346","first-page":"477","volume-title":"Pharmacology of Cerebral Ischemia","author":"HP Lorez","year":"1990","unstructured":"H. P. Lorez, J. Haevey, L. Wright, S. Kollar, G. Blaszat, B. Thomas, J. R. Martin, R. Kettler, M. Da Prada: Moclobemide exhibits neuroprotective effects in hypoxic rat brain. In: J. Krieglstein, H. Oberpichler, eds. Pharmacology of Cerebral Ischemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, pp. 477\u2013484, 1990."},{"key":"3_CR347","first-page":"55","volume":"36","author":"GF Oxenkrug","year":"1984","unstructured":"G. F. Oxenkrug, R. McCauley, I. McIntyre, C. Filipowicz: Effect of clorgyline and deprenyl on rat pineal melatonin. J Pharm Pharmacol 36: 55 W, 1984.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR348","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF01251917","volume":"61","author":"GF Oxenkrug","year":"1985","unstructured":"G. F. Oxenkrug, I. McIntyre, R. McCauley, C. Filipowicz: Selective inhibition of MAO-A but not MAO-B activity increases rat pineal melatonin. J Neural Transm 61: 265\u2013270, 1985.","journal-title":"J Neural Transm"},{"key":"3_CR349","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-079X.1988.tb00772.x","volume":"5","author":"GF Oxenkrug","year":"1988","unstructured":"G. F. Oxenkrug, I. McIntyre, R. McCauley, A. Yuwiler: The effect of selective MAO inhibitors on rat pineal melatonin synthesis in viro. J Pineal Res 5: 99\u2013109, 1988.","journal-title":"J Pineal Res"},{"key":"3_CR350","first-page":"98","volume-title":"5-Hydroxytryptamine in Psychiatry: Spectrum of Ideas","author":"GF Oxenkrug","year":"1990","unstructured":"G. F. Oxenkrug: The acute effect of monoamine oxidase inhibitors on serotonin conversion to melatonin. In: M. Sandler, A. Coppen, S. Harnett, eds. 5-Hydroxytryptamine in Psychiatry: Spectrum of Ideas. Oxford: University Press, pp. 98\u2013109, 1990."},{"key":"3_CR351","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF01260919","volume":"66","author":"GF Oxenkrug","year":"1986","unstructured":"G. F. Oxenkrug, R. B. McCauley, D. J. Fontana, I. M. McIntyre, R. L. Commissaris: Possible melatonin involvement in the hypotensive effect of MAO inhibitors. J Neural Transm 66: 271\u2013280, 1986.","journal-title":"J Neural Transm"},{"key":"3_CR352","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/0028-3908(81)90057-5","volume":"20","author":"PE Keane","year":"1981","unstructured":"P. E. Keane, J. Menager, M. Strolin Benedetti: The effect of monoamine oxidase A and B inhibitors on rat serum prolactin. Neuropharmacology 20: 1157\u20131162, 1981.","journal-title":"Neuropharmacology"},{"key":"3_CR353","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0014-2999(82)90099-1","volume":"81","author":"MA Ventura","year":"1982","unstructured":"M. A. Ventura: Effects of clorgyline and deprenil on corticosterone levels in rats. Eur J Pharmacol 81: 349\u2013355, 1982.","journal-title":"Eur J Pharmacol"},{"key":"3_CR354","first-page":"154","volume":"155","author":"J Knoll","year":"1965","unstructured":"J. Knoll, Z. Ecsery, K. Kelemen, J. Nievel, B. Knoll: Phenylisopropylmethyl-propinylamine (E-250), a new psychic energizer. Arch Int Pharmacodyn Ther 155: 154\u2013164, 1965.","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"3_CR355","first-page":"359","volume-title":"Progress in Catecholamine Research, Part B: Central Aspects","author":"M Prada Da","year":"1988","unstructured":"M. Da Prada, R. Kettler, H. H. Keller, W. P. Burkard: Ro 19\u20136327, a reversible highly selective inhibitor of type B monoamine oxidase, completely devoid of tyramine-potentiating effects: comparison with selegiline. In: Progress in Catecholamine Research, Part B: Central Aspects. New York: Alan R. Liss, pp. 359\u2013363, 1988."},{"key":"3_CR356","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/0006-2952(78)90525-7","volume":"27","author":"PC Waldmeier","year":"1978","unstructured":"P. C. Waldmeier, A. E. Feiner: Deprenyl: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 27: 801\u2013802, 1978.","journal-title":"Biochem Pharmacol"},{"key":"3_CR357","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0014-2999(75)90238-1","volume":"34","author":"C Braestrup","year":"1975","unstructured":"C. Braestrup, H. Andersen. A. Randrup: The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34: 181\u2013187, 1975.","journal-title":"Eur J Pharmacol"},{"key":"3_CR358","first-page":"211","volume":"31","author":"G Zsilla","year":"1982","unstructured":"G. Zsilla, J. Knoll: The action of (\u2014)deprenyl on monoamine turnover rate in rat brain. Adv Biochem Psychopharm 31: 211\u2013217, 1982.","journal-title":"Adv Biochem Psychopharm"},{"key":"3_CR359","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.2042-7158.1986.tb04468.x","volume":"38","author":"G Zsilla","year":"1986","unstructured":"G. Zsilla, P. F\u00f6ldi, G. Held, A. M. Szekely, J. Knoll: The effect of repeated doses of (\u2014)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol J Pharmacol Pharm 38: 57\u201367, 1986.","journal-title":"Pol J Pharmacol Pharm"},{"key":"3_CR360","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF01244706","volume":"85","author":"DE Dluzen","year":"1991","unstructured":"D. E. Dluzen, J. L. McDermott: The effect of long-term treatment with deprenyl on basal and L-DOPA evoked dopamine release in vitro from the corpus striatum of aged rats. J Neural Transm [Gen Sect] 85: 145\u2013156, 1991.","journal-title":"J Neural Transm [Gen Sect]"},{"key":"3_CR361","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF01249097","volume":"60","author":"J Lauber","year":"1984","unstructured":"J. Lauber, P. C. Waldmeier: Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS. J Neural Transm 60: 247\u2013264, 1984.","journal-title":"J Neural Transm"},{"key":"3_CR362","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/BF00432018","volume":"84","author":"R Ortmann","year":"1985","unstructured":"R. Ortmann, M. Schaub, A. Feiner, J. Lauber, P. Christen, P. C. Waldmeier: Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors. Psychopharmacology 84: 22\u201327, 1985.","journal-title":"Psychopharmacology"},{"key":"3_CR363","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4612-5010-4_6","volume-title":"Neuropsychopharmacology of the Trace Amines","author":"R Ortmann","year":"1985","unstructured":"R. Ortmann, M. Schaub, P. C. Waldmeier: Effect of psychoactive drugs on behavior induced by 2-phenylethylamine in rats. In: A.A. Boulton, L. Ma\u00eetre, P. R. Bieck, P. Riederer, eds. Neuropsychopharmacology of the Trace Amines. Clifton: Humana, pp. 63\u201374, 1985."},{"key":"3_CR364","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/BF01244780","volume":"74","author":"S Turkish","year":"1988","unstructured":"S. Turkish, P. H. Yu, A. J. Greenshaw: Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects. J Neural Transm 74: 141\u2013148, 1988.","journal-title":"J Neural Transm"},{"key":"3_CR365","first-page":"45","volume":"25","author":"J Knoll","year":"1987","unstructured":"J. Knoll: R-(\u2014)-Deprenyl (Selegiline, MoverganR) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm [Suppl] 25: 45\u201366, 1987.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR366","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1600-0404.1989.tb01787.x","volume":"126","author":"J Knoll","year":"1989","unstructured":"J. Knoll: The pharmacology of selegiline ((-)deprenyl). New Aspects. Acta Neurol Scand 126: 83\u201391, 1989.","journal-title":"Acta Neurol Scand"},{"key":"3_CR367","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2165\/00002512-199101030-00006","volume":"1","author":"P Chrisp","year":"1991","unstructured":"P. Chrisp, G. J. Mammen, E. M. Sorkin: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson\u2019s disease. Drugs & Aging 1: 228\u2013248, 1991.","journal-title":"Drugs & Aging"},{"key":"3_CR368","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/ana.410260518","volume":"26","author":"G Cohen","year":"1989","unstructured":"G. Cohen, M. B. Spina: Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 26: 689\u2013690, 1989.","journal-title":"Ann Neurol"},{"key":"3_CR369","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0024-3205(91)90466-O","volume":"48","author":"M-C Carrillo","year":"1991","unstructured":"M.-C. Carrillo, S. Knai, M. Nokubo, K. Kitani: (\u2014)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517\u2013521, 1991.","journal-title":"Life Sci"},{"key":"3_CR370","first-page":"67","volume":"55","author":"J Knoll","year":"1988","unstructured":"J. Knoll: Extension of life span of rats by long-term (\u2014)deprenyl treatment. Mount Sinai J Med 55: 67\u201374, 1988.","journal-title":"Mount Sinai J Med"},{"key":"3_CR371","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0047-6374(88)90128-5","volume":"46","author":"J Knoll","year":"1988","unstructured":"J. Knoll: The striatal dopamine dependency of life span in male rats. Longevity study with (\u2014)deprenyl. Mechanisms of Ageing and Development 46: 237\u2013262, 1988.","journal-title":"Mechanisms of Ageing and Development"},{"key":"3_CR372","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0024-3205(90)90299-7","volume":"47","author":"NW Milgram","year":"1990","unstructured":"N. W. Milgram, R. J. Racine, P. Nellis, A. Mendonca, G. O. Ivy: Maintenance on L-deprenyl prolongs life in aged male rats. Life Sci 47: 415\u2013420, 1990.","journal-title":"Life Sci"},{"key":"3_CR373","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0014-2999(84)90700-3","volume":"106","author":"G Cohen","year":"1984","unstructured":"G. Cohen. P. Pasik, B. Cohen, A. Leist, C. Mytilineou, M. D. Yahr: Pargyline and deprenyl prevent the neurotoxicity of methyl-4-phenyl-1\u20132,3,6-tetrahydro-pyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209\u2013210, 1984.","journal-title":"Eur J Pharmacol"},{"key":"3_CR374","first-page":"58","volume":"40","author":"WC Koller","year":"1990","unstructured":"W. C. Koller, L. T. Giron: Selegiline HCl: selective MAO type B inhibitor. Neurology (Suppl) 40: 58\u201360, 1990.","journal-title":"Neurology (Suppl)"},{"key":"3_CR375","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0014-2999(90)90672-S","volume":"184","author":"KT Finnegan","year":"1990","unstructured":"K. T. Finnegan, J. J. Skratt, I. Irwin, L. E. DeLanney, J. W. Langston: Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol 184: 119\u2013126, 1990.","journal-title":"Eur J Pharmacol"},{"key":"3_CR376","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/BF01946641","volume":"40","author":"M Prada Da","year":"1984","unstructured":"M. Da Prada, H. H. Keller, L. Pieri, R. Kettler, W. E. Haefely: The pharmacology of Parkinson\u2019s disease: basic aspects and recent advances. Experientia 40: 1165\u20131172, 1984.","journal-title":"Experientia"},{"key":"3_CR377","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2125.1978.tb00883.x","volume":"6","author":"GP Reynolds","year":"1978","unstructured":"G. P. Reynolds, J. D. Elsworth K. Blau, M. Sandler, A. J. Lees, G. M. Stern: Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542\u2013544, 1978.","journal-title":"Br J Clin Pharmacol"},{"key":"3_CR378","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF01246964","volume":"43","author":"GP Reynolds","year":"1978","unstructured":"G. P. Reynolds, P. Riederer, M. Sandler, K. Jellinger, D. Seemann: Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (\u2014)deprenyl administration. J Neural Transm 43: 271\u2013277, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR379","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/0006-2952(78)90490-2","volume":"27","author":"LL Simpson","year":"1978","unstructured":"L. L. Simpson: Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine. Biochem Pharmacol 27: 1591\u20131595, 1978.","journal-title":"Biochem Pharmacol"},{"key":"3_CR380","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1212\/WNL.32.5.503","volume":"32","author":"F Karoum","year":"1982","unstructured":"F. Karoum, L. W. Chuang, T. Eisler, D. B. Calne, M. R. Liebowitz, M. D. Quitkin, D. F. Klein, R. J. Wyatt: Metabolism of (-)deprenyl to amphetamine and metamphetamine may BEresponsible for deprenyl\u2019s therapeutic benefit: a biochemical study. Neurology 32: 503\u2013509, 1982.","journal-title":"Neurology"},{"key":"3_CR381","first-page":"55","volume-title":"Parkinson-Syndrom: Kombinations- und Begleit-Therapien","author":"M Prada Da","year":"1980","unstructured":"M. Da Prada, R. Kettler, H. H. Keller, M. Pierl: Einflu\u00df von L-Deprenyl und Ergotderivaten auf das monoaminerge System der Ratte. In: P.-A Fischer, ed. Parkinson-Syndrom: Kombinations- und Begleit-Therapien. Stuttgart: Schattauer Verlag, pp. 55\u201373, 1980."},{"key":"3_CR382","first-page":"118","volume":"Ther217","author":"M. Pieri","year":"1975","unstructured":"M. Pieri, L. Pieri, A. Saner, M. Da Prada, W. Haefely: A comparison of drug-induced rotation in rats lesioned in the medial forebrain bundle with 5, 6-dihydroxytryptamine or 6-hydroxydopamine. Archs Int Pharmacodyn Ther217: 118\u2013130, 1975.","journal-title":"Archs Int Pharmacodyn"},{"key":"3_CR383","first-page":"257","volume":"3","author":"U Ungerstedt","year":"1973","unstructured":"U. Ungerstedt, A. Avemo, E. Avemo. T. Ljungberg, C. Ranje: Animal model of Parkinsonism. Adv Neurol 3: 257\u2013271, 1973.","journal-title":"Adv Neurol"},{"key":"3_CR384","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/0006-8993(81)90427-3","volume":"230","author":"JM Rabey","year":"1981","unstructured":"J. M. Rabey, P. Passettiner, A. Bystritsky, J.Engel, M.Goldstein: The regulation of striatal DOPA synthesis by \u03b1 2-adrenoceptors. Brain Res 230: 422\u2013426, 1981.","journal-title":"Brain Res"},{"key":"3_CR385","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/BF00426641","volume":"59","author":"W Kostiniwski","year":"1978","unstructured":"W. Kostiniwski, M. Jerlicz, A. B. Bidzinsky, M. Hauptmann: Evidence for existence of two opposite noradrenergic brain system controlling behaviour. Psychopharmacology 59: 311\u2013312, 1978.","journal-title":"Psychopharmacology"},{"key":"3_CR386","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1016\/0006-2952(80)90009-X","volume":"29","author":"JCK Lai","year":"1980","unstructured":"J. C. K. Lai, T. K. C. Leung, J. F. Guest, L. Lim, A. N. Davison: The monoamine oxidase inhibitors clorgyline and L-deprenyl also effect the uptake of dopamine, noradrenaline and 5-hydroxitryptamine by rat brain synaptosomal preparations. Biochem Pharmacol 29: 2763\u20132770, 1980.","journal-title":"Biochem Pharmacol"},{"key":"3_CR387","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0014-2999(89)90418-4","volume":"163","author":"HL Wiener","year":"1989","unstructured":"H. L. Wiener, A. Hashim, A. Lajtha, H. Sershen: Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 163: 191\u2013194, 1989.","journal-title":"Eur J Pharmacol"},{"key":"3_CR388","first-page":"297","volume":"31","author":"LG H\u00e5rsing","year":"1979","unstructured":"L. G. Jr. H\u00e5rsing, K. Magyar, K. Tekes, E. S. Vizi, J. Knoll: Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition. Pol J Pharmacol Pharm 31: 297\u2013307, 1979.","journal-title":"Pol J Pharmacol Pharm"},{"key":"3_CR389","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0166-2236(79)90044-4","volume":"2","author":"J Knoll","year":"1979","unstructured":"J. Knoll: (\u2014)Deprenyl: the MAO inhibitor without the cheese effect. Trends Neurosci 2: 111\u2013113, 1979.","journal-title":"Trends Neurosci"},{"key":"3_CR390","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/BF00426954","volume":"57","author":"JD Elsworth","year":"1978","unstructured":"J. D. Elsworth, V. Glover, G. P. Reynolds, M. Sandler, A. J. Lees, P. Phua-pradit, K. M. Shaw, G. M. Stern, P. Kumar: Deprenyl administration in man: a selective monoamine oxidase inhibitor without the cheese effect. Psychopharmacology 57: 33\u201338, 1978.","journal-title":"Psychopharmacology"},{"key":"3_CR391","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00634237","volume":"331","author":"JR Fozard","year":"1985","unstructured":"J. R. Fozard, M. Zreika, M. Robin, M. G. Palfreyman: The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72, 145. Naunyn Schmiedeberg\u2019s Arch Pharmacol 331: 186\u2013193, 1985.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR392","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1476-5381.1983.tb11059.x","volume":"80","author":"V Glover","year":"1983","unstructured":"V. Glover, C. J. Pycock, M. Sandler: Tyramine-induced noradrenaline release from rat brain slices: prevention by (\u2014)deprenyl. Br J Pharmacol 80: 141\u2013148, 1983.","journal-title":"Br J Pharmacol"},{"key":"3_CR393","first-page":"45","volume-title":"Monoamine Oxidase Inhibitors \u2014 The State of the Art","author":"J Knoll","year":"1981","unstructured":"J. Knoll: The pharmacology of selective MAO inhibitors. In: M. B. H. Youdim, E. S. Paykel, eds. Monoamine Oxidase Inhibitors \u2014 The State of the Art. New York: Wiley, pp. 45\u201361, 1981."},{"key":"3_CR394","first-page":"253","volume-title":"Enzyme Activated Irreversible Inhibitors","author":"J Knoll","year":"1978","unstructured":"J. Knoll: The pharmacology of selective irreversible monoamine oxidase inhibitors. In: N. Seiler, M.J. Jung, J. Koch-Weser, eds. Enzyme Activated Irreversible Inhibitors. Amsterdam: Elsevier North-Holland, pp. 253\u2013269, 1978."},{"key":"3_CR395","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000407510","volume":"19","author":"J Knoll","year":"1983","unstructured":"J. Knoll, T. T. Yen, J. Dallo: Long-lasting, true aphrodisiac effect of (\u2014)deprenyl in sluggish old male rats. Mod Probl Pharmacopsychiat 19: 135\u2013153, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"issue":"126","key":"3_CR396","first-page":"93","volume":"80","author":"EH Heinonen","year":"1989","unstructured":"E. H. Heinonen, V. Vyllyla, K. Sotaniemi, R. Lammintausta, J. S. Salonen et al.: Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 80[Suppl 126]: 93\u201399, 1989.","journal-title":"Acta Neurol Scand"},{"key":"3_CR397","first-page":"131","volume":"32","author":"HO Borbe","year":"1990","unstructured":"H. O. Borbe, G. Niebch, B. Nickel: Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethyl-selegiline in the rat. J Neural Transm[Suppl] 32: 131\u2013137, 1990.","journal-title":"J Neural Transm[Suppl]"},{"key":"3_CR398","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/jat\/14.5.330","volume":"14","author":"JE Meeker","year":"1990","unstructured":"J. E. Meeker, P. C. Reynolds: Postmortem tissue methamphetamine concentrations following selegiline administration. J Anal Toxicol 14: 330\u2013331, 1990.","journal-title":"J Anal Toxicol"},{"key":"3_CR399","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.2042-7158.1984.tb04401.x","volume":"36","author":"K Magyar","year":"1984","unstructured":"K. Magyar, L. Tothfalusi: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm 36: 373\u2013384, 1984.","journal-title":"Pol J Pharmacol Pharm"},{"key":"3_CR400","doi-asserted-by":"crossref","first-page":"14648","DOI":"10.1016\/S0021-9258(17)38619-2","volume":"260","author":"RB Silverman","year":"1985","unstructured":"R. B. Silverman, C. K. Hiebert, M. L. Vazquez: Inactivation of monoamine oxidase by allylamine does not result in flavin attachment. J Biol Chem 260: 14648\u201314652, 1985.","journal-title":"J Biol Chem"},{"key":"3_CR401","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/0006-2952(86)90538-1","volume":"35","author":"IA McDonald","year":"1986","unstructured":"I. A. McDonald, M. G. Palfreyman, M. Zreika, P. Bey: (Z)-2-(2, 4-Dichlorophenoxy)methyl-3-fluoroallylamine (MDL 72, 638): a clorgyline analogue with surprising selectivity for monoamine oxidase type B. Biochem Pharmacol 35: 349\u2013351, 1986.","journal-title":"Biochem Pharmacol"},{"key":"3_CR402","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1021\/jm00367a002","volume":"27","author":"P Bey","year":"1984","unstructured":"P. Bey, J. Fozard, J. M. Lacoste, I. A. McDonald, M. Zreika, M. G. Palfreyman: (E)-2-(3,4-Dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase. J Med Chem 27: 9\u201310, 1984.","journal-title":"J Med Chem"},{"key":"3_CR403","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1471-4159.1984.tb00920.x","volume":"43","author":"M Zreika","year":"1984","unstructured":"M. Zreika, I. A. McDonald, P. Bey, M. G. Palfreyman: MDL 72, 145, an enzyme-activated irreversible inhibitor with selectivity for monoamine oxidase type B. J Neurochem 43: 448\u2013454, 1984.","journal-title":"J Neurochem"},{"key":"3_CR404","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1476-5381.1986.tb10179.x","volume":"87","author":"JR Fozard","year":"1986","unstructured":"J. R. Fozard, M. G. Palfreyman, M. Robin, M. Zreika: Selective inhibition of monoamine oxidase type B by MDL 72145 increases the central effects of L-DOPA without modifying its cardiovascular effects. Br J Pharmacol 87: 257\u2013264, 1986.","journal-title":"Br J Pharmacol"},{"key":"3_CR405","first-page":"563","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"MG Palfreyman","year":"1984","unstructured":"M. G. Palfreyman, M. Zreika, I. McDonald, J. Fozard, P. Bey: MDL 72, 145, an irreversible inhibitor of MAO-B. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 563\u2013564, 1984."},{"key":"3_CR406","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF02263478","volume":"1","author":"M Zreika","year":"1989","unstructured":"M. Zreika, J. R. Fozard, M. W. Dudley, P. Bey, I. A. McDonald, M. G. Palfreyman: MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson\u2019s disease. J Neural Transm [P-D Sect] 1: 243\u2013254, 1989.","journal-title":"J Neural Transm [P-D Sect]"},{"key":"3_CR407","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/j.1471-4159.1985.tb10543.x","volume":"45","author":"MG Palfreyman","year":"1985","unstructured":"M. G. Palfreyman, I. A. McDonald, J. R. Fozard, Y. Mely, A. J. Sleight, M. Zreika, J. Wagner, P. Bey, P. J. Lewis: Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-\u03b2-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase. J Neurochem 45: 1850\u20131860, 1985.","journal-title":"J Neurochem"},{"key":"3_CR408","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0014-2999(86)90185-8","volume":"130","author":"MG Palfreyman","year":"1986","unstructured":"M. G. Palfreyman, A. K. Mir, M. Kubina, D. N. Middlemiss, M. Richards, M. D. Tricklebank, J. R. Fozard: Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase. Eur J Pharmacol 130: 73\u201389, 1986.","journal-title":"Eur J Pharmacol"},{"key":"3_CR409","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/0006-291X(89)92466-2","volume":"160","author":"C Danzin","year":"1989","unstructured":"C. Danzin, J.-N. Collard, P. Marchai, D. Schirlin: Selective inactivation of MAO-B by benzyl-dimethyl-silyl-methanamines in vitro. Biochem. Bio-phys Res Commun 160: 540\u2013544, 1989.","journal-title":"Biochem. Bio-phys Res Commun"},{"key":"3_CR410","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/0045-2068(87)90028-9","volume":"15","author":"RB Silverman","year":"1987","unstructured":"R. B. Silverman, M. K. Vadnere: (Aminoalkyl)trimethylgermanes, the first organo-germanium mechanism-based inactivators: am new class of monoamine oxidase activators. Bioorg Chem 15: 328\u2013332, 1987.","journal-title":"Bioorg Chem"},{"key":"3_CR411","first-page":"1297","volume-title":"Psychopharmacology: The Third Generation of Progress","author":"DS Robinson","year":"1987","unstructured":"D. S. Robinson, N. M. Kurtz: Monoamine oxidase inhibiting drugs: pharmacologic and therapeutic issues. In: H. Y. Meltzer, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, pp. 1297\u20131304, 1987."},{"key":"3_CR412","first-page":"361","volume-title":"Enzymes","author":"M Dixon","year":"1979","unstructured":"M. Dixon, E. C. Webb: Enzymes, 3rd Ed., London: Longman, pp. 361\u2013368, 1979.","edition":"3"},{"key":"3_CR413","volume-title":"Understanding Enzymes","author":"T Palmer","year":"1981","unstructured":"T. Palmer: Understanding Enzymes. New York: Wiley, 1981."},{"key":"3_CR414","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF02246226","volume":"106","author":"AM Cesura","year":"1992","unstructured":"A. M. Cesura, R. Kettler, R. Imhof, M. Da Prada: Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology 106[Suppl]: 15\u201316, 1992.","journal-title":"Psychopharmacology"},{"key":"3_CR415","first-page":"165","volume":"32","author":"AM Cesura","year":"1990","unstructured":"A. M. Cesura, D. Muggli-Maniglio, G. Lang, R. Imhof, M. Da Prada: Monoamine oxidase inhibition by moclobemide and 2-aminoethyl-carboxamide derivatives: mode of action and kinetic characteristics. J Neural Transm [Suppl] 32: 165\u2013170, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR416","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0031-6989(88)80543-5","volume":"4","author":"M Prada Da","year":"1988","unstructured":"M. Da Prada, R. Kettler, A. M. Cesura, J. G. Richards: Reversible, enzyme-activated monoamine oxidase inhibitors: new advances. Pharmacol Res Comm 20 [Suppl] 4: 21\u201333, 1988.","journal-title":"Pharmacol Res Comm 20 [Suppl]"},{"key":"3_CR417","first-page":"337","volume":"63","author":"SW Williams","year":"1979","unstructured":"S. W. Williams, J. F. Morrison: The kinetic of reversible tight-binding inhibition. Meth Enzymol 63: 337\u2013467, 1979.","journal-title":"Meth Enzymol"},{"key":"3_CR418","first-page":"5","volume":"28","author":"M Prada Da","year":"1989","unstructured":"M. Da Prada, R. Kettler, H. H. Keller, W. P. Burkard, W. E. Haefely: Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm [Suppl] 28: 5\u201320, 1989.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR419","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0447.1990.tb05317.x","volume":"360","author":"M Prada Da","year":"1990","unstructured":"M. Da Prada, R. Kettler, W. P. Burkard, H. P. Lorez, W. Haefely: Some basic aspects of reversible inhibitors of monoamine oxidase-A. Acta Psy-chiatr Scand [Suppl] 360: 7\u201312, 1990.","journal-title":"Acta Psy-chiatr Scand [Suppl]"},{"key":"3_CR420","first-page":"183","volume-title":"Monoamine Oxidase: Basic and Clinical Frontiers","author":"M Prada Da","year":"1981","unstructured":"M. Da Prada, H. H. Keller, R. Kettler, R. Schaffner, M. Pieri, W. P. Burkard, A. Korn, W. E. Haefely: Ro 11\u20131163, a specific and short-acting MAO inhibitor with antidepressant properties. In: K. Kamijo, E. Usdin, T. Nagatsu, eds. Monoamine Oxidase: Basic and Clinical Frontiers. Amsterdam: Excerpta Medica, pp. 183\u2013196, 1981."},{"key":"3_CR421","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000407520","volume":"19","author":"M Prada Da","year":"1983","unstructured":"M. Da Prada, R. Kettler, H. H. Keller, W. E. Haefely: Neurochemical effects in vitro and in vivo of the antidepressant Ro 11\u20131163, a specific and short-acting MAO-A inhibitor. Mod Probl Pharmacopsychiat 19: 231\u2013245, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"3_CR422","first-page":"137","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"M Prada Da","year":"1984","unstructured":"M. Da Prada, R. Kettler, W. P. Burkard, W. E. Haefely: Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 137\u2013154, 1984."},{"issue":"6","key":"3_CR423","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000297493","volume":"155","author":"BA Callingham","year":"1989","unstructured":"B. A. Callingham: Biochemical aspects of the pharmacology of moclobemide. The implications of animal studies. Br J. Psychiatry 155 [Suppl] 6: 53\u201360, 1989.","journal-title":"Br J. Psychiatry"},{"key":"3_CR424","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1600-0447.1990.tb05348.x","volume":"360","author":"R Kettler","year":"1990","unstructured":"R. Kettler, M. Da Prada, W. P. Burkard: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand [Suppl] 360: 101\u2013102, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000407502","volume":"19","author":"PC Waldmeier","year":"1983","unstructured":"P. C. Waldmeier, P. A. Baumann, A. Delini-Stula, R. Bernasconi, K. Sigg, P. Buech, A. E. Feiner: Characterization of a new short-acting and specific inhibitor of type A monoamine oxidase. Mod Probl Pharmacopsychiat 19: 31\u201352, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"3_CR426","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF00501885","volume":"329","author":"PC Waldmeier","year":"1985","unstructured":"P. C. Waldmeier: On the reversibility of reversible MAO inhibitors. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 329: 305\u2013310, 1985.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"6","key":"3_CR427","first-page":"84","volume":"155","author":"WP Burkard","year":"1989","unstructured":"W. P. Burkard, M. Da Prada, H. H. Keller, R. Kettler, W. Haefely: Preclinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry 155 [Suppl 6]: 84\u201388, 1989.","journal-title":"Br J Psychiatry"},{"key":"3_CR428","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF00165029","volume":"335","author":"HH Keller","year":"1987","unstructured":"H. H. Keller, R. Kettler, G. Keller, M. Da Prada: Short-acting novel MAO-inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16\u20136491. Naunyn Schmiedeberg\u2019s Arch Pharmacol 335: 12\u201320, 1987.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR429","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1600-0447.1990.tb05351.x","volume":"360","author":"M-P Schoerlin","year":"1990","unstructured":"M.-P. Schoerlin, M. Da Prada: Species-specific biotransformation of moclobemide: a comparative study in rats and humans. Acta Psychiatr Scand [Suppl] 360: 108\u2013110, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR430","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF02246227","volume":"106","author":"A Colzi","year":"1992","unstructured":"A. Colzi, F. d\u2019Agostini, A. M. Cesura, M. Da Prada: Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant. Psychopharmacology 106 [Suppl]: 17\u201320, 1992.","journal-title":"Psychopharmacology"},{"key":"3_CR431","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0022-3565(25)23664-3","volume":"248","author":"WP Burkard","year":"1989","unstructured":"W. P. Burkard, E. P. Bonetti, M. Da Prada, J. R. Martin, P. Polc, R. Schaffner, R. Scherschlicht, F. Hefti, R. K. M. M\u00fcller, P.-C. Wyss, W. E. Haefely: Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmac Exp Ther 248: 391\u2013399, 1989.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR432","first-page":"689","volume-title":"Cognitive performance enhancing effects of the reversible MAO-inhibitor moclobemide in animals","author":"JR Martin","year":"1989","unstructured":"J. R. Martin, R. Schaffner, L. Rumennik, G. P. Vincent, J. Sepinwall, H.-P. Lorez, W. E. Haefely: Cognitive performance enhancing effects of the reversible MAO-inhibitor moclobemide in animals. In: R. J. Wurtman, S. Corkin, H. J. Growdon, E. Ritter-Walker, eds. Cambridge MA: Alzheimer\u2019s Disease (Center for Brain Sciences and Metabolism Charitable Trust), pp. 689\u2013694, 1989."},{"key":"3_CR433","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF02252919","volume":"2","author":"MS Benedetti","year":"1990","unstructured":"M. Strolin Benedetti, R. Kettler, P. Marrari, M. Cini, M. Da Prada, P. Dostert: The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain. J Neural Transm [P-D Sect] 2: 239\u2013248, 1990.","journal-title":"J Neural Transm [P-D Sect]"},{"key":"3_CR434","first-page":"171","volume":"32","author":"GF Oxenkrug","year":"1990","unstructured":"G. F. Oxenkrug, P. J. Requintina, A. Yuwiler: Does moclobemide stimulate melatonin synthesis as the other selective MAO-A inhibitors do? J Neural Transm [Suppl] 32: 171\u2013175, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR435","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0278-5846(88)90064-4","volume":"12","author":"PR Bieck","year":"1988","unstructured":"P. R. Bieck, K.-H. Antonin, R. Balon, G. F. Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Prog Neuro-Psychopharmacol Biol Psychiat 12: 93\u2013101, 1988.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"3_CR436","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0278-5846(90)90065-O","volume":"14","author":"M Scheinin","year":"1990","unstructured":"M. Scheinin, M. Koulu, O. Vakkuri, J. Vuorinen, H. Zimmer: Moclobemide, an inhibitor of MAO-A, does not increase daytime melatonin levels in normal humans. Prog Neuro-Psychopharmacol Biol Psychiatry 14: 73\u201382, 1990.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3_CR437","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1600-0447.1990.tb05350.x","volume":"360","author":"M Prada Da","year":"1990","unstructured":"M. Da Prada, W. P. Burkard: Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats. Acta Psychiatr Scand [Suppl] 360: 106\u2013107, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR438","first-page":"17","volume":"26","author":"BA Callingham","year":"1988","unstructured":"B. A. Callingham, R. S. Ovens: Some in vitro effects of moclobemide and other MAO inhibitors on responses to sympathomimetic amines. J Neural Transm [Suppl] 26: 17\u201329, 1988.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR439","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-3-642-46625-0_5","volume":"90","author":"H B\u00f6nisch","year":"1988","unstructured":"H. B\u00f6nisch, U. Trendelenburg: The mechanism of action of indirectly acting sympathomimetic amines. Handbook Experimental Pharmacol 90: 247\u2013277, 1988.","journal-title":"Handbook Experimental Pharmacol"},{"key":"3_CR440","first-page":"227","volume-title":"Design of Enzyme Inhibitors as Drugs","author":"IA McDonald","year":"1988","unstructured":"I. A. McDonald, P. Boy, M. G. Palfreyman: Monoamine oxidase inhibitors. In: M. Sandler, J. Smith, eds. Design of Enzyme Inhibitors as Drugs. Oxford: Oxford University Press, pp. 227\u2013244, 1988."},{"key":"3_CR441","first-page":"800","volume":"35","author":"B Schl\u00e4ppi","year":"1985","unstructured":"B. Schl\u00e4ppi: The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid. Arzneim-Forsch\/Drug Res 35: 800\u2013803, 1985.","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"3_CR442","first-page":"390","volume-title":"Biological Psychiatry","author":"EP Bonetti","year":"1991","unstructured":"E. P. Bonetti, R. Scherschlicht, M. Da Prada: Safety of the RIMA antidepressant moclobemide: minimal interactions with dietary tyramine and 5-HT uptake blockers. In: G. Racagni, M. Brunello, T. Fukuda eds. Biological Psychiatry. Amsterdam: Elsevier, pp. 390\u2013392, 1991."},{"key":"3_CR443","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/clpt.1987.169","volume":"42","author":"M-P Schoerlin","year":"1987","unstructured":"M.-P. Schoerlin, M. Mayersohn, A. Korn, H. Eggers: Disposition kinetics of moclobemide, a monoamine oxidase A enzyme inhibitor. Single and multiple dosing in normal subjects. Clin Pharmacol Ther 42: 395\u2013404, 1987.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR444","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0447.1990.tb05345.x","volume":"360","author":"TW Guentert","year":"1990","unstructured":"T. W. Guentert, G. Tucker, A. Korn, J. P. Pfefen, P. Haefelfinger, M. P. Schoerlin: Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr Scand [Suppl] 360: 91\u201393, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR445","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-0447.1990.tb05344.x","volume":"360","author":"R Jauch","year":"1990","unstructured":"R. Jauch, E. Griesser, G. Oesterhelt, W. Arnold, W. Meister, W. H. Ziegler, T. W. Guentert: Biotransformation of moclobemide in humans. Acta Psychiatr Scand [Suppl] 360: 87\u201390, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR446","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1600-0447.1990.tb05346.x","volume":"360","author":"K Stoeckel","year":"1990","unstructured":"K. Stoeckel, J. P. Pfefen, M. Mayersohn, M. P. Schoerlin, C. Andressen, E. E. Ohnhaus, F. Frey, T. W. Guentert: Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand [Suppl] 360: 94\u201397, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR447","first-page":"115","volume":"26","author":"M-P Schoerlin","year":"1988","unstructured":"M.-P. Schoerlin, M. Mayersohn, B. Hoevels, H. Eggers, M. Dellenbach, J.-P. Pfefen: Effect of food intake on the relative bioavailability of moclobemide (Ro 11\u20131163). J Neural Transm [Suppl] 26: 115\u2013121, 1988.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR448","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF02246232","volume":"106","author":"AFD Cole","year":"1992","unstructured":"A. F. D. Cole, J. G. Baxter, B. J. Jackson, P. Hew-Wing, T. W. Guentert, D. Lalka: Pharmacokinetic and metabolic aspects of the moclobemide-food interaction. Psychopharmacology 106 [Suppl]: 37\u201339, 1992.","journal-title":"Psychopharmacology"},{"key":"3_CR449","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1600-0447.1990.tb05347.x","volume":"360","author":"M-P Schoerlin","year":"1990","unstructured":"M.-P. Schoerlin, R. A. Blouin, J. P. Pfefen, T. W. Guentert: Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquine. Acta Psychiatr Scand [Suppl] 360: 98\u2013100, 1990.","journal-title":"Acta Psychiatr Scand [Suppl]"},{"key":"3_CR450","first-page":"11","volume":"16","author":"M-P Schoerlin","year":"1989","unstructured":"M.-P. Schoerlin, T. W. Guentert: Pharmacokinetic und Metabolismus reversibler MAO-A-Hemmer beim Menschen. Psychiat Prax 16: 11\u201317, 1989.","journal-title":"Psychiat Prax"},{"key":"3_CR451","first-page":"71","volume-title":"Biological Oxidation of Nitrogen","author":"H Oelschl\u00e4ger","year":"1978","unstructured":"H. Oelschl\u00e4ger, D. J. Temple: The role of N-oxidation in the metabolism of morpholine containing drugs. In: J. W. Gorrod, ed. Biological Oxidation of Nitrogen. Amsterdam: Elsevier North-Holland, pp. 71\u201382, 1978."},{"key":"3_CR452","first-page":"369","volume":"17","author":"RF Squires","year":"1968","unstructured":"R. F. Squires, J. B. Lassen: Some pharmacological and biochemical properties of \u03b3-morpholino-butyrophenone (NSD 2023), a new monoamine oxidase inhibitor. Biochem. Pharmacol 17: 369\u2013384, 1968.","journal-title":"Pharmacol"},{"issue":"4","key":"3_CR453","first-page":"51","volume":"29","author":"SO Olsson","year":"1971","unstructured":"S. O. Olsson, J. Schrold: A comparison of FG 5310, a new selective monoamine oxidase inhibitor, and other MAO inhibitors on the blood pressure response to tyramine. Acta Pharmacol Toxicol 29 [Suppl 4]: 51, 1971.","journal-title":"Acta Pharmacol Toxicol"},{"key":"3_CR454","volume-title":"Abstract 1997 P, IUPHAR 9th International Congress of Pharmacology, London, July 20-August 3","author":"E Morier","year":"1984","unstructured":"E. Morier, A. L. Helgonalch, M. Poisson, P. H. Huchez, R. Rips: Abstract 1997 P, IUPHAR 9th International Congress of Pharmacology, London, July 20-August 3, 1984."},{"key":"3_CR455","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1471-4159.1988.tb10584.x","volume":"50","author":"J-P Kan","year":"1988","unstructured":"J.-P. Kan, R. Steinberg, J. Leclerq, P. Worms, R. Bizi\u00e8re: Monoamine oxi-dase-inhibiting properties of SR 95191, a new pyrazidine derivative in the rat. Evidence for selective and reversible inhibition of monoamine oxidase type A in vivo but not in vitro. J Neurochem 50: 1137\u20131144, 1988.","journal-title":"J Neurochem"},{"key":"3_CR456","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0022-3565(25)22705-7","volume":"240","author":"JP Kan","year":"1987","unstructured":"J. P. Kan, R. Steinberg, C. Mouget-Goniot, P. Worms, K. Bizi\u00e8re: SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. Biochemical characterization of monoamine oxidase inhibition. J Pharmac Exp Ther 240: 251\u2013258, 1987.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR457","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0022-3565(25)22702-1","volume":"240","author":"P Worms","year":"1987","unstructured":"P. Worms, J. P. Kan, C. G. Wermuth, R. Roncucci, K. Bizi\u00e8re: SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. J Pharmac Exp Ther 240: 241\u2013250, 1987.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR458","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0022-3565(25)22979-2","volume":"255","author":"MH Fernandez","year":"1990","unstructured":"M. H. Fernandez, P. Soares-da-Silva: Effects of MAO-A and MAO-B selective inhibitors Ro 41\u20131049 and Ro 19\u201363427 on the deamination of newly formed dopamine in the rat kidney. J Pharmac Exp Ther 255: 1309\u20131313, 1990.","journal-title":"J Pharmac Exp Ther"},{"key":"3_CR459","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1471-4159.1987.tb13143.x","volume":"48","author":"AM Cesura","year":"1987","unstructured":"A. M. Cesura, M. D. Galva, R. Imhof and M. Da Prada: Binding of [3H]Ro 16\u20136491, a reversible inhibitor of monoamine oxidase type B, to human brain mitochondria and platelet membranes. J Neurochem 48: 170\u2013176, 1987.","journal-title":"J Neurochem"},{"issue":"IV","key":"3_CR460","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0031-6989(88)80547-2","volume":"20","author":"AM Cesura","year":"1988","unstructured":"A. M. Cesura, R. Imhof, M. D. Galva, R. Kettler, M. Da Prada: Interaction of the novel inhibitor of MAO-B Ro 19\u20136327 and Ro 16\u20136491 with the active site of the enzyme. Pharmacol Res Comm 20 [Suppl] IV: 51\u201361, 1988.","journal-title":"Pharmacol Res Comm"},{"key":"3_CR461","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/j.1471-4159.1988.tb10570.x","volume":"50","author":"AM Cesura","year":"1988","unstructured":"A. M. Cesura, R. Imhof, B. Takacs, M. D. Galva, G. B. Picotti, M. Da Prada: [3H]Ro 16\u20136491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes. J Neurochem 50: 1037\u20131043, 1988.","journal-title":"J Neurochem"},{"key":"3_CR462","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-3-7091-8994-8_25","volume-title":"Early Diagnosis and Preventive Therapy in Parkinson\u2019s Disease","author":"R Kettler","year":"1989","unstructured":"R. Kettler, M. Da Prada: Platelet MAO-B activity in humans and stump-tail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19\u20136327. In: H. Przuntek, P. Riederer, eds. Early Diagnosis and Preventive Therapy in Parkinson\u2019s Disease. Wien: Springer Verlag, pp. 213\u2013219, 1989."},{"key":"3_CR463","first-page":"211","volume":"32","author":"R Kettler","year":"1990","unstructured":"R. Kettler, A. M. Cesura, J. Dingemanse, M. Da Prada: MAO-B inhibition in rabbit tissues and in human platelets by Ro 19\u20136327 shows similar time course. J Neural Transm [Suppl] 32: 211\u2013214, 1990.","journal-title":"J Neural Transm [Suppl]"},{"key":"3_CR464","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1017\/S0317167100032492","volume":"18","author":"M Prada Da","year":"1991","unstructured":"M. Da Prada: New Approaches to the treatment of age-related brain disorders. Can J Neurol Sci 18: 384\u2013386, 1991.","journal-title":"Can J Neurol Sci"},{"key":"3_CR465","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF01418415","volume":"40","author":"CJ Bench","year":"1991","unstructured":"C. J. Bench, G. W. Price, A. A. Lammertsma, J. C. Cremer, S. K. Luthra, D. Turton, R. J. Dolan, R. Kettler, J. Dingemanse, M. Da Prada, M. Bizi\u00e8re, G. R. McClelland, V. L. Jamieson, N. B. Wood, R. S. J. Frackowiak: Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19\u20136327. Eur J Clin Pharmacol 40: 169\u2013173, 1991.","journal-title":"Eur J Clin Pharmacol"},{"key":"3_CR466","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0014-2999(83)90443-0","volume":"94","author":"PC Waldmeier","year":"1983","unstructured":"P. C. Waldmeier, A. E. Feiner, K. F. Tipton: The monoamine oxidase inhibiting properties of CGP 11305 A. Eur J Pharmacol 94: 73\u201383, 1983.","journal-title":"Eur J Pharmacol"},{"key":"3_CR467","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0014-2999(83)90446-6","volume":"94","author":"PC Waldmeier","year":"1983","unstructured":"P.C. Waldmeier, J.-J. Feldtrauer, K. Stoecklin, E. Paul: Reversibility of the interaction of CGP 11305 A with MAO-A in vivo. Eur J Pharmacol 94: 101\u2013108, 1983.","journal-title":"Eur J Pharmacol"},{"key":"3_CR468","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/0006-2952(91)90126-P","volume":"41","author":"MC Anderson","year":"1991","unstructured":"M. C. Anderson, P. C. Waldmeier, K. F. Tipton: The inhibition of monoamine oxidase by brofaromine. Biochem. Pharmacol 41: 1871\u20131877, 1991.","journal-title":"Biochem. Pharmacol"},{"key":"3_CR469","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0014-2999(90)90313-U","volume":"180","author":"PC Waldmeier","year":"1990","unstructured":"P. C. Waldmeier, K. St\u00f6cklin: Binding of [3H]brofaromine to monoamine oxidase A in vivo: displacement by clorgyline and moclobemide. Eur J Pharmacol 180: 297\u2013304, 1990.","journal-title":"Eur J Pharmacol"},{"key":"3_CR470","doi-asserted-by":"crossref","unstructured":"P. C. Waldmeier, P. A. Baumann: Effect of CGP 11305 A, a new reversible and selective inhibitor of MAO-A, o biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 324: 20\u201325.","DOI":"10.1007\/BF00647833"},{"key":"3_CR471","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0014-2999(89)90016-2","volume":"169","author":"PC Waldmaier","year":"1989","unstructured":"P. C. Waldmaier, K. St\u00f6cklin: The reversible MAO inhibitor brofaromine, inhibits serotonin uptake in vivo. Eur J Pharmacol 169: 197\u2013204, 1989.","journal-title":"Eur J Pharmacol"},{"key":"3_CR472","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1055\/s-2007-1014438","volume":"24","author":"HJ M\u00f6ller","year":"1991","unstructured":"H. J. M\u00f6ller, G. Wendt, P. Waldmeier: Brofaromine \u2014 a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings. Pharmacopsychiatry 24: 50\u201354, 1991.","journal-title":"Pharmacopsychiatry"},{"key":"3_CR473","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1055\/s-2007-1017217","volume":"19","author":"A Delini-Stula","year":"1986","unstructured":"A. Delini-Stula, C. Hunn: Effects of imipramine and brofaromine, a selective and reversible MAO-A inhibitor, on novelty-oriented behavior in rats. Pharmacopsychiatry 19: 245\u2013246, 1986.","journal-title":"Pharmacopsychiatry"},{"key":"3_CR474","first-page":"185","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"N Hengen","year":"1984","unstructured":"N. Hengen, M. Jedrychowski, E.Hoffmann: Pharmacokinetics of CGP 11305 A in man after acute and prolonged oral treatment. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 185\u2013191, 1984."},{"key":"3_CR475","first-page":"276","volume-title":"Psychiatry Today. Accomplishments and Promises","author":"PH Degen","year":"1989","unstructured":"P. H. Degen, W. Dieterle, W. Schneider, W. Theobald: Pharmacokinetics of the MAO-A inhibitor brofaromine HCI in elderly. In: C. N. Stefanis, C. R. Soldatos, A. D. Ravabilas. Psychiatry Today. Accomplishments and Promises. Amsterdam: Excerpta Medica, p. 276, 1989."},{"key":"3_CR476","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0378-4347(00)82952-7","volume":"488","author":"W Schneider","year":"1989","unstructured":"W. Schneider, B. Keller, P. H. Degen: Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection. J Chromatogr 488: 275\u2013282, 1989.","journal-title":"J Chromatogr"},{"key":"3_CR477","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.2042-7158.1978.tb13198.x","volume":"30","author":"JP Kan","year":"1978","unstructured":"J. P. Kan, A. Malone, M. Strolin Benedetti: Monoamine oxidase inhibitory properties of 5-hydroxymethyl-3-m-tolyloxazolidin-2-one (toloxatone). J Pharm Pharmacol 30: 190\u2013192, 1978.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR478","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.2042-7158.1979.tb13651.x","volume":"31","author":"PE Keane","year":"1979","unstructured":"P. E. Keane, J. P. Kan, N. Sontag, M. Strolin Benedetti: Monoamine oxidase inhibition and brain amine metabolism after oral treatment with toloxatone in the rat. J Pharm Pharmacol 31: 752\u2013754, 1979.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR479","first-page":"73","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"AL Green","year":"1984","unstructured":"A. L. Green: Assessment of the potency of reversible MAO inhibitors in vivo. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 73\u201381, 1984."},{"key":"3_CR480","first-page":"107","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"PC Waldmeier","year":"1984","unstructured":"P. C. Waldmeier, A. E. Feiner, J. Lauber: Reversible monoamine oxidase inhibitors: relation between effects on enzymatic activity measured ex vivo and on amine metabolism. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 107\u2013126, 1984."},{"key":"3_CR481","first-page":"333","volume":"Besan\u00e7on","author":"V. Rovei","year":"1985","unstructured":"V. Rovei, F. Rumigny: Biochimie, pharmacocin\u00e9tique et biotransformation DEla toloxatone (Humoryl), un nouvel inhibiteur reversible DEla MAO-A. Extraits du Compte Rendu du Congr\u00e8s DEPsychiatrie et DENeurologie DELangue Fran\u00e7aise. LXXXIII Session Besan\u00e7on: 333\u2013343, 1985,","journal-title":"LXXXIII Session"},{"key":"3_CR482","first-page":"276","volume":"32","author":"MS Benedetti","year":"1982","unstructured":"M. Strolin Benedetti, V. Rovei, S. J. Dencker, A. Nagz, R.Johansson: Pharmacokinetics of toloxatone in man following intravenous and oral administrations. Arzneim-Forsch\/Drug Res 32: 276\u2013280, 1982.","journal-title":"Arzneim-Forsch\/Drug Res"},{"key":"3_CR483","first-page":"633","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"V Rovei","year":"1984","unstructured":"V. Rovei, S. Vajta, J. P. LeMoing, M. Strolin Benedetti: Metabolism of toloxatone in man. K. F. Tipton, P. Dostert, M. Strolin-Benedetti. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 633\u2013634, 1984"},{"key":"3_CR484","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/00498257909038731","volume":"9","author":"A Malnoe","year":"1979","unstructured":"A. Malnoe, M. Strolin Benedetti: Metabolic fate of 3-methylphenyl)-5-hy-droxymethyl-2-oxazolidinone (toloxatone), a new antidepressant agent, in man. Xenobiotica 9: 281\u2013288, 1979.","journal-title":"Xenobiotica"},{"key":"3_CR485","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1471-4159.1981.tb00599.x","volume":"36","author":"JP Kan","year":"1981","unstructured":"J. P. Kan, M. Strolin Benedetti: Characteristics of the inhibition of rat brain monoamine oxidase in vitro by MD 780515. J Neurochem 36: 1561\u20131571, 1981.","journal-title":"J Neurochem"},{"key":"3_CR486","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1471-4159.1983.tb11312.x","volume":"40","author":"CJ Fowler","year":"1983","unstructured":"C. J. Fowler, M. Strolin Benedetti: Cimoxatone is a reversible tight-binding inhibitor of the A form of rat brain monoamine oxidase. J. Neurochem 40: 510\u2013513, 1983.","journal-title":"J. Neurochem"},{"key":"3_CR487","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/0024-3205(80)90604-9","volume":"26","author":"JP Kan","year":"1980","unstructured":"J. P. Kan, M. Strolin Benedetti: Antagonism between long acting monoamine oxidase inhibitors (MAOI) and MD 780515, a new specific and reversible MAOI. Life Sci 26: 2165\u20132171, 1980.","journal-title":"Life Sci"},{"key":"3_CR488","first-page":"173","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"V Rovei","year":"1984","unstructured":"V. Rovei, M. Mitchard, M. Strolin Benedetti: Pharmacokinetics and metabolism of cimoxatone in rat, dog and man. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 173\u2013184, 1984."},{"key":"3_CR489","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF00512469","volume":"323","author":"MS Benedetti","year":"1983","unstructured":"M. Strolin Benedetti, T. Boucher, C. J. Fowler: The deamination of noradrenaline and 5-hydroxytryptamine by rat brain and heart monoamine oxidase and their inhibition by cimoxatone, toloxatone and MD 770222. Naunyn Schmiedeberg\u2019s Arch Pharmacol 323: 315\u2013320, 1983.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR490","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/0006-2952(83)90177-6","volume":"32","author":"V Rovei","year":"1983","unstructured":"V. Rovei, F. Chanoine, M. Strolin Benedetti, R. Zini, J. P. Tillement: Plasma protein binding of the reversible type A MAO inhibitor cimoxatone. Biochem Pharmacol 32: 2303\u20132308, 1983.","journal-title":"Biochem Pharmacol"},{"key":"3_CR491","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.2042-7158.1983.tb04297.x","volume":"35","author":"P Dostert","year":"1983","unstructured":"P. Dostert, M. Strolin Benedetti, C. Guffroy: Different stereoselective inhibition of monoamine oxidase B by the R- and S-enantiomers of MD 780236. J Pharm Pharmacol 35: 161\u2013165, 1983.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR492","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/bj2090235","volume":"209","author":"KF Tipton","year":"1983","unstructured":"K. F. Tipton, C. J. Fowler, J. M. McCrodden, M. Strolin Benedetti: The enzyme-activated irreversible inhibition of type B monoamine oxidase by 3-(4-[(3-chlorophenyl)-methylphenyl)-5-[(methylamino)methyl]-2-oxazo-lidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions. Biochem J 209: 235\u2013242, 1983.","journal-title":"Biochem J"},{"key":"3_CR493","doi-asserted-by":"publisher","first-page":"8891","DOI":"10.1021\/ja00206a018","volume":"111","author":"KS Gates","year":"1989","unstructured":"K. S. Gates, R. B. Silverman: Model studies for the mechanism of inactivation of monoamine oxidase by 5-(aminomethyl)-3-aryl-2-oxazolidi-nones. J Am Chem Soc 111: 8891\u20138895, 1989.","journal-title":"J Am Chem Soc"},{"key":"3_CR494","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000407506","volume":"19","author":"MS Benedetti","year":"1983","unstructured":"M. Strolin Benedetti, P. Dostert, C. Guffroy, K. F. Tipton: Partial or total protection from long-acting monoamine oxidase inhibitors (MAOIs) by new short-acting MAOIs of type A MD 780515 and type B MD 780236. Mod Probl Pharmacopsychiat 19: 82\u2013104, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"3_CR495","first-page":"203","volume-title":"Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors","author":"MS Benedetti","year":"1984","unstructured":"M. Strolin Benedetti, V. Rovei, A. Thiola, A. Donath: Metabolism of MD 240928, a short-acting type B MAOI in rat, dog and man. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease: Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 203\u2013216, 1984."},{"key":"3_CR496","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.2042-7158.1983.tb02911.x","volume":"35","author":"MS Benedetti","year":"1983","unstructured":"M. Strolin Benedetti, J. Dow, T. Boucher, P. Dostert: Metabolism of the monoamine oxidase-B inhibitor, MD 780236 and its enantiomers by the A and B forms of the enzyme in the rat. J Pharm Pharmacol 35: 837\u2013840, 1983.","journal-title":"J Pharm Pharmacol"},{"key":"3_CR497","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1515\/9783111521350-108","volume-title":"Flavins and Flavoproteins","author":"W Weyler","year":"1984","unstructured":"W. Weyler, J. I. Salach, R. T. Coutts, G. B. Baker: Nonstereoselective reduction of monoamine oxidase from bovine liver by analogs of amphetamine. In: R. C. Bray, P. C. Engel, S. G. Mayhew eds. Flavins and Flavoproteins. New York: Walter de Gruyter, pp. 595\u2013598, 1984."},{"key":"3_CR498","first-page":"1401","volume":"31","author":"AL Ask","year":"1982","unstructured":"A. L. Ask, K. Hoegberg, L. Schmidt, H. Kiessling, S. B. Ross: (+)-4-Di-methylamino-2, \u03b1-dimethylphenethylamine [FLA 336 (+)], a selective inhibitor of the A form of monoamine oxidase in the rat brain. Biochem. Pharmacol 31: 1401\u20131406, 1982.","journal-title":"Pharmacol"},{"key":"3_CR499","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1600-0773.1982.tb01042.x","volume":"51","author":"AL Ask","year":"1982","unstructured":"A. L. Ask, I. Fagervall, S. F. Ross: Evidence for a selective inhibition by FLA 336 (+) of the monoamine oxidase in serotonergic neurones in the rat brain. Acta Pharmacol Toxicol 51: 395\u2013396, 1982.","journal-title":"Acta Pharmacol Toxicol"},{"key":"3_CR500","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1016\/0006-2952(84)90205-3","volume":"33","author":"AL Ask","year":"1984","unstructured":"A. L. Ask, I. Fagervall, M. Jonze, D. Kelder, R. Nygren, S. B. Ross: Effects of acute and repeated administration of amiflamine on monoamine oxidase inhibition in the rat. Biochem Pharmacol 33: 2839\u20132847, 1984.","journal-title":"Biochem Pharmacol"},{"key":"3_CR501","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/BF00504992","volume":"327","author":"AL Ask","year":"1984","unstructured":"A. L. Ask: Selective inhibition by amiflamine of monoamine oxidase type A in rat brain, liver and duodenum. Naunyn Schmiedeberg\u2019s Arch Pharmacol 327: 56\u201363, 1984.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR502","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF00508779","volume":"334","author":"P Blier","year":"1986","unstructured":"P. Blier, C. DeMontigny, A.J. Azzaro: Effect of repeated amiflamine administration on serotonergic and noradrenergic neurotransmission: electrophysiological studies in the rat CNS. Naunyn Schmiedeberg\u2019s Arch Pharmacol 334: 253\u2013260, 1986.","journal-title":"Naunyn Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3_CR503","first-page":"194","volume":"4","author":"H Standish-Barry","year":"1985","unstructured":"H. Standish-Barry, A. C. P. Sim, B. Olsson, K. Rix: An open label study of amiflamine \u2014 a selective MAO-A inhibitor \u2014 in depressive illness. IVth World Cong Biol Psychiat 4: 194, 1985.","journal-title":"IVth World Cong Biol Psychiat"},{"key":"3_CR504","first-page":"194","volume-title":"Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors","author":"G Graffner","year":"1984","unstructured":"G. Graffner, G. Alvan, M. Grind, D. Lake-Bakaar, J. E. Lindgren, J. Lundstroem, H. Selander: Pharmacokinetics and metabolism of amiflamine in rat, dog and man. In: K. F. Tipton, P. Dostert, M. Strolin Benedetti, eds. Monoamine Oxidase and Disease. Prospects for Therapy with Reversible Inhibitors. New York: Academic Press, pp. 194\u2013201, 1984."},{"key":"3_CR505","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/j.1471-4159.1979.tb02296.x","volume":"32","author":"DL Nelson","year":"1979","unstructured":"D. L. Nelson, A. Herbet, Y. Petillot, L. Pichot, J. Glowinsky, M. Hamon: [3H]Harmaline as a specific ligand for MAO-A. I. Properties of the active site of MAO-A from rat and bovine brain. J Neurochem 32: 1817\u20131827, 1979.","journal-title":"J Neurochem"},{"key":"3_CR506","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/j.1471-4159.1991.tb08177.x","volume":"56","author":"T May","year":"1991","unstructured":"T. May, H. Rommelspacher, M. Pawlik: [3H]Harman binding experiments. I. A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat. J Neurochem 56: 490\u2013499, 1991.","journal-title":"J Neurochem"},{"key":"3_CR507","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/j.1471-4159.1991.tb08178.x","volume":"56","author":"T May","year":"1991","unstructured":"T. May, M. Pawlik, H. Rommelspacher: [3H]Harman binding experiments. II. Regional and subcellular distribution of specific [3H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat. J Neurochem 56: 500\u2013508, 1991.","journal-title":"J Neurochem"},{"key":"3_CR508","first-page":"220","volume-title":"Neuromodulators and Psychiatric Disorders","author":"GR Elliot","year":"1977","unstructured":"G. R. Elliot, R. B. Holman: Tryptolines as potential modulators of serotoninergic function. In: E. Usdin, D. Hamberg, J. Barchas eds. Neuromodulators and Psychiatric Disorders. New York: Oxford University Press, pp. 220\u2013228, 1977."},{"key":"3_CR509","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/0306-4522(81)90163-9","volume":"6","author":"MBH Youdim","year":"1981","unstructured":"M. B. H. Youdim, B. Oppenheim: The effect of l, 2, 3, 4-tetrahydro-\u03b2-car-boline on monoamine metabolism in the human platelet and platelet aggregation. Neurosci 6: 801\u2013810, 1981.","journal-title":"Neurosci"},{"key":"3_CR510","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/0006-2952(76)90489-5","volume":"25","author":"LR Meyerson","year":"1977","unstructured":"L. R. Meyerson, K. D. McMurtrey, V. E. Davis: Neuramine-derived alkaloids: substrate-preferred inhibitors of type A monoamine oxidase in vitro. Biochem Pharmacol 25: 1013\u20131020, 1977.","journal-title":"Biochem Pharmacol"},{"key":"3_CR511","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/jm00163a025","volume":"33","author":"ME Bembenek","year":"1990","unstructured":"M. E. Bembenek, C. W. Abell, L. A. Chrisey, M. D. Rozwadowska, W. Gessner, A. Brossi: Inhibition of monoamine oxidase A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahy-dro-, 3,4-dihydro-, and fully aromatic isoquinolines. J Med Chem 33: 147\u2013152, 1990.","journal-title":"J Med Chem"},{"key":"3_CR512","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0924-977X(91)90544-5","volume":"1","author":"HL White","year":"1991","unstructured":"H. L. White, O. Beek, G. Rigdon, G. W. Kraemer, B. R. Cooper: Biochemical and pharmacological properties of BW 1370U87 \u2014 a novel, selective monoamine oxidase-A inhibitor. Eur Neuropsychopharmacol 1: 315\u2013317, 1991.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3_CR513","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.6867724","volume":"221","author":"RE Becker","year":"1983","unstructured":"R. E. Becker, C. T. Giambalvo, R. A. Fox, M. Macho: Endogenous inhibitors of monoamine oxidase present in human cerebrospinal fluid. Science 221: 476\u2013478, 1983.","journal-title":"Science"},{"key":"3_CR514","first-page":"447","volume":"32","author":"T Egashira","year":"1990","unstructured":"T. Egashira, S. Goto, F. Murayama, Y. Yamanaka: Inhibition of MAO activity, 3H-imipramine binding, 3H-paroxetine binding and 3H-5-HT uptake by human cerebrospinal fluid. J Neural Transm [Suppl] 32: 447\u2013456, 1990.","journal-title":"J Neural Transm"},{"key":"3_CR515","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/0006-2952(80)90534-1","volume":"29","author":"V Glover","year":"1980","unstructured":"V. Glover, M. A. Reveley, M. Sandler: A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 29: 467\u2013470, 1980.","journal-title":"Biochem Pharmacol"},{"key":"3_CR516","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/0024-3205(86)90155-4","volume":"38","author":"I Armando","year":"1986","unstructured":"I. Armando, V. Glover, M. Sandler: Distribution of endogenous benzodiazepine receptor ligand-monoamine oxidase inhibiting (tribulin) activity in tissues. Life Sci 38: 2063\u20132067, 1986.","journal-title":"Life Sci"},{"key":"3_CR517","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000407508","volume":"19","author":"V Glover","year":"1983","unstructured":"V. Glover, I. Armando, A. Clow, M. Sandler: Endogenous urinary monoamine oxidase inhibitor: the benzodiazepine connection. Mod Probl Pharmacopsychiat 19: 118\u2013125, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"3_CR518","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/0024-3205(83)90778-6","volume":"33","author":"A Clow","year":"1983","unstructured":"A. Clow, V. Glover, I. Armando, M. Sandler: New endogenous benzodiazepine receptor ligand in human urine: identity with endogenous monoamine oxidase inhibitor? Life Sci 33: 735\u2013741, 1983.","journal-title":"Life Sci"},{"key":"3_CR519","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1471-4159.1988.tb01089.x","volume":"51","author":"V Glover","year":"1988","unstructured":"V. Glover, J. Halket, P. Watkins, A. Clow, B. Goodwin, M. Sandler: Isation: identity with the purified endogenous monoamine oxidase inhibitor, tribulin. J Neurochem 51: 656\u2013659, 1988.","journal-title":"J Neurochem"},{"key":"3_CR520","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF01249116","volume":"84","author":"J Jarman","year":"1991","unstructured":"J. Jarman, A. Przyborowska, V. Glover, J. Halket, P. T. Davies, F. C. Rose, M. Sandler: Urinary output of endogenous monoamine oxidase inhibitor and isatin during acute migraine attacks. J Neural Transm [Gen Sect] 84: 129\u2013134, 1991.","journal-title":"J Neural Transm"},{"key":"3_CR521","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF01250998","volume":"79","author":"IM McIntyre","year":"1990","unstructured":"I. M. McIntyre, T. R. Norman: Serotonergic effects of isatin: an endogenous MAO inhibitor related to tribulin. J Neural Transm [Gen Sect] 79: 35\u201340, 1990.","journal-title":"J Neural Transm"},{"key":"3_CR522","first-page":"77","volume":"28","author":"M Stabl","year":"1989","unstructured":"M. Stabl, K. Bizi\u00e8re, W. Schmid-Burgk, R. Amrein: Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm Suppl 28: 77\u201389, 1989.","journal-title":"J Neural Transm Suppl"},{"issue":"42","key":"3_CR523","first-page":"2","volume":"82","author":"L Botte","year":"1990","unstructured":"L. Botte, C. Gilles, J. L. Evrard, P. Mester, C. Wolfrum, M. Berger, K. Hellstern, J. Ward: Moclobemide versus placebo in the treatment of depression: A multicenter study in Belgium. Acta Psychiat Scand 82 Suppl: 42, 2 1990.","journal-title":"Acta Psychiat Scand"},{"key":"3_CR524","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF02246250","volume":"106","author":"J Angst","year":"1992","unstructured":"J. Angst, M. Stabl: Efficacy of moclobemide in different patient groups: a meta analysis of studies. Psychopharmacol 106 Suppl: 109\u2013113, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR525","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF02246250","volume":"106","author":"E Moll","year":"1992","unstructured":"E. Moll, M. Stabl, R. Wegscheider, R. Amrein: Long-term treatment with moclobemide. Psychopharmacol 106 Suppl: 109\u2013113, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR526","first-page":"1","volume":"26","author":"MBH Youdim","year":"1988","unstructured":"M. B. H. Youdim, M. Da Prada, R. Amrein: The cheese effect and new reversible MAO-A inhibition. J Neural Transm Suppl 26: 1\u2013136, 1988.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR527","first-page":"1","volume":"28","author":"GD Burrows","year":"1989","unstructured":"G. D. Burrows, M. Da Prada: Reversible MAO-A inhibitors as antidepressants. J Neural Transm Suppl 28: 1\u2013106, 1989.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR528","unstructured":"Psychiatr Prax 16, Suppl 1, 1989."},{"issue":"360","key":"3_CR529","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1600-0447.1990.tb05316.x","volume":"82","author":"J Angst","year":"1990","unstructured":"J. Angst: Use of reversible inhibitors of monoamine oxidase-A in major depression and other psychiatric disorders. Acta Psychiat Scand 82 Suppl 360: 5\u201333, 1990.","journal-title":"Acta Psychiat Scand"},{"issue":"360","key":"3_CR530","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-0447.1990.tb05322.x","volume":"82","author":"RG Priest","year":"1990","unstructured":"R. G. Priest: The treatment of depression in the 1990s \u2014 a focus on moclobemide. Acta Psychiat Scand 82, Suppl 360: 39\u2013110, 1990.","journal-title":"Acta Psychiat Scand"},{"issue":"10","key":"3_CR531","first-page":"264","volume":"29","author":"G Racagni","year":"1991","unstructured":"G. Racagni, T. Fukuda, N. Brunello: MAO inhibitors: basic and clinical studies. Biol. Psychiat 29 (11 S): 10 264\u2013267, 1991.","journal-title":"Psychiat"},{"key":"3_CR532","volume-title":"RIMA, reversible inhibitors of MAO-A: the new proposal in the treatment of depression","author":"D Kemali","year":"1991","unstructured":"D. Kemali, M. Casacchia: RIMA, reversible inhibitors of MAO-A: the new proposal in the treatment of depression. 5th World Congress of Biological Psychiat, Florence, June 9\u201314, 1991. Satellite symposium."},{"key":"3_CR533","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02253581","volume":"106","author":"J Angst","year":"1992","unstructured":"J. Angst, H. L. Freeman, S.A. Montgomery, R. G. Priest, G. Racagni: R. I. M. A.: A new concept in the treatment of depression. Proceedings of 2nd internat, symposium on moclobemide, Davos, Switzerland, 1991. Psychopharmacol 106 Suppl: 1\u2013141, 1992.","journal-title":"Psychopharmacol"},{"issue":"6","key":"3_CR534","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1192\/S0007125000297523","volume":"155","author":"M Versiani","year":"1989","unstructured":"M. Versiani, V. Oggero, P. Alterwain, R. Capponi, F. Dajas, G. Heinze-Martin, C. A. Marquez, M. A. Poleo, L. E. Rivero-Almanzor, L. Rosel, W. Schmid-Burgk, R. Ucha-Udabe: A double blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes. Br J Psychiat 155 Suppl 6: 72\u201377, 1989.","journal-title":"Br J Psychiat"},{"key":"3_CR535","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/BF02246248","volume":"106","author":"D Bakisch","year":"1992","unstructured":"D. Bakisch, J. Bradwejn, N. Nair, J. McClure, R. Remick, L. Bulger: A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicenter study. Psychopharmacol 106 Suppl: 98\u2013101, 1992.","journal-title":"Psychopharmacol"},{"issue":"6","key":"3_CR536","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1192\/S0007125000297535","volume":"155","author":"U Baumhackl","year":"1989","unstructured":"U. Baumhackl, L. Bizi\u00e8re, R. Fischbach, Ch. Geretsegger, G. Hebenstreit, E. Radruayr: Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM III): An Austrian double-blind, multicenter study. Brit J Psychiat 155 Suppl 6: 78\u201383, 1989.","journal-title":"Brit J Psychiat"},{"key":"3_CR537","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1600-0447.1984.tb01206.x","volume":"70","author":"JK Larsen","year":"1984","unstructured":"J. K. Larsen, P. Holm, P. L. Mikkelsen: Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial. Acta Psychiat Scand 70: 254\u2013260, 1984.","journal-title":"Acta Psychiat Scand"},{"key":"3_CR538","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-2007-1017421","volume":"17","author":"M Casacchia","year":"1984","unstructured":"M. Casacchia, A. Carolei, C. Barba, M. Frontoni, A. Rossi, G. Meco, M. R. Zylberman: A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor. Pharmacopsychiat 17: 122\u2013125, 1984.","journal-title":"Pharmacopsychiat"},{"key":"3_CR539","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0165-0327(85)90069-2","volume":"8","author":"TR Norman","year":"1985","unstructured":"T. R. Norman, D. Ames, G. D. Burrows, B. Davies: A controlled study of a specific MAO-A reversible inhibitor (Ro 11\u20131163) and amitriptyline in depressive illness. J Affect Disorders 8: 29\u201335, 1985.","journal-title":"J Affect Disorders"},{"key":"3_CR540","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-2007-1017218","volume":"19","author":"HP Kapfhammer","year":"1986","unstructured":"H. P. Kapfhammer, P. Hoff, E. Golling, E. R\u00fcther, M. Schmauss: Cimoxatone and Moclobemide, two new MAO inhibitors, in the treatment of major depressive disorder. Pharmacopsychiat 19: 247\u2013248, 1986.","journal-title":"Pharmacopsychiat"},{"key":"3_CR541","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00004850-198704000-00011","volume":"2","author":"K Lensch","year":"1987","unstructured":"K. Lensch, G. Fuchs, J. Boning, U. Milech: A clinical study of the selective MAO-A inhibitor moclobemide (Ro 11\u20131163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion. Intern et Clin Psychopharmacol 2: 165\u2013171, 1987.","journal-title":"Intern et Clin Psychopharmacol"},{"key":"3_CR542","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1055\/s-2007-1014598","volume":"22","author":"M Casacchia","year":"1989","unstructured":"M. Casacchia, A. Rossi: A comparison of moclobemide and imipramine in treatment od depression. Pharmacopsychiat 22: 152\u2013155, 1989.","journal-title":"Pharmacopsychiat"},{"key":"3_CR543","series-title":"Presented at the International Symposium \u201cThe Treatment of Depression in the 1990\u2019s\u201d","volume-title":"Moclobemide (Ro 11\u20131163) versus desipramine in the treatment of endogenous depression","author":"I Gabelic","year":"1989","unstructured":"I. Gabelic, E. Moll: Moclobemide (Ro 11\u20131163) versus desipramine in the treatment of endogenous depression. Presented at the International Symposium \u201cThe Treatment of Depression in the 1990\u2019s\u201d. Lissabon, Portugal, 1989."},{"key":"3_CR544","first-page":"65","volume":"11","author":"CN Stefanis","year":"1989","unstructured":"C. N. Stefanis, B. Alevizos, G. Papadimitriou, J. Hatzimanolis, M. Marki-anos: Clinical experience with a new monoamine oxidase inhibitor, moclobemide (Ro 11\u20131163). Curr Med Res Opin 11: 65\u201372, 1989.","journal-title":"Curr Med Res Opin"},{"key":"3_CR545","first-page":"189","volume":"32","author":"G Laux","year":"1990","unstructured":"G. Laux, W. Classen, E. Sofic, T. Becker, K. P. Lesch, M. Struck, M. Beckmann: Clinical, biochemical and psychometric findings with the new MAO-A inhibitors moclobemide and brofaromine in patients with major depressive disorders. J Neural Transm Suppl 32: 189\u2013195, 1990.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR546","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1600-0447.1989.tb10298.x","volume":"79","author":"C Koczkas","year":"1989","unstructured":"C. Koczkas, P. Holm, A. Karlsson, A. Nagy, E. Ose, H. P\u00e9tursson, L. Ul-veras, O. Wenedikter: Moclobemide and clomipramine ind endogenous depression. A randomized clinical trial. Acta Psychiat Scand 79: 523\u2013529, 1989.","journal-title":"Acta Psychiat Scand"},{"key":"3_CR547","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1600-0447.1990.tb05326.x","volume":"360","author":"HJ Funke","year":"1990","unstructured":"H.J. Funke, E. Moritz, K. Hellstern, H. Malanowsky: Moclobemide in the treatment of depression: Single centre study Germany. Acta Psychiat Scand 82 Suppl 360: 46\u201347, 1990.","journal-title":"Acta Psychiat Scand 82 Suppl"},{"key":"3_CR548","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1600-0447.1990.tb05327.x","volume":"360","author":"J Civeira","year":"1990","unstructured":"J. Civeira, S. Gervera, J. Giner, S. R. Allen, K. Hellstern, H. Malanowski, R. Wirz, K. Klar: Moclobemide versus clomipramine in the treatment of depression: A multicenter trial in Spain. Arch Psychiat Scand 82 Suppl 360: 48\u201349, 1990.","journal-title":"Arch Psychiat Scand 82 Suppl"},{"key":"3_CR549","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1600-0447.1990.tb05329.x","volume":"360","author":"G Beckers","year":"1990","unstructured":"G. Beckers, A. Vereeken, E. de Bleeker, C. Jaunes, G. Sieben, J. Faid-herbe, C. Wolfrum, M. Berger, K. Hellstern, J. Ward: Moclobemide vs. amitriptyline in the treatment of depression: two double-blind multicentre studies in Belgium. Acta Psychiat Scand 82, Suppl 360: 52\u201353, 1990.","journal-title":"Acta Psychiat Scand 82, Suppl"},{"key":"3_CR550","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1600-0447.1990.tb05328.x","volume":"360","author":"M Dierick","year":"1990","unstructured":"M. Dierick, P. Cattiez, G. Franck, P. Burton, J. Defleur, W. Hermans, A. Roelandts, C. Wolfrum, M. Berger, K. Hellstern, J. Ward: Moclobemide versus clomipramine in the treatment of depression: A double-blind multicentre study in Belgium. Acta Psychiat Scand 82 Suppl 360: 50\u201351, 1990.","journal-title":"Acta Psychiat Scand 82 Suppl"},{"key":"3_CR551","doi-asserted-by":"crossref","unstructured":"J. D. Guelfi, C. Payan, J. Fermanian, A. M. Pedarriosse, R. Manfredi: Moclobemide versus clomipramine in endogenous depression: a double-blind randomized clinical trial. Brit J Psychiat 1992. In press.","DOI":"10.1192\/bjp.160.4.519"},{"key":"3_CR552","first-page":"524","volume":"80","author":"L Barrelet","year":"1991","unstructured":"L. Barrelet, B. Blajev, L. Bolzani, C. de Saussure, A. Kasas, H. Van, J. P. Gachoud: Etude multicentrique comparant l\u2019efficacit\u00e9 et la tol\u00e9rance du moclob\u00e9mide et DEla fluvoxamine chez des patients hospitalis\u00e9s et ambulatoires pr\u00e9sentant un \u00e9pisode d\u00e9pressif majeur. Schweiz Rundsch Med Prax 80: 524\u2013528, 1991.","journal-title":"Schweiz Rundsch Med Prax"},{"key":"3_CR553","first-page":"111","volume":"IX","author":"I Schweitzer","year":"1989","unstructured":"I. Schweitzer, J. Tiller, K. Maquire, B. Davies: Treatment of atypical depression with moclobemide: A sequential double controlled study. Int J Clin Pharm Res IX: 111\u2013117, 1989.","journal-title":"Int J Clin Pharm Res"},{"key":"3_CR554","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1600-0447.1990.tb05319.x","volume":"82","author":"Y Lecrubier","year":"1990","unstructured":"Y. Lecrubier, J. D. Guelfi: Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression. Acta Psychiat Scand Suppl 82: 18\u201323, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR555","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1600-0447.1989.tb10299.x","volume":"79","author":"JK Larsen","year":"1989","unstructured":"J. K. Larsen, P. Holm, E. Hoyer, A. Mejlhede, P. L. Mikkelsen, A. Olesen, E. Schaumburg: Moclobemide and clomipramine in reactive depression. A placebo controlled randomized clinical trial. Acta Psychiat Scand 79: 530\u2013536, 1989.","journal-title":"Acta Psychiat Scand"},{"key":"3_CR556","first-page":"2245","volume":"48","author":"M Burner","year":"1990","unstructured":"M. Burner: Antid\u00e9presseur inhibiteur r\u00e9versible et s\u00e9lectif DEla MAO-A. M\u00e9d hyg 48: 2245\u20132247, 1990.","journal-title":"M\u00e9d hyg"},{"key":"3_CR557","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-2007-1017219","volume":"19","author":"P Hoff","year":"1986","unstructured":"P. Hoff, H. Golling, H. P. Kapfhammer, R. Lund, G. Pakesch, E. R\u00fcther, M. Schmauss: Cimoxatone and moclobemide, two new MAO-inhibitors: influence on sleep parameters in patients with major depressive disorder. Pharmacopsychiat 19: 249\u2013250, 1986.","journal-title":"Pharmacopsychiat"},{"key":"3_CR558","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0165-0327(90)90145-X","volume":"20","author":"JM Monti","year":"1990","unstructured":"J. M. Monti, P. Alterwain, D. Monti: The effects of moclobemide on nocturnal sleep of depressed patients. J Affect Disord 20: 201\u2013208, 1990.","journal-title":"J Affect Disord"},{"key":"3_CR559","first-page":"70","volume":"5","author":"SR Allen","year":"1990","unstructured":"S. R. Allen, T. Lorscheid, T. Vranesic, R. Amrein: Monoamine oxidase inhibitors (MAO\u2019s) and sleep. Human Psychopharmacol: clinical and experimental 5: 70\u201371, 1990.","journal-title":"Human Psychopharmacol: clinical and experimental"},{"key":"3_CR560","first-page":"261","volume":"51","author":"R Anand","year":"1990","unstructured":"R. Anand, K. A. Wesnes: Cognition-enhancing effects of moclobemide, a reversible MAO-inhibitor, in humans. Adv Neurology 51: 261\u2013268, 1990.","journal-title":"Adv Neurology"},{"key":"3_CR561","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1600-0447.1990.tb05338.x","volume":"82","author":"K Wesnes","year":"1990","unstructured":"K. Wesnes, R. Anand, T. Lorscheid: Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of aging and dementia. Acta Psychiat Scand Suppl 82: 71\u201372, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR562","first-page":"1","volume":"11","author":"JU Postma","year":"1985","unstructured":"J. U. Postma, D. Vranesic: Moclobemide in the treatment of depression in demented geriatric patients. Acta Therapeutica 11: 1\u20134, 1985.","journal-title":"Acta Therapeutica"},{"key":"3_CR563","first-page":"66","volume":"6","author":"J Kummer","year":"1989","unstructured":"J. Kummer, L. Gundel, T. Lorscheid: Efficacy and safety of moclobemide (150\u2013300 mg) compared to maprotiline (75\u2013150 mg) in the treatment of geriatric depressed patients. In Amrein et al. Brit J Psychiat 155 Suppl 6: 66\u201371, 1989.","journal-title":"Brit J Psychiat 155 Suppl"},{"key":"3_CR564","first-page":"264","volume":"29","author":"V Chan-Palay","year":"1991","unstructured":"V. Chan-Palay: Depression and Alzheimer\u2019s disease: A role for moclobemide: Biol Psychiat 29 (11 S): 264, 1991.","journal-title":"Biol Psychiat"},{"key":"3_CR565","series-title":"Presented at 9th congress of the European society of child and adolescent psychiatry-ESCAP","volume-title":"Moclobemide in attention deficit disorder with hyperactivity. Double-blind comparison with placebo","author":"P Bailador","year":"1991","unstructured":"P. Bailador, A. Delfino: Moclobemide in attention deficit disorder with hyperactivity. Double-blind comparison with placebo. Presented at 9th congress of the European society of child and adolescent psychiatry-ESCAP, London 1991."},{"key":"3_CR566","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/BF02246258","volume":"106","author":"E Trott","year":"1992","unstructured":"E. Trott, H. J. Friese, M. Menzel, G. Nissen: The use of moclobemide in children with attention deficit hyperactive disorder. Psychopharmacol 106 Suppl: 134\u2013136, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR567","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00543787","volume":"25","author":"S Gasic","year":"1983","unstructured":"S. Gasic, A. Korn, H. G. Eichler, et al: Cardiocirculatory effects of moclobemide (Ro 11\u20131163), a new reversible, short-acting MAO-inhibitor with preferential type inhibition, in healthy volunteers and depressive patients. Eur J Clin Pharmacol 25: 173\u2013177, 1983.","journal-title":"Eur J Clin Pharmacol"},{"key":"3_CR568","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1600-0447.1990.tb05337.x","volume":"82","author":"E Moll","year":"1990","unstructured":"E. Moll, W. Hetzel: Moclobemide (Ro 11\u20131163) safety in depressed patients. Acta Psychiat Scand Suppl 82: 69\u201370, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR569","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF02246238","volume":"106","author":"JG Ramaekers","year":"1992","unstructured":"J. G. Ramaekers, H. F. Swijgamn, J. F. O\u2019Hanlon: Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacol 106 Suppl: 62\u201367, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR570","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-0447.1990.tb05339.x","volume":"82","author":"R Blois","year":"1990","unstructured":"R. Blois, J. M. Gaillard: Effects of moclobemide on sleep in healthy human subjects. Acta Psychiat Scand Suppl 82: 73\u201375, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR571","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF02246236","volume":"106","author":"I Hindmarch","year":"1992","unstructured":"I. Hindmarch, I. Kerr: Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacol 106 Suppl: 49\u201355, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR572","first-page":"185","volume":"32","author":"W Classen","year":"1990","unstructured":"W. Classen, G. Laux: Psychometric alterations in treatment with the MAO-A inhibitor moclobemide. J Neural Transm Suppl 32: 185\u2013188, 1990.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR573","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/00048679009062902","volume":"24","author":"GM Newburn","year":"1990","unstructured":"G. M. Newburn, A. R. Fraser, D. B. Menkes, P. E. Mullen: A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. Aust New Zealand J Psychiat 24: 475\u2013479, 1990.","journal-title":"Aust New Zealand J Psychiat"},{"key":"3_CR574","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00652232","volume":"88","author":"A Korn","year":"1986","unstructured":"A. Korn, H. G. Eichler, R. Fischbach, S. Gasic: Moclobemide, a new reversible MAO-inhibitor \u2014 interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacol 88: 153\u2013157, 1986.","journal-title":"Psychopharmacol"},{"key":"3_CR575","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-0447.1990.tb05318.x","volume":"82","author":"JWG Tiller","year":"1990","unstructured":"J. W. G. Tiller: Antidepressants, alcohol and psychomotor performance. Acta Psychiat Scand Suppl 82: 13\u201317, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR576","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1600-0447.1990.tb05343.x","volume":"82","author":"R Zimmer","year":"1990","unstructured":"R. Zimmer, R. Gieschke, R. Fischbach, S. Gasic: Interaction studies with moclobemide. Acta Psychiat Scand Suppl 82: 84\u201386, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR577","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF02245787","volume":"100","author":"I Berlin","year":"1990","unstructured":"I. Berlin, A. Cournot, R. Zimmer, A. M. Pedarriosse, R. Manfredi, P. Mo-linier, A. J. Puech: Evalution and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects. Psychopharmacol 100: 40\u201345, 1990.","journal-title":"Psychopharmacol"},{"key":"3_CR578","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF02246233","volume":"106","author":"TW Guentert","year":"1992","unstructured":"T. W. Guentert, M. Schmitt, J. Dingemanse, J. H. G. Jonkman: Influence of moclobemide on Ibuprofen-induced fecal blood loss. Psychopharmacol 106 Suppl: 40\u201342, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR579","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/BF02246229","volume":"106","author":"R Amrein","year":"1992","unstructured":"R. Amrein, T. W. Guentert, J. Dingemanse, T. Lorscheid, M. Stabl, W. Schmid-Burgk: Interaction of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacol 106 Suppl: 24\u201331, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR580","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0165-1781(87)90036-9","volume":"22","author":"JWG Tiller","year":"1987","unstructured":"J. W. G. Tiller, K. P. Maguire, B. M. Davies: Tyramine pressor response with moclobemide - A reversible monoamine oxidase inhibitor. Psychiat Res 22: 213\u2013220, 1987.","journal-title":"Psychiat Res"},{"key":"3_CR581","first-page":"903","volume":"43","author":"W Schmid-Burgk","year":"1988","unstructured":"W. Schmid-Burgk, R. Gieschke, S. Allen, R. Amrein: Moclobemide, a new reversible monoamine oxidase inhibitor, and tyramine interaction studies. Curr Ther Res., Clin Exp 43: 903\u2013917, 1988.","journal-title":"Curr Ther Res., Clin Exp"},{"key":"3_CR582","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005344-198801000-00003","volume":"11","author":"A Korn","year":"1988","unstructured":"A. Korn, M. Da Prada, W. Raffesberg, S. Gasic, H. G. Eichler: Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 11: 17\u201323, 1988.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"3_CR583","first-page":"25","volume":"16","author":"PR Bieck","year":"1989","unstructured":"P. R. Bieck: Hypertensive Krisen unter reversiblen Hemmstoffen der Monoaminoxidase, Ergebnisse von Tyramin-Interaktionsstudien. Psychiat Praxis 16, Suppl 1: 25\u201331, 1989.","journal-title":"Psychiat Praxis"},{"key":"3_CR584","first-page":"21","volume":"28","author":"PR Bieck","year":"1989","unstructured":"P. R. Bieck, K. H. Antonin: Tyrmine potentiation during treatment with MAO-inhibitors. J Neural Transm Suppl 28: 21\u201331, 1989.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR585","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1472-8206.1989.tb00029.x","volume":"3","author":"CD Burgees","year":"1989","unstructured":"C. D. Burgees, G. W. Mellsop: Interaction between moclobemide and oral tyramine in depressed patients. Fundam Clin Pharmacol 3: 47\u201352, 1989.","journal-title":"Fundam Clin Pharmacol"},{"key":"3_CR586","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/clpt.1989.149","volume":"46","author":"I Berlin","year":"1989","unstructured":"I. Berlin, R. Zimmer, A. Cournot, C. Payan, A. M. Pedarriosse, A. J. Puech: Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 46: 344\u2013351, 1989.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR587","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/026988118900300107","volume":"3","author":"S Wijnands","year":"1989","unstructured":"S. Wijnands, P. C. Chang, G. J. Blauw, J. Van-den-Krogt, R. Gieschke, M. P. Schoerlin, P. Van-Brummelen: Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol 3: 36\u201344, 1989.","journal-title":"J Psychopharmacol"},{"key":"3_CR588","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0447.1990.tb05342.x","volume":"82","author":"R Zimmer","year":"1990","unstructured":"R. Zimmer: Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: Comparison between moclobemide and other MAO inhibitors. Acta Psychiat Scand Suppl 82: 81\u201383, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR589","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1600-0447.1990.tb05341.x","volume":"82","author":"R Zimmer","year":"1990","unstructured":"R. Zimmer, A.J. Puech, F. Philipp, A. Korn: Interaction between orally administered tyramine and moclobemide. Acta Psychiat Scand Suppl 82: 78\u201380, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR590","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1600-0447.1990.tb05346.x","volume":"82","author":"K Stoeckel","year":"1990","unstructured":"K. Stoeckel, J. P. Pfefen, M. Mayersohn, M. P. Schoerlin, C. Andressen, E. E. Ohnhaus, F. Frey, T. W. Guentert. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiat Scand Suppl 82: 94\u201397, 1990.","journal-title":"Acta Psychiat Scand Suppl"},{"key":"3_CR591","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/j.1552-4604.1991.tb01904.x","volume":"31","author":"JR Cusson","year":"1991","unstructured":"J. R. Cusson, E. Goldenberg, P. Larochelle: Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans. J Clin Pharmacol 31: 462\u2013467, 1991.","journal-title":"J Clin Pharmacol"},{"key":"3_CR592","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/026988119100500112","volume":"5","author":"SJ Warrington","year":"1991","unstructured":"S.J. Warrington, P. Turner, T. G. K. Mant, P. Morrison, G. Hywood, V. Glover, B. L. Goodwin, M. Sandler, P. St. John-Smith, G. R. McClelland: Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. J Psychopharmacol 5: 82\u201391, 1991.","journal-title":"J Psychopharmacol"},{"key":"3_CR593","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02246235","volume":"106","author":"J Dingemanse","year":"1992","unstructured":"J. Dingemanse, A. Korn, J. P. Pfefen, T. W. G\u00fcntert: Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacol 106 Suppl: 46\u201348, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR594","first-page":"97","volume":"26","author":"R Gieschke","year":"1988","unstructured":"R. Gieschke, W. Schmid-Burgk, R. Amrein: Interaction of moclobemide a new reversible monoamine oxidase inhibitor with oral tyramine. J Neural Transm Suppl 26: 97\u2013104, 1988.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR595","first-page":"31","volume":"26","author":"M Prada Da","year":"1988","unstructured":"M. Da Prada, G. Z\u00fcrcher, I. W\u00fcthrich, W. E. Haefely: On tyramine, food, beverages and the reversible MAO-inhibitor moclobemide. J Neural Transm Suppl 26: 31\u201356, 1988.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR596","volume-title":"Psychiatry Today. Accomplishments and Promises","year":"1989","unstructured":"C. N. Stefanis, C. R. Soldatos, A. D. Rabavilas (Eds.): Psychiatry Today. Accomplishments and Promises. VIII World Congr. of Psychiatry, Athens 1989. Abstracts. Excerpta Medica, Amsterdam, Oxford, New York (Internat Congr Ser No 899)."},{"key":"3_CR597","volume-title":"5th World congress on Biological Psychiatry","author":"MJ M\u00f6ller","year":"1991","unstructured":"M.J. M\u00f6ller, E. S. Paykel: 5th World congress on Biological Psychiatry, Florence 1991. Symposium \u201cRenaissance of monoamine oxidase inhibitors: the new selective and reversible generation\u201d."},{"key":"3_CR598","first-page":"616","volume-title":"Findings in healthy volunteers and early results in depressed patients. Monoamine oxidase and disease. Prospects for Ther with reversible inhibitors","author":"A Delini-Stula","year":"1984","unstructured":"A. Delini-Stula: Profile of Action of CGP 11\u2013305 A, a new reversible and selective MAO-A inhibitor, in man: Findings in healthy volunteers and early results in depressed patients. Monoamine oxidase and disease. Prospects for Ther with reversible inhibitors. Based on the Proc of a conf held 26\u201328 Oct 1983 in Paris, France. Ed. K. F. Tipton, P. Dosiert, M. Strolin Benedetti. London, Academic Press: 616\u2013617, 1984."},{"key":"3_CR599","first-page":"622","volume-title":"Prospects for Ther with reversible inhibitors","author":"F Holsboer","year":"1984","unstructured":"F. Holsboer, A. Gerken, A. Steiger, O. Benkert: Antidepressive effects of CGP 11\u2013305 A inhibitor. Monoamine oxidase and disease. Prospects for Ther with reversible inhibitors. Based on the Proc of conf held 26\u201328 Oct 1983 in Paris, France. Ed K. F. Tipton, P. Dostert, M. Strolin Benedetti. London, Academic Press 622\u2013623, 1984."},{"key":"3_CR600","first-page":"262","volume":"20","author":"A Steiger","year":"1987","unstructured":"A. Steiger, F. Holboer, A. Gerken, L. Demisch, O. Benkert: Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in endogenous depression. Phar-macopsychiat 20: 262\u2013269, 1987.","journal-title":"Phar-macopsychiat"},{"key":"3_CR601","first-page":"32","volume":"16","author":"HJ Moeller","year":"1989","unstructured":"H. J. Moeller, G. Wendt: Brofaromine - A selective, reversible and short acting MAO-A inhibitor. Psychiat Prax 16: 32\u201336, 1989.","journal-title":"Psychiat Prax"},{"key":"3_CR602","first-page":"33","volume":"28","author":"W Schiwy","year":"1989","unstructured":"W. Schiwy, W. R. Heath, A. Delini-Stula: Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients. J Neural Transm Suppl 28: 33\u201344, 1989.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR603","first-page":"211","volume":"22","author":"A Oezdaglar","year":"1989","unstructured":"A. Oezdaglar, K. Wiedemann, C. J. Lauer, J. C. Krieg: Brofaromine (CGP 11 305 A) in the treatment of panic disorders. Pharmacopsychiat 22: 211\u2013212, 1989.","journal-title":"Pharmacopsychiat"},{"key":"3_CR604","first-page":"230","volume":"32","author":"K Nahunek","year":"1990","unstructured":"K. Nahunek, J. Svestka, R. Rysanek, E. Ceskoya: Brofaromine in the treatment of endogenous depression. An open study, Activ nerv super 32: 230\u2013231, 1990.","journal-title":"Activ nerv super"},{"key":"3_CR605","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1055\/s-2007-1014495","volume":"23","author":"J Fritze","year":"1990","unstructured":"J. Fritze, T. Becker, V. Ziegler, G. Laux, P. Riederer: Brofaromine (CGP 11 305 A) in treatment of depression: Biological estimation of plasma concentrations. Pharmacopsychiat 23: 131\u2013134, 1990.","journal-title":"Pharmacopsychiat"},{"key":"3_CR606","first-page":"18","volume":"132","author":"M Zapletalek","year":"1990","unstructured":"M. Zapletalek, F. Faltus, J. Svestka, J. Molcan, U. Binz, G. Wendt: Selective and reversible MAO-inhibitor brofaromine compared with tranylcypromine. Muench med Wochenschr Suppl 132: 18\u201320, 1990.","journal-title":"Muench med Wochenschr Suppl"},{"key":"3_CR607","first-page":"21","volume":"132","author":"EK Fischer","year":"1990","unstructured":"E. K. Fischer, M. Heim, H.J. Moller, R. Uebelhack, M. Wolfersdorf, I. Borner, U. Binz, G. Wendt: Selective MAO-inhibition vs inhibition of monoamine-reuptake. Clinical study with brofaromine and imipramine. Muench med Wochenschr Suppl 132: 21\u201324, 1990.","journal-title":"Muench med Wochenschr Suppl"},{"key":"3_CR608","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0165-1781(91)90032-K","volume":"36","author":"E Moencamp","year":"1991","unstructured":"E. Moencamp, J. Haffmans: Brofaromine vs maprotiline plus lithium in treatment resistant depressed outpatients, letter. Psychiat research 36: 333\u2013335, 1991.","journal-title":"Psychiat research"},{"issue":"119","key":"3_CR609","first-page":"58","volume":"29","author":"WA Nolen","year":"1991","unstructured":"W. A. Nolen, P. F. Bouvy, J. Haffmans: MAO-inhibitors in resistant depression. Biol Psychiat 29 (119): 58, 1991.","journal-title":"Biol Psychiat"},{"key":"3_CR610","first-page":"230","volume":"96","author":"G Laux","year":"1988","unstructured":"G. Laux, T. Becker, M. Struck: Switching form MAO-A inhibitors to tricyclic antidepressants: Wash-out still obligatory? Psychopharmacol 96 Suppl: 230, 1988.","journal-title":"Psychopharmacol"},{"key":"3_CR611","first-page":"505","volume-title":"Monoamine oxidase and disease. Prospects for Ther with reversible inhibitors","author":"PR Bieck","year":"1984","unstructured":"P. R. Bieck, K. H. Antonin, G. Cremer, C. Gleiter: Tyramine pressor effects of CGP 11\u2013305 A in comparison to tranylcypromine after prolonged treatment of human volunteers. Monoamine oxidase and disease. Prospects for Ther with reversible inhibitors. Based on the proc of a conf held 26\u201328 Oct 1983 in Paris, France ed. K. F. Tipton, P. Dosiert, M. Strolin Benedetti. London, Academic Press: 505\u2013513, 1984."},{"key":"3_CR612","first-page":"147","volume":"5","author":"A Delini-Stula","year":"1988","unstructured":"A. Delini-Stula, E. Radeke, P. C. Waldmeier: Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol-Ser 5: 147\u2013158, 1988.","journal-title":"Psychopharmacol-Ser"},{"key":"3_CR613","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/clpt.1989.26","volume":"45","author":"PR Bieck","year":"1989","unstructured":"P. R. Bieck, L. Firkusny, C. Schick, K. H. Antonin, E. Nilsson, R. Schulz, M. Schwenk, H. Wollmann: Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 45: 260\u2013269, 1989.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR614","first-page":"13","volume":"132","author":"KH Antonin","year":"1990","unstructured":"K. H. Antonin, M. Jedrychowski, P. R. Bieck: Brofaromine, pharma-kodynamische und pharmakokinetische Untersuchungen an gesunden Probanden mit einem neuen reversiblen und selektiven Hemmstoff der MAO-A. Muench med Wschr Suppl 132: 13\u201317, 1990.","journal-title":"Muench med Wschr Suppl"},{"key":"3_CR615","first-page":"113","volume":"341","author":"B Muehlbauer","year":"1990","unstructured":"B. Muehlbauer, G. Gradin-Frimmer, P. Bieck: Safety of reversible monoamine oxidase inhibitors (MAOI): Interaction of brofaromine with sympa-thonimetic drugs in healthy volunteers. Naunyn-Schmiedebergs Arch Pharmacol 341 Suppl: 113, 1990.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"3_CR616","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/clpt.1991.6","volume":"49","author":"MP Schoerlin","year":"1991","unstructured":"M. P. Schoerlin, M. Meyersohn, B. Hoevels, H. Eggers, M. Dellenbach, J. P. Pfefen: Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther 49: 32\u201338, 95 1991.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR617","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/BF00215489","volume":"92","author":"A Steiger","year":"1987","unstructured":"A. Steiger, F. Holsboer, O. Benkert: Effects of brofaromine (CGP 11\u2013305 A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers. Psychopharmacol 92: 110\u2013114, 1987.","journal-title":"Psychopharmacol"},{"key":"3_CR618","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00427124","volume":"62","author":"S Upper","year":"1979","unstructured":"S. Upper, D. L. Murphy, S. Slater, M. S. Buchsbaum: Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacol 62: 123\u2013128, 1979.","journal-title":"Psychopharmacol"},{"key":"3_CR619","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/archpsyc.1982.04290050001001","volume":"39","author":"WZ Potter","year":"1982","unstructured":"W. Z. Potter, D. L. Murphy, T. A. Wehr, M. Linnoila, F. K. Goodwin: Clorgyline. A new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiat 39: 505\u2013510, 1982.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR620","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1192\/bjp.145.1.39","volume":"145","author":"TP Zahn","year":"1984","unstructured":"T. P. Zahn, T. R. Insel, D. L. Murphy: Psychophysiological changes during pharmacological treatment of patients with obsessive compulsive disorder. Br J Psychiat 145: 39\u201344, 1984.","journal-title":"Br J Psychiat"},{"key":"3_CR621","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/archpsyc.1985.01790330042005","volume":"42","author":"A Zametkin","year":"1985","unstructured":"A. Zametkin, J. L. Rapoport, D. L. Murphy et al: Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiat 42: 962\u2013966, 1985.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR622","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF00432251","volume":"78","author":"RM Cohen","year":"1982","unstructured":"R. M. Cohen, D. Pickar, D. Garnett et al: REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacol 78: 137\u2013140, 1982.","journal-title":"Psychopharmacol"},{"key":"3_CR623","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/archpsyc.1982.04290050023006","volume":"39","author":"D Pickar","year":"1982","unstructured":"D. Pickar, D. L. Murphy, R. M. Cohen, I. C. Campell, S. Upper: Selective and nonselective monoamine oxidase inhibitors: Behavioral disturbances during their administration to depressed patients. Arch Gen Psychiat 39: 535\u2013540, 1982.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR624","first-page":"331","volume":"9","author":"MF Poirier","year":"1983","unstructured":"M. F. Poirier, J. P. Olie, H. Loo et al: Antidepressant activity, pharmacokinetics and biochemical properties of cimoxatone, a new reversible type A MAOI. Encephale 9: 331\u2013343, 1983.","journal-title":"Encephale"},{"key":"3_CR625","first-page":"622","volume-title":"Based on the Proc of conf held 26\u201328 Oct 1983 in Paris, France","author":"MF Poirier","year":"1984","unstructured":"M. F. Poirier, J. R. Susini, P. Deniker, V. Rovei, M. Strolin-Benedetti, J. M. Languillat: Cimoxatone in depressed patients: Clinical pharmacokinetic and biochemical results of an open study. Based on the Proc of conf held 26\u201328 Oct 1983 in Paris, France. Ed K. F. Tipton, P. Dostert, M. Strolin-Benedetti. London, Academic Press: 622\u2013623, 1984."},{"key":"3_CR626","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/clpt.1983.228","volume":"34","author":"CT Dollery","year":"1983","unstructured":"C. T. Dollery, M. J. Brown, D. S. Davies et al: Oral absorption and concentration-effect relationship of tyramine with and without cimoxatone, a type-A specific inhibitor of monoamine oxidase. Clin Pharmacol Ther 34: 651\u2013662, 1983.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR627","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1055\/s-2007-1017219","volume":"19","author":"P Hoff","year":"1986","unstructured":"P. Hoff, H. Golling, H. P. Kapfhammer, et al: Cimoxatone and moclobemide, two new MAO-inhibitors: Influence on sleep parameters in patients with major depressive disorder. Pharmacopsychiat 19: 249\u2013250, 1986.","journal-title":"Pharmacopsychiat"},{"key":"3_CR628","first-page":"1201","volume":"64","author":"Y Poisno","year":"1988","unstructured":"Y. Poisno, J. Gouvernet, R. Sambuc: A multicentre double-blind trial of sulpiride versus toloxatone in patients with reactive depressions and somatization receiving non-specialized care. Sem Hop 64: 1201\u20131205, 1988.","journal-title":"Sem Hop"},{"key":"3_CR629","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/BF02253598","volume":"106","author":"P Lemoine","year":"1992","unstructured":"P. Lemoine, C. Mirabaud: A double-blind comparison of moclobemide and toloxatone in out-patients presenting with a major depressive disorder. Psychopharmacol 106 Suppl: 118\u2013119, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR630","first-page":"139","volume":"45","author":"P Azoyan","year":"1990","unstructured":"P. Azoyan, R. Gamier, F. J. Baud, M. L. Efthymiou: Toloxatone poisoning: Report of 122 cases. Therapy 45: 139\u2013144, 1990.","journal-title":"Therapy"},{"key":"3_CR631","first-page":"504","volume":"14","author":"D Pateron","year":"1990","unstructured":"D. Pateron, G. Babany, A. Hadengue, B. Delafosse, C. Degott, C. Sylvain, D. Larrey, J. P. Benhamou: (Fatal fulminant hepatitis in 2 women taking toloxatone (Humoryl)). Gastroenterol Clin Biol 14: 504\u2013506, 1990.","journal-title":"Gastroenterol Clin Biol"},{"key":"3_CR632","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1212\/WNL.31.1.19","volume":"31","author":"T Eisler","year":"1981","unstructured":"T. Eisler, H. Teravainen, R. Nelson, H. Krebs, V. Weise, C. R. Lake, M. H. Ebert, N. Whetzel, D. L. Murphy, I. J. Kopin, D. B. Calne: Deprenyl in Parkinson\u2019s disease. Neurology 31: 19\u201323, 1981.","journal-title":"Neurology"},{"key":"3_CR633","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1600-0404.1989.tb01796.x","volume":"126","author":"MD Yahr","year":"1989","unstructured":"M. D. Yahr, T. S. Elizan, D. Moros: Selegiline in the treatment of Parkinson\u2019s disease \u2014 long-term experience. Acta Neurol Scand Suppl 126: 157\u2013161, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR634","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/archneur.1989.00520480017012","volume":"46","author":"TS Elizan","year":"1989","unstructured":"T. S. Elizan, M. D. Yahr, D. A. Moros, M. R. Mendoza, S. Pang, C. A. Bodian: Selegiline use to prevent progression of Parkinson\u2019s disease. Experience in 22 DEnovo patients. Arch Neurol 46: 1275\u20131279, 1989.","journal-title":"Arch Neurol"},{"key":"3_CR635","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1600-0404.1990.tb01565.x","volume":"81","author":"H Teravainen","year":"1990","unstructured":"H. Teravainen: Selegiline in Parkinson\u2019s disease. Acta Neurol Scand 81: 333\u2013336, 1990.","journal-title":"Acta Neurol Scand"},{"key":"3_CR636","first-page":"283","volume":"19","author":"E Csanda","year":"1983","unstructured":"E. Csanda, M. Tarczy, A. Takats, I. Mogyoros, A. Koves, G. Katona: L-deprenyl in the treatment of Parkinson\u2019s disease. J Neural Transm Suppl 19: 283\u2013290, 115 1983.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR637","first-page":"105","volume":"25","author":"E Csanda","year":"1987","unstructured":"E. Csanda, M. Tarczy: Selegiline in the early and late phases of Parkinson\u2019s disease. J Neural Transm Suppl 25: 105\u2013113, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR638","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/archneur.1991.00530130039017","volume":"48","author":"TS Elizan","year":"1991","unstructured":"T. S. Elizan, D. A. Moros, M. D. Yahr: Early combination of selegiline and low dose levodopa as initial symptomatic therapy in Parkinson\u2019s disease. Experience in 26 patients receiving combined therapy for 16 months. Arch Neurol 48: 31\u201334, 1991.","journal-title":"Arch Neurol"},{"key":"3_CR639","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1055\/s-2007-1019488","volume":"16","author":"A Perenyi","year":"1983","unstructured":"A. Perenyi, G. Bagdy, M. Arato: An early phase II trial with L-deprenyl for the treatment of neuroleptic induced parkisonism. Pharmacopsychiat 16: 143\u2013146, 118 1983.","journal-title":"Pharmacopsychiat"},{"key":"3_CR640","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","volume":"321","author":"The Parkinson Study Group","year":"1989","unstructured":"The Parkinson Study Group: Effect of deprenyl on the progression of disability in early Parkinson\u2019s disease. N Engl J Med 321: 1364\u20131371, 1989.","journal-title":"N Engl J Med"},{"key":"3_CR641","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/archneur.1989.00520460028009","volume":"46","author":"The Parkinson Study Group","year":"1989","unstructured":"The Parkinson Study Group: DATATOP: A multicenter controlled clinical trial in early Parkinson\u2019s disease. Arch Neurol 46: 1052\u20131060, 1989.","journal-title":"Arch Neurol"},{"key":"3_CR642","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1126\/science.2502843","volume":"245","author":"JW Tetrud","year":"1989","unstructured":"J. W. Tetrud, J. W. Langston: The effect of deprenyl (selegiline) on the natural history of Parkinson\u2019s disease. Science 245: 519\u2013522, 1989.","journal-title":"Science"},{"key":"3_CR643","first-page":"61","volume":"3","author":"JW Langston","year":"1990","unstructured":"J. W. Langston: Selegiline as neuroprotective therapy in Parkinson\u2019s disease. Neurology 40 Suppl 3: 61\u201366, 1990.","journal-title":"Neurology 40 Suppl"},{"key":"3_CR644","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJM199005243222111","volume":"322","author":"Deprenyl for the treatment of early Parkinson\u2019s disease (letters)","year":"1990","unstructured":"Deprenyl for the treatment of early Parkinson\u2019s disease (letters). N Engl J Med 322: 1526\u20131528, 1990.","journal-title":"N Engl J Med"},{"key":"3_CR645","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1126\/science.249.4966.303-b","volume":"249","author":"Deprenyl and the progression of Parkinson\u2019s disease (letters)","year":"1990","unstructured":"Deprenyl and the progression of Parkinson\u2019s disease (letters). Science 249: 303\u2013304, 1990.","journal-title":"Science"},{"key":"3_CR646","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01253131","volume":"36","author":"W Birkmayer","year":"1975","unstructured":"W. Birkmayer, P. Riederer, M. B. Youdim, W. Linauer: The potentiation of the anti akinetic effect after L-dopa treatment by and inhibitor of MAO-B, deprenyl. J Neural Transm 36: 303\u2013326, 1975.","journal-title":"J Neural Transm"},{"key":"3_CR647","unstructured":"L. Ambrozi, W. Birkmayer, P. Riederer, M. B. H. Youdim: L-dopa and (-)-deprenyl in the treatment of Parkinson\u2019s disease: A long-term study. Proc Brit Pharm Soc: 423P\u2013424P, 1987."},{"key":"3_CR648","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0140-6736(77)91940-7","volume":"1","author":"W Birkmayer","year":"1977","unstructured":"W. Birkmayer, P. Riederer, L. Ambrozi, M. B. Youdim: Implications of combined treatment with \u201cMadopar\u201d and L-deprenyl in Parkinson\u2019s disease. A long-term study. Lancet 1: 439\u2013443, 1977.","journal-title":"Lancet"},{"key":"3_CR649","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(77)90725-5","volume":"2","author":"AJ Lees","year":"1977","unstructured":"A.J. Lees, K.M. Shaw, L.J. Kohout, G. M. Stern, J. D. Elsworth, M. Sandler, M. B. Youdim: Deprenyl in Parkinson\u2019s disease. Lancet 2: 791\u2013195, 1977.","journal-title":"Lancet"},{"key":"3_CR650","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF01246960","volume":"43","author":"W Birkmayer","year":"1978","unstructured":"W. Birkmayer: Long-term treatment with L-deprenyl. J Neural Transm 43: 239\u2013244, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR651","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF01246959","volume":"43","author":"MD Yahr","year":"1978","unstructured":"M. D. Yahr: Overview of present day treatment of Parkinson\u2019s disease. J Neural Transm 43: 227\u2013238, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR652","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF01246962","volume":"43","author":"UK Rinne","year":"1978","unstructured":"U.K. Rinne, T. Siirtola, V. Sonninen: L-deprenyl treatment of on-off phenomena in Parkinson\u2019s disease. J Neural Transm 43: 253\u2013262, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR653","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF01246961","volume":"43","author":"GM Stern","year":"1978","unstructured":"G. M. Stern, A. J. Lees, M. Sandler: Recent observations on the clinical pharmacology of (-)-deprenyl. J Neural Transm 43: 245\u2013251, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR654","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF01246963","volume":"43","author":"E Csanda","year":"1978","unstructured":"E. Csanda, J. Antal, M. Antony, A. Csanaky: Experiences with L-deprenyl in Parkinsonism. J Neural Transm 43: 263\u2013269, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR655","first-page":"197","volume":"16","author":"CM Lander","year":"1979","unstructured":"C. M. Lander, A. Lees, G. Stern: Oscillations in performance in levodopa-treated parkinsonians: Treatment with bromocriptine and L-deprenyl. Clin Exp Neurol 16: 197\u2013203, 1979.","journal-title":"Clin Exp Neurol"},{"key":"3_CR656","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/jnnp.43.11.1016","volume":"43","author":"M Schachter","year":"1980","unstructured":"M. Schachter, C. D. Marsden, J. D. Parkes, P. Jenner, B. Testa: Deprenyl in the management of response fluctuations in patients with Parkinson\u2019s disease on levodopa. J Neurol Neurosurg Psychiat 43: 1016\u20131021, 1980.","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"3_CR657","first-page":"643","volume":"27","author":"M Streifler","year":"1980","unstructured":"M. Streifler, J. Vardi, N. Borenstein et al: Beta type mono-amine oxidase (MAO) inhibitors in long-term levodopa-treated Parkinsonism: A combined clinical trial L-deprenyl. Curr Ther Res., Clin Exp 27: 643\u2013648, 1980.","journal-title":"Clin Exp"},{"key":"3_CR658","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01276576","volume":"55","author":"J Wajsbort","year":"1982","unstructured":"J. Wajsbort, K. Kartmazov, B.Oppenheim et al: The clinical and biochemical investigation of L-deprenyl in Parkinson\u2019s disease with special reference to the \u201con-off\u201d effect. J Neural Transm 55: 201\u2013215, 1982.","journal-title":"J Neural Transm"},{"key":"3_CR659","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1600-0404.1983.tb01522.x","volume":"95","author":"W Birkmayer","year":"1983","unstructured":"W. Birkmayer: Deprenyl (selegiline) in the treatment of Parkinson\u2019s disease. Acta Neurol Scand Suppl 95: 103\u2013105, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR660","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-0404.1983.tb01523.x","volume":"95","author":"UK Rinne","year":"1983","unstructured":"U. K. Rinne: Deprenyl (selegiline) in the treatment of Parkinson\u2019s disease. Acta Neurol Scand Suppl 95: 107\u2013111, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR661","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1600-0404.1983.tb01528.x","volume":"95","author":"R Portin","year":"1983","unstructured":"R. Portin, U. K. Rinne: The effect of deprenyl (selegiline) on cognition and emotion in parkinsonian patients undergoing long-term levodopa treatment. Acta Neurol Scand Suppl 95: 135\u2013144, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR662","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0404.1983.tb01527.x","volume":"95","author":"J Presthus","year":"1983","unstructured":"J. Presthus, A. Hajba: Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson\u2019s disease. Acta Neurol Scand Suppl 95: 127\u2013133, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR663","first-page":"265","volume":"19","author":"M Streifler","year":"1983","unstructured":"M. Streifler, M. J. Rabey: Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients. J Neural Transm Suppl 19: 265\u2013272, 1983.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR664","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-0404.1983.tb01526.x","volume":"95","author":"F Gerstenbrand","year":"1983","unstructured":"F. Gerstenbrand, G. Ransmayr, W. Poewe: Deprenyl (selegiline) in combination treatment of Parkinson\u2019s disease. Acta Neurol Scand Suppl 95: 123\u2013126, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR665","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1600-0404.1983.tb01521.x","volume":"95","author":"MD Yahr","year":"1983","unstructured":"M. D. Yahr, J. R. Mendoza, D. Moros, K. J. Bergmann: Treatment of Parkinson\u2019s disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline). Acta Neurol Scand Suppl 95: 95\u2013102, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR666","first-page":"159","volume":"37","author":"P Riederer","year":"1983","unstructured":"P. Riederer, K. Jellinger, W. Danielczyk, D. Seemann, G. Ulm, G. Reynolds, P. Birkmayer, H. Koppel: Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson\u2019s disease: Biochemical and clinical observations. Adv Neurol 37: 159\u2013176, 1983.","journal-title":"Adv Neurol"},{"key":"3_CR667","first-page":"328","volume":"19","author":"Clinical efficacy of deprenyl, a specific inhibitor of MAO-B","year":"1983","unstructured":"Clinical efficacy of deprenyl, a specific inhibitor of MAO-B. Psychopharmacol Bull 19: 328\u2013342, 1983.","journal-title":"Psychopharmacol Bull"},{"key":"3_CR668","first-page":"549","volume":"40","author":"E Csanda","year":"1984","unstructured":"E. Csanda, M. Tarczy, A. Takats, I. Mogyoros, A. Koves, K. Bihari: Adjuvant drugs in the treatment of on-off phenomena in Parkinson\u2019s disease. Adv Neurol 40: 549\u2013556, 1984.","journal-title":"Adv Neurol"},{"key":"3_CR669","first-page":"13","volume":"84","author":"AN Lieberman","year":"1984","unstructured":"A. N. Lieberman, G. Gopinathan, A. Neophytides, E. Hiesiger, J. Nelson, R. Walker, A. Goodgold: Deprenyl in the treatment of Parkinson\u2019s disease. A specific type B monoamine oxidase inhibitor. NY State J Med 84: 13\u201316, 1984.","journal-title":"NY State J Med"},{"key":"3_CR670","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/j.1600-0404.1985.tb03233.x","volume":"71","author":"P Bordersen","year":"1985","unstructured":"P. Bordersen, A. Philbert, G. Gulliksen, A. Stigard: The effect of L-deprenyl on on-off phenomena in Parkinson\u2019s disease. Acta Neurol Scand 71: 494\u2013497, 1985.","journal-title":"Acta Neurol Scand"},{"key":"3_CR671","first-page":"432","volume":"40","author":"F Trebini","year":"1985","unstructured":"F. Trebini, D. Daniele, S. Gillio, L. Scarzella: Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. Acta Neurol 40: 432\u2013439, 1985.","journal-title":"Acta Neurol"},{"key":"3_CR672","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF01245973","volume":"64","author":"W Birkmayer","year":"1985","unstructured":"W. Birkmayer, J. Knoll, P. Riederer, M. B. Youdim, V. Hars, J. Marton: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment of Parkinson\u2019s disease: a long-term study. J Neural Transm 64: 113\u2013127, 1985.","journal-title":"J Neural Transm"},{"key":"3_CR673","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF02229194","volume":"6","author":"P Giovannini","year":"1985","unstructured":"P. Giovannini, M. P. Grassi, G. Scigliano, I. Piccolo, P. Soliveri, T. Carac-eni: Deprenyl in Parkinson disease: Personal experience. Ital J Neurol Sci 6: 207\u2013212, 1985.","journal-title":"Ital J Neurol Sci"},{"key":"3_CR674","first-page":"219","volume":"22","author":"W Birkmayer","year":"1986","unstructured":"W. Birkmayer, G. D. Birkmayer: Effect of (\u2014)deprenyl in long-term treatment of Parkinson\u2019s disease. A 10-year experience. J Neural Transm Suppl 22: 219\u2013225, 1986.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR675","first-page":"247","volume":"22","author":"E Csanda","year":"1986","unstructured":"E. Csanda, M. Tarczy, A. Takats: (\u2014)Deprenyl in the treatment of decompensated Parkinson\u2019s disease. J Neural Transm Suppl 22: 247\u2013252, 1986.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR676","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF02230431","volume":"7","author":"S Ruggieri","year":"1986","unstructured":"S. Ruggieri, A. Denaro, G. Meco, A. Carta, F. Stocchi, A. Agnoli: Multicenter trial of L-deprenyl in Parkinson\u2019s disease. Ital J Neurol Sci 7: 133\u2013137, 1986.","journal-title":"Ital J Neurol Sci"},{"key":"3_CR677","first-page":"235","volume":"22","author":"P Giovannini","year":"1986","unstructured":"P. Giovannini, E. Martignoni, I. Piccolo, C. Pacchetti, M. P. Grassi, G. Nappi, T. Caraceni: (\u2014)Deprenyl in Parkinson\u2019s disease: A two-year study in the different evolutive stages. J Neural Transm Suppl 22: 235\u2013246, 1986.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR678","first-page":"455","volume":"41","author":"E Ferrari","year":"1986","unstructured":"E. Ferrari, N. Caccudi, M. De-Mari et al: Selegiline (deprenyl) as coadju-vant in treatment of Parkinson\u2019s disease. Acta Neurol 41: 455\u2013461, 1986.","journal-title":"Acta Neurol"},{"key":"3_CR679","first-page":"157","volume":"25","author":"AJ Lees","year":"1987","unstructured":"A. J. Lees: Current controversies in the use of selegiline hydrochloride. J Neural Transm Suppl 25: 157\u2013162, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR680","first-page":"149","volume":"25","author":"UK Rinne","year":"1987","unstructured":"U. K. Rinne: R-(\u2014)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson\u2019s disease. J Neural Transm Suppl 25: 149\u2013155, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR681","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/978-3-7091-2287-7_2","volume":"25","author":"MD Yahr","year":"1987","unstructured":"M. D. Yahr: R-(\u2014)-deprenyl and parkinsonism: J Neural Transm Suppl 25: 5\u201312, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR682","first-page":"137","volume":"25","author":"PA Fischer","year":"1987","unstructured":"P. A. Fischer, H. Baas: Therapeutic efficacy of R-(\u2014)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm Suppl 25: 137\u2013147, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR683","first-page":"123","volume":"25","author":"LI Golbe","year":"1987","unstructured":"L. I. Golbe, R. C. Duvoisin: Double-blind trial of R-(\u2014)-deprenyl for the \u201con-off\u201d effect complicating Parkinson\u2019s disease. J Neural Transm Suppl 25: 123\u2013129, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR684","first-page":"97","volume":"25","author":"H Przuntek","year":"1987","unstructured":"H. Przuntek, W. Kuhn: The effect of R-(\u2014)-deprenyl in DEnovo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm Suppl 25: 97\u2013104, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR685","first-page":"163","volume":"25","author":"G Ulm","year":"1987","unstructured":"G. Ulm, F. Fornadi: R-(\u2014)-deprenyl in the treatment of end-of-dose akinesia. J Neural Transm Suppl 25: 163\u2013172, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR686","first-page":"131","volume":"25","author":"W Poewe","year":"1987","unstructured":"W. Poewe, F. Gerstenbrand, G. Ransmayr: Experience with selegiline in the treatment of Parkinson\u2019s disease. J Neural Transm Suppl 25: 131\u2013135, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR687","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1600-0404.1987.tb03567.x","volume":"76","author":"J Presthus","year":"1987","unstructured":"J. Presthus, J. Berstad, K. Lien: Selegiline (L-deprenyl) and low-dose levodopa treatment of Parkinson\u2019s disease. A double-blind crossover trial. Acta Neurol Scand 76: 200\u2013203, 1987.","journal-title":"Acta Neurol Scand"},{"key":"3_CR688","first-page":"646","volume":"87","author":"AN Liebermann","year":"1987","unstructured":"A. N. Liebermann, G. Gopinathan, A. Neophytides, S. H. Foo: Deprenyl versus placebo in Parkinson disease: a double-blind study. NY State J med 87: 646\u2013649, 1987.","journal-title":"NY State J med"},{"key":"3_CR689","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00002826-198810000-00001","volume":"11","author":"LI Golbe","year":"1988","unstructured":"L. I. Golbe. Deprenyl as symptomatic therapy in Parkinson\u2019s disease. Clin Neuropharmacol 11: 387\u2013400, 1988.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR690","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","volume":"11","author":"LI Golbe","year":"1988","unstructured":"L. I. Golbe, A. N. Lieberman, M. D. Muenter, J. E. Ahlskog, G. Gopinathan, A. N. Neophytides, S. H. Foo, R. C. Duvoisin: Deprenyl in the treatment of symptom fluctuations in advanced Parkinson\u2019s disease. Clin Neuropharmacol 11: 45\u201355, 1988.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR691","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1212\/WNL.39.8.1109","volume":"39","author":"LI Golbe","year":"1989","unstructured":"L. I. Golbe: Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson\u2019s disease. Neurology 39: 1109\u20131111, 1989.","journal-title":"Neurology"},{"key":"3_CR692","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1600-0404.1989.tb01797.x","volume":"126","author":"UK Rinne","year":"1989","unstructured":"U. K. Rinne: Combination of a dopamine agonist, MAO-B inhibitor and levodopa, a new strategy in the treatment of early Parkinson\u2019s disease. Acta Neurol Scand 126: 165\u2013169, 1989.","journal-title":"Acta Neurol Scand"},{"key":"3_CR693","first-page":"113","volume":"126","author":"EH Heinonen","year":"1989","unstructured":"E. H. Heinonen, U. K. Rinne, J. Tuominen: Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment. Acta Neurol Scand Suppl 126: 113\u2013118, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR694","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1600-0404.1989.tb01795.x","volume":"126","author":"H Przuntek","year":"1989","unstructured":"H. Przuntek, W. Kuhn, P. Kraus: The effect of R-(\u2014)-deprenyl in DEnovo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid. Acta Neurol Scand Suppl 126: 153\u2013156, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR695","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0404.1989.tb01793.x","volume":"126","author":"AJ Lees","year":"1989","unstructured":"A. J. Lees, J. Frankel, V. Eatough, G. M. Stern: New approaches in the use of selegiline for the treatment of Parkinson\u2019s disease. Acta Neurol Scand Suppl 126: 139\u2013145, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR696","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1600-0404.1989.tb01799.x","volume":"126","author":"VV Myllyla","year":"1989","unstructured":"V. V. Myllyla, K. A. Sotaniemi, J. Tuominen, E. H. Heinonen: Selegiline as primary treatment in early phase Parkinson\u2019s disease \u2014 an interim report. Acta Neurol Scand Suppl 126: 177\u2013182, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR697","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1001\/archneur.1989.00520480022013","volume":"46","author":"TS Elizan","year":"1989","unstructured":"T. S. Elizan, M. D. Yahr, D. A. Moros, M. R. Mendoza, S. Pang, C. A. Bodian: Selegiline as an adjunct to conventional levodopa therapy in Parkinson\u2019s disease. Experience with this type B Monoamine oxidase inhibitor in 200 patients. Arch Neurol 46: 1280\u20131283, 1989.","journal-title":"Arch Neurol"},{"key":"3_CR698","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1600-0404.1989.tb01794.x","volume":"126","author":"B Sivertsen","year":"1989","unstructured":"B. Sivertsen, E. Dupont, B. Mikkelsen, P. Mogensen, C. Rasmussen, F. Boesen, E. Heinonen: Selegiline and levodopa in early or moderately advanced Parkinson\u2019s disease: A double-blind controlled short- and long-term study. Acta Neurol Scand Suppl 126: 147\u2013152, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR699","unstructured":"U. K. Rinne: New strategies in the treatment of Parkinson\u2019s disease. Acta Neurol Scand Suppl 82: 1990."},{"key":"3_CR700","first-page":"437","volume":"53","author":"F Fornadi","year":"1990","unstructured":"F. Fornadi, G. Ulm: Early combination with deprenyl a retrospective analysis. Adv Neurol 53: 437\u2013440, 1990.","journal-title":"Adv Neurol"},{"key":"3_CR701","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00002826-199002000-00003","volume":"13","author":"JM Cedarbaum","year":"1990","unstructured":"J. M. Cedarbaum, M. Silvestri, M. Clark, A. Harts, H. Kutt: L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson\u2019s disease. Clin Neuropharmacol 13: 29\u201335, 1990.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR702","first-page":"431","volume":"53","author":"TS Elizan","year":"1990","unstructured":"T. S. Elizan, M. D. Yahr, D. A. Moros, M. R. Mendoza, S. Pang, C. A. Bodian: L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson\u2019s disease: experience in 200 patients. Adv Neurol 53: 431\u2013435, 1990.","journal-title":"Adv Neurol"},{"key":"3_CR703","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000407513","volume":"19","author":"W Birkmayer","year":"1983","unstructured":"W. Birkmayer, J. Knoll, P. Riederer, J. B. Youdim: (\u2014)-deprenyl leads to prolongation of L-dopa efficacy in Parkinson\u2019s disease. Mod Probl Pharmacopsychiat 19: 170\u2013176, 1983.","journal-title":"Mod Probl Pharmacopsychiat"},{"key":"3_CR704","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0047-6374(85)90001-6","volume":"30","author":"J Knoll","year":"1985","unstructured":"J. Knoll: The facilitation of dopaminergic activity in the aged brain by (\u2014)deprenyl. A proposal for a strategy to improve the quality of life in senescence. Mech Ageing Dev 30: 109\u2013122, 1985.","journal-title":"Mech Ageing Dev"},{"key":"3_CR705","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0404.1989.tb01791.x","volume":"126","author":"PF Teychenne","year":"1989","unstructured":"P. F. Teychenne, S. Parker: Double-blind, crossover placebo controlled trial of selegiline in Parkinson\u2019s disease - an interim analysis. Acta Neurol Scand Suppl 126: 119\u2013125, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR706","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1600-0404.1989.tb01792.x","volume":"126","author":"C Chouza","year":"1989","unstructured":"C. Chouza, R. Aljanati, A. Scaramelli, O. De-Median, J. L. Caamano, R. Buzo, A. Fernandez, S. Romero: Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clinical disability in parkinsonian patients. Acta Neurol Scand Suppl 126: 127\u2013137, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR707","first-page":"115","volume":"25","author":"M Grundmann","year":"1987","unstructured":"M. Grundmann, K. Schimrigk: Levodopa and monoamine oxidase inhibitor combination therapy. A controlled clinical trial. J Neural Transm Suppl 25: 115\u2013119, 1987.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR708","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1600-0404.1991.tb03973.x","volume":"83","author":"G Nappi","year":"1991","unstructured":"G. Nappi, E. Martignoni, R. Horowski, C. Pacchetti, E. Rainer, P. Bruggi, I. Runge: Lisuride plus selegiline in the treatment of early Parkinson\u2019s disease. Acta Neurol Scand 83: 407\u2013410, 1991.","journal-title":"Acta Neurol Scand"},{"key":"3_CR709","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1212\/WNL.38.9.1387","volume":"38","author":"O Rascol","year":"1988","unstructured":"O. Rascol, J. L. Montastruc, J. M. Senard, J. F. Demonet, M. Simonetta, A. Rascol: Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: A double-blind crossover placebo-controlled trial. Neurology 38: 1387\u20131391, 1988.","journal-title":"Neurology"},{"key":"3_CR710","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/00002826-198910000-00010","volume":"12","author":"JP Frankel","year":"1989","unstructured":"J. P. Frankel, P. A. Kempster, C. M. Stibe, V. M. Eatough, M. Nathanson, A. J. Lees, G. M. Stern. A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson\u2019s disease. Clin Neuropharmacol 12: 448\u2013451, 1989.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR711","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/WNL.41.6.859","volume":"41","author":"JO Rinne","year":"1991","unstructured":"J. O. Rinne, M. Roytta, L. Paljarvi, J. Rummukainen, U. K. Rinne: Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson\u2019s disease. Neurology 41: 859\u2013861, 1991.","journal-title":"Neurology"},{"key":"3_CR712","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/0024-3205(80)90350-1","volume":"26","author":"J Mann","year":"1980","unstructured":"J. Mann, S. Gershon: L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26: 877\u2013882, 1980.","journal-title":"Life Sci"},{"key":"3_CR713","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF00431109","volume":"73","author":"N Mendis","year":"1981","unstructured":"N. Mendis, C. M. B. Pare, M. Sandler et al: Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacol 73: 87\u201390, 1981.","journal-title":"Psychopharmacol"},{"key":"3_CR714","first-page":"182","volume":"18","author":"JJ Mann","year":"1982","unstructured":"J. J. Mann, A. Frances, E. D. Peselow, S. Gershon: Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor in endogenous and non-endogenous depression. Psychopharmacol Bull 18: 182\u2013184, 1982.","journal-title":"Psychopharmacol Bull"},{"key":"3_CR715","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1192\/bjp.142.5.508","volume":"142","author":"J Mendlewicz","year":"1983","unstructured":"J. Mendlewicz, M. B. Youdim: L-deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: a double-blind evaluation: Br J Psychiat 142: 508\u2013511, 1983.","journal-title":"Br J Psychiat"},{"key":"3_CR716","first-page":"333","volume":"19","author":"J Mann","year":"1983","unstructured":"J. Mann, S. F. Aarons, A. Frances, W. Bernstein, C. Douglas, M. Sickles: Symptoms of atypical depression as a predictor of response to l-deprenyl. Psychopharmacol bull 19: 333\u2013335, 1983.","journal-title":"Psychopharmacol bull"},{"key":"3_CR717","first-page":"62","volume":"45","author":"JJ Mann","year":"1984","unstructured":"J. J. Mann, S. F. Aarons, A. J. Frances, R. D. Brown: Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiat 45: 62\u201366, 1984.","journal-title":"J Clin Psychiat"},{"key":"3_CR718","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archpsyc.1984.01790190051006","volume":"41","author":"FM Quitkin","year":"1984","unstructured":"F. M. Quitkin, M. R. Liebowitz, J.W. Stewart, P.J. McGrath, W. Harrison, J. G. Rabkin, J. Markowitz, S.O. Davies: L-deprenyl in atypical depressives. Arch Gen Psychiat 41: 777\u2013781, 1984.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR719","first-page":"63","volume":"25","author":"PJ McGrath","year":"1989","unstructured":"P. J. McGrath, J. W. Stewart, W. Harrison, S. Wager, E. N. Nunes, F. M. Quitkin: A placebo controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 25: 63\u201367, 1989.","journal-title":"Psychopharmacol Bull"},{"key":"3_CR720","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archpsyc.1989.01810010047007","volume":"46","author":"JJ Mann","year":"1989","unstructured":"J. J. Mann, S. F. Aarons, P. J. Wilner, J. G. Keilp, J. A. Sweeney, T. Pearlstein, A. J. Frances, J. H. Kocsis, R. P. Brown: A controlled study of the antidepressant efficacy and side effects of (\u2014)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiat 46: 45\u201350, 1989.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR721","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0165-0327(80)90013-0","volume":"2","author":"J Mendlewicz","year":"1980","unstructured":"J. Mendlewicz, M. B. Youdim: Antidepressant ptoentiation of 5-hydroxy-tryptophan by L-deprenyl in affective illness. J Affective Disord 2: 137\u2013146, 1980.","journal-title":"J Affective Disord"},{"key":"3_CR722","volume-title":"The State of the Art","author":"P Riederer","year":"1981","unstructured":"P. Riederer, G. P. Reynolds, M. B. H. Youdim: Monoamine oxidase \u2014 The State of the Art. M. B. H. Youdim and E. S. Paykel Eds. Wiley, Chichester 63, 1981."},{"key":"3_CR723","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF01249880","volume":"59","author":"W Birkmayer","year":"1984","unstructured":"W. Birkmayer, P. Riederer, W. Linauer, J. Knoll: L-deprenyl plus L-phen-ylalanine in the treatment of depression. J Neural Transm 59: 81\u201387, 1984.","journal-title":"J Neural Transm"},{"key":"3_CR724","first-page":"241","volume":"52","author":"HC Sabelli","year":"1991","unstructured":"H. C. Sabelli: Rapid treatment of depression with selegiline-phenylalanine combination. J Clin Psychiat 52: 241, 1991.","journal-title":"J Clin Psychiat"},{"key":"3_CR725","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-2007-1017117","volume":"20","author":"E Martini","year":"1987","unstructured":"E. Martini, I. Pataky, K. Szilagyi, V. Venter: Brief information of an early phase-II-study with deprenyl in demented patients. Pharmacopsychiat 20: 256\u2013257, 1987.","journal-title":"Pharmacopsychiat"},{"key":"3_CR726","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/BF00216016","volume":"91","author":"PN Tariot","year":"1987","unstructured":"P. N. Tariot, T. Sunderland, H. Weingartner, D. L. Murphy, J. A. Welkowitz, K. Thompson, R. M. Cohen: Cognitive effects of L-deprenyl in Alzheimer\u2019s disease. Psychopharmacol 91: 489\u2013495, 1987.","journal-title":"Psychopharmacol"},{"key":"3_CR727","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/archpsyc.1987.01800170041007","volume":"44","author":"PN Tariot","year":"1987","unstructured":"P. N. Tariot, R. M. Cohen, T. Sunderland, P. A. Newhouse, D. Yount, A. M. Mellow, H. Weingartner, E. A. Mueller, D. L. Murphy: L-deprenyl in Alzheimer\u2019s disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiat 44: 427\u2013433, 1987.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR728","first-page":"23","volume":"8","author":"PN Tariot","year":"1988","unstructured":"P. N. Tariot, T. Sunderland, R. M. Cohen, P. A. Newhouse, E. A. Mueller, D. L. Murphy: Tranylcypromine compared with L-deprenyl in Alzheimer\u2019s disease. J Clin Psychopharmacol 8: 23\u201327, 1988.","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR729","first-page":"306","volume":"12","author":"N Campi","year":"1990","unstructured":"N. Campi, G. P. Todeschini, L. Scarzella: Selegiline versus L-acetylcarnitine in the treatment of Alzheimer type dementia. Clin Ther 12: 306\u2013314, 1990.","journal-title":"Clin Ther"},{"key":"3_CR730","first-page":"376","volume":"12","author":"A Falsaperla","year":"1990","unstructured":"A. Falsaperla, P. A. Monici-Preti, C. Oliani: Selegiline versus oxiracetam in patients with Alzheimer type dementia. Clin Ther 12: 376\u2013384, 1990.","journal-title":"Clin Ther"},{"key":"3_CR731","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/00002826-199004000-00004","volume":"13","author":"GL Piccinin","year":"1990","unstructured":"G. L. Piccinin, G. Finali, M. Piccirilli: Neuropsychological effects of L-deprenyl in Alzheimer\u2019s type dementia. Clin Neuropharmacol 13: 147\u2013163, 1990.","journal-title":"Clin Neuropharmacol"},{"key":"3_CR732","first-page":"109","volume":"1","author":"A Agnoli","year":"1990","unstructured":"A. Agnoli, N. Martucci, G. Fabbrini, A. E. Buckley, M. Fioravanti: Monoamine oxidase and dementia: Treatment with an inhibitor of MAO-B activity. Dementia 1: 109\u2013114, 1990.","journal-title":"Dementia"},{"key":"3_CR733","first-page":"315","volume":"12","author":"A Monteverde","year":"1990","unstructured":"A. Monteverde, P. Gnemmi, F. Rossi, A. Monteverde, G. C. Finali: Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clin Ther 12: 315\u2013322, 1990.","journal-title":"Clin Ther"},{"key":"3_CR734","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF02251133","volume":"3","author":"E Martignoni","year":"1991","unstructured":"E. Martignoni, G. Bono, F. Blandini, E. Sinforiami, P. Merlo, G. Nappi: Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of the Alzheimer type. Influence of treatment with L-deprenyl. J Neural Transm Park Dis Dement Sect 3: 15\u201325, 1991.","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"3_CR735","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000116655","volume":"31","author":"A Mangoni","year":"1991","unstructured":"A. Mangoni, M. P. Grassi, L. Frattola, R. Piolti, S. Bassi, A. Motta, A. Marcone, S. Smirne: Effect of MAO-B inhibitor in the treatment of Alzheimer disease. Eur Neurol 31: 100\u2013107, 1991.","journal-title":"Eur Neurol"},{"key":"3_CR736","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/sleep\/10.5.491","volume":"10","author":"SE Roselaar","year":"1987","unstructured":"S. E. Roselaar, N. Langdon, C. B. Lock, P. Jenner, J. D. Parkes: Selegiline in narcolepsy. Sleep 10: 491\u2013495, 1987.","journal-title":"Sleep"},{"key":"3_CR737","first-page":"627","volume":"19","author":"DR Wood","year":"1983","unstructured":"D. R. Wood, F. W. Reimherr, P. H. Wender: The use of L-deprenyl in the treatment of attention deficit disorder, residual type. Psychopharmacol bull 19: 627\u2013629, 1983.","journal-title":"Psychopharmacol bull"},{"key":"3_CR738","unstructured":"M. Mauro, O. Scarpino, G.Pelliccioni et al: Dopaminergic treatment in a case of Lafora\u2019s disease. Boll Lega Ital Epilessia 54\u201355: 63\u201365, 1986."},{"key":"3_CR739","first-page":"103","volume":"37","author":"G Bodo","year":"1989","unstructured":"G. Bodo, K. Elkan, G. Bencze: Prevention of motion sickness with selegil-inum hydrochloricum. Ther Hung 37: 103\u2013106, 1989.","journal-title":"Ther Hung"},{"key":"3_CR740","first-page":"303","volume":"4","author":"P Lavie","year":"1980","unstructured":"P. Lavie, J. Wajsbort, M. B. H. Youdim: Deprenyl does not cause insomnia in parkinsonian patients: Commun Psychopharmacol 4: 303\u2013307, 1980.","journal-title":"Commun Psychopharmacol"},{"key":"3_CR741","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/00004714-198908000-00024","volume":"9","author":"PJ McGrath","year":"1989","unstructured":"P.J. McGrath, J. W. Stewart, F. M. Quitkin: A possible L-deprenyl induced hypertensive reaction (letter). J Clin Psychopharmacol 9: 330\u2013331, 1989.","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR742","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/BF00427904","volume":"86","author":"T Sunderland","year":"1985","unstructured":"T. Sunderland, E. A. Mueller, R. M. Cohen et al: Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacol 86: 432\u2013437, 1985.","journal-title":"Psychopharmacol"},{"key":"3_CR743","first-page":"340","volume":"19","author":"G Simpson","year":"1983","unstructured":"G. Simpson, K. White, E. Pi, J. Razani, R. Sloane: Monoamine oxidase inhibition and tyramine sensitivity in 1-deprenyl-treated subjects. Psychopharmacol bull 19: 340\u2013342, 1983.","journal-title":"Psychopharmacol bull"},{"key":"3_CR744","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1192\/S0007125000297468","volume":"6","author":"GM Simpson","year":"1989","unstructured":"G. M. Simpson, J. De-Leon: Tyramine and new monoamine oxidase inhibitor drugs. Br J Psychiat Suppl 6: 32\u201337, 1989.","journal-title":"Br J Psychiat Suppl"},{"key":"3_CR745","first-page":"103","volume":"37","author":"G Bodo","year":"1989","unstructured":"G. Bodo, K. Elkan, G. Bencze: Prevention of motion sickness with selegilinum hydrochloricum. Ther Hung 37: 103\u2013106, 1989.","journal-title":"Ther Hung"},{"key":"3_CR746","first-page":"21","volume":"51","author":"JO Cole","year":"1990","unstructured":"J. O. Cole, J. A. Bodkin: Antidepressant drug side effects. J Clin Psychiat 51: 21\u201326, 1990.","journal-title":"J Clin Psychiat"},{"key":"3_CR747","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1017\/S0317167100030730","volume":"17","author":"O Suchowersky","year":"1990","unstructured":"O. Suchowersky, J. DEVries: Possible interactions between deprenyl and prozac. Can J Neurol Sci 17: 352\u2013353, 1990.","journal-title":"Can J Neurol Sci"},{"key":"3_CR748","first-page":"105","volume":"5","author":"PF D\u2019Arcy","year":"1991","unstructured":"P. F. D\u2019Arcy: Life threatening interaction between pethidine and selegiline. Int Pharm J 5: 105, 1991.","journal-title":"Int Pharm J"},{"key":"3_CR749","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/0140-6736(91)92219-R","volume":"337","author":"GL Zornberg","year":"1991","unstructured":"G. L. Zornberg, J. A. Bodkin, B. M. Cohen: Severe adverse interaction between pethidine and selegiline Lancet 337: 246, 1991.","journal-title":"Lancet"},{"key":"3_CR750","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/BF00635714","volume":"28","author":"FA Wiesel","year":"1985","unstructured":"F. A. Wiesel, J. Raaflaub, R. Kettler: Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. Eur J Clin Pharmacol 28: 89\u201395, 1985.","journal-title":"Eur J Clin Pharmacol"},{"issue":"IV","key":"3_CR751","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0031-6989(88)80581-2","volume":"20","author":"A Korn","year":"1988","unstructured":"A. Korn, H. G. Eichler, W. Raffesberg, S. Gasic, M. Rotter: The effect of single dose and chronic moclobemide treatment on Clonidine induced changes in blood pressure and norepinephrine and MHPG levels in plasma in man. Pharmacol res commun 20 suppl IV: 145\u2013146, 1988.","journal-title":"Pharmacol res commun"},{"key":"3_CR752","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2125.1989.tb05357.x","volume":"27","author":"M Koulu","year":"1989","unstructured":"M. Koulu, M. Scheinin, A. Kaarttinen, J. Kallio, K. Pyykko, J. Vuorinen, R. H. Zimmer: Inhibition of monoamine oxidase by moclobemide: Effects on monoamine metabolism and secretion of anterior pituitary hormones and Cortisol in healthy volunteers. Br J Clin Pharmacol 27: 243\u2013255, 1989.","journal-title":"Br J Clin Pharmacol"},{"key":"3_CR753","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/0024-3205(90)90529-Z","volume":"47","author":"M Scheinin","year":"1990","unstructured":"M. Scheinin, M. Koulu, S. Karhuvaara, R. H. Zimmer: Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Life-Sci: 47: 1491\u20131499, 1990.","journal-title":"Life-Sci"},{"key":"3_CR754","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2125.1990.tb05445.x","volume":"30","author":"I Berlin","year":"1990","unstructured":"I. Berlin, R. Zimmer, H. M. Thiede, C. Payan, T. Hergueta, L. Robin, A. J. Puech: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol 30: 805\u2013816, 1990.","journal-title":"Br J Clin Pharmacol"},{"key":"3_CR755","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/BF02246239","volume":"106","author":"J Dingemanse","year":"1992","unstructured":"J. Dingemanse, I. Berlin, C. Payan, H. M. Thiede, A. J. Puech: Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects. Psychopharmacol 106 Suppl: 68\u201370, 1992.","journal-title":"Psychopharmacol"},{"key":"3_CR756","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1600-0447.1984.tb01231.x","volume":"70","author":"F Dajas","year":"1984","unstructured":"F. Dajas, A. Lista, L. Barbeito: High urinary norepinephrine excretion in major depressive disorders: Effects of a new type of MAO-inhibitor (Moclobemide, Ro 11\u20131163). Acta Psychiat Scand 70: 432\u2013437, 1984.","journal-title":"Acta Psychiat Scand"},{"key":"3_CR757","unstructured":"P. R. Bieck, H. Kemmler, K. H. Antonin, K. Tipton: Evidence for \u201clocal\u201d gastrointestinal effects of MAO-inhibition on metabolism and transport of tyramine in human. Pharmacol Res Communicat 20, Suppl IV: 129\u2013130, 1988."},{"key":"3_CR758","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/BF01037949","volume":"25","author":"PC Waldmeier","year":"1983","unstructured":"P. C. Waldmeier, K. H. Antonin, J. J. Feldtrauer, C. Grunenwald, E. Paul, J. Lauber, P. Bieck: Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11 305. Eur J Clin Pharmacol 25: 361\u2013368, 1983.","journal-title":"Eur J Clin Pharmacol"},{"key":"3_CR759","first-page":"R110","volume":"335","author":"C Schick","year":"1987","unstructured":"C. Schick, P. R. Bieck: Changes of urinary 3-methoxy-4-hydroxyphenyl-glycol (MHPG) excretion during subchronic treatment with different MAO-inhibitors in healthy subjects. Naunyn-Schmiedeberg\u2019s Arch Pharmacol Supp 335: R110, 1987.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol Supp"},{"key":"3_CR760","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/archpsyc.1982.04290050007002","volume":"39","author":"M Linnoila","year":"1982","unstructured":"M. Linnoila, P. Karoum, W. Z. Potter: Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch Gen Psychiat 39: 513\u2013516, 1982.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR761","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0278-5846(84)90145-3","volume":"8","author":"WZ Potter","year":"1984","unstructured":"W. Z. Potter, F. Karoum, M. Linnoila: Common mechanism of action of biochemically \u201cspecific\u201d antidepressants. Prog Neuro-Psychopharmacol Biol Psychiat 8: 153\u2013161, 1984.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiat"},{"key":"3_CR762","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archpsyc.1985.01790330049006","volume":"42","author":"A Zametkin","year":"1985","unstructured":"A. Zametkin, J. L. Rapoport, D. L. Murphy et al: Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry 42: 969\u2013973, 1985.","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR763","series-title":"Psychopharmacol Ser 3","volume-title":"Clinical pharmacology in psychiatry","author":"DL Murphy","year":"1987","unstructured":"D. L. Murphy, T. Sunderland, N. A. Garrick, C. S. Aulakh, R. M. Cohen: Selective Amine Oxidase inhibitors: Basic to clinical studies and back. Clinical pharmacology in psychiatry (Psychopharmacol Ser 3). Eds Dahl, Gram, Paul, Potter. Springer Berlin, Heidelberg, 1987."},{"key":"3_CR764","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/clpt.1988.8","volume":"43","author":"RL Hauger","year":"1988","unstructured":"R. L. Hauger, M. Scheinin, L. J. Siever, M. Linnoila, W. Z. Potter: Dissociation of norepinephrine turnover from alpha 2 responses after clorgyline. Clin Pharmacol Ther 43: 32\u201338, 1988.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR765","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/archpsyc.1988.01800260060008","volume":"45","author":"RN Golden","year":"1988","unstructured":"R. N. Golden, S. P. Markey, E. D. Risby, M. V. Rudorfer, R. W. Cowdry, W. Z. Potter: Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiat 45: 150\u2013154, 1988.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR766","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/archpsyc.1985.01790350045009","volume":"42","author":"WZ Potter","year":"1985","unstructured":"W. Z. Potter, M. Scheinin, R. N. Golden et al: Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites. Arch Gen Psychiat 42: 1171\u20131177, 1985.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR767","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00428420","volume":"85","author":"RJ Ross","year":"1985","unstructured":"R. J. Ross, M. Scheinin, P. Lesieur et al: The effect of clorgyline on noradrenergic function. Psychopharmacol 85: 227\u2013230, 1985.","journal-title":"Psychopharmacol"},{"key":"3_CR768","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/archpsyc.1983.01790080097012","volume":"40","author":"M Linnoila","year":"1983","unstructured":"M. Linnoila, F. Karoum, W. Z. Potter: Effects of antidepressant treatments on dopamine turnover in depressed patients. Arch Gen Psychiat 40: 1015\u20131017, 1983.","journal-title":"Arch Gen Psychiat"},{"key":"3_CR769","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/clpt.1987.195","volume":"42","author":"ED Risby","year":"1987","unstructured":"E. D. Risby, J. K. Hsiao, T. Sunderland, H. Agren, M. V. Rudorfer, W. Z. Potter: The effects of antidepressants on cerebrospinal fluid homovanillic acid 5-hydroxyindolacetic ratio. Clin Pharmacol Ther 42: 547\u2013554, 1987.","journal-title":"Clin Pharmacol Ther"},{"key":"3_CR770","first-page":"547","volume":"17","author":"EJ Filinger","year":"1989","unstructured":"E.J. Filinger: Platelet monoamine oxidase inhibition by clorgyline in chronic schizophrenics. Med Sci Res 17: 547\u2013548, 1989.","journal-title":"Med Sci Res"},{"key":"3_CR771","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0165-1781(82)90019-1","volume":"6","author":"LJ Siever","year":"1982","unstructured":"L. J. Siever, T. W. Uhde, D. L. Murphy: Possible subsensitization of alpha 2-adrenergic receptors by chronic monoamine oxidase inhibitor treatment in psychiatric patients. Psychiat Res 6: 293\u2013302, 1982.","journal-title":"Psychiat Res"},{"key":"3_CR772","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0165-1781(92)90086-I","volume":"7","author":"LJ Siever","year":"1982","unstructured":"L. J. Siever, T. W. Uhde, T. R. Insel et al: Growth hormone response to Clonidine unchanged by chronic clorgyline treatment. Psychiat Res 7: 139\u2013143, 1982.","journal-title":"Psychiat Res"},{"key":"3_CR773","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0165-1781(83)90087-2","volume":"9","author":"LJ Siever","year":"1983","unstructured":"L. J. Siever, M. S. Kafka, T. R. Insel, C. R. Lake, D. L. Murphy: Effect of long-term clorgyline administration on human platelet alpha-adrenergic receptor binding and platelet cyclic AMP responses. Psychiat Res 9: 37\u201344, 1983.","journal-title":"Psychiat Res"},{"key":"3_CR774","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0278-5846(88)90064-4","volume":"12","author":"PR Bieck","year":"1988","unstructured":"P. R. Bieck, K. H. Antonin, R. Balon, G.Oxenkrug: Effect of brofaromine and pargyline on human plasma melatonin concentrations. Progr Neuro-Psychopharmacol 12: 93\u2013101, 1988.","journal-title":"Progr Neuro-Psychopharmacol"},{"key":"3_CR775","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0165-1781(86)90067-3","volume":"17","author":"DL Murphy","year":"1986","unstructured":"D. L. Murphy, L. Tamarkin, T. Sunderland, N. A. Garrick, R. M. Cohen: Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. Psychiat Res 17: 119\u2013127, 1986.","journal-title":"Psychiat Res"},{"key":"3_CR776","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF00546712","volume":"26","author":"MS Benedetti","year":"1984","unstructured":"M. S. Benedetti, A. Eschalier, A. Lesage et al: Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man. Eur J Clin Pharmacol 26: 71\u201377, 1984.","journal-title":"Eur J Clin Pharmacol"},{"key":"3_CR777","first-page":"99","volume-title":"5-Hydroxytryptamine in Psychiatry, a spectrum of ideas","author":"GF Oxenkrug","year":"1991","unstructured":"G. F. Oxenkrug: The acute effect of monoamine oxidase inhibitors on serotonin conversion to melatonin. In: 5-Hydroxytryptamine in Psychiatry, a spectrum of ideas. Editors: M. Sandler, A. Copper and S. Harnett. Oxford University Press, Oxford, New York, Tokyo: 99\u2013109, 1991."},{"key":"3_CR778","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bst0070143","volume":"7","author":"GP Reynolds","year":"1979","unstructured":"G. P. Reynolds, P. Riederer, M. Sandler: 2-Phenylethylamine and amphetamine in human brain: Effects of L-deprenyl in Parkinson\u2019s disease (proceedings). Biochem Soc Trans 7: 143\u2013145, 1979.","journal-title":"Biochem Soc Trans"},{"key":"3_CR779","first-page":"91","volume":"22","author":"MBH Youdim","year":"1986","unstructured":"M. B. H. Youdim: Pharmacology of MAO-B inhibitors: Mode of action of (\u2014)deprenyl in Parkinson\u2019s disease. J Neural Transm Suppl 22: 91\u2013105, 1986.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR780","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/j.1471-4159.1986.tb01747.x","volume":"46","author":"P Riederer","year":"1986","unstructured":"P. Riederer, M. B. H. Youdim: Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with 1-deprenyl. J Neurochem 46: 1359\u20131365, 1986.","journal-title":"J Neurochem"},{"key":"3_CR781","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-0404.1983.tb01516.x","volume":"95","author":"P Riederer","year":"1983","unstructured":"P. Riederer, K. Jellinger: Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta Neurol Scand Suppl 95: 43\u201355, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR782","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432208","volume":"86","author":"CG Gottfries","year":"1985","unstructured":"C. G. Gottfries: Alzheimer\u2019s disease and senile dementia: Biochemical characteristics and aspects of treatment. Psychopharmacol 86: 245\u2013252, 1985.","journal-title":"Psychopharmacol"},{"key":"3_CR783","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1600-0404.1989.tb01781.x","volume":"80","author":"P Riederer","year":"1989","unstructured":"P. Riederer, C. Konradi, G. Hebenstreit, M. B. H. Youdim: Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand Suppl 80: 41\u201345, 1989.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR784","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1600-0404.1983.tb01520.x","volume":"95","author":"M Koulu","year":"1983","unstructured":"M. Koulu, R. Lammintausta: Human growth hormone and dopaminergic drugs, with special reference to deprenyl (selegiline): A summary of studies on volunteers. Acta Neurol Scand 95: 91\u201394, 1983.","journal-title":"Acta Neurol Scand"},{"key":"3_CR785","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF01246964","volume":"43","author":"GP Reynolds","year":"1978","unstructured":"G. P. Reynolds, P. Riederer, M. Sandler, K. Jellinger, D. Seemann: Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (\u2014)deprenyl administration. J Neural Transm 43: 271\u2013277, 1978.","journal-title":"J Neural Transm"},{"key":"3_CR786","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF00435308","volume":"70","author":"C Thornton","year":"1980","unstructured":"C. Thornton, C. J. Dore, J. D. Elsworth et al: The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmacol 70: 163\u2013166, 1980.","journal-title":"Psychopharmacol"},{"key":"3_CR787","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1212\/WNL.32.5.503","volume":"32","author":"F Karoum","year":"1982","unstructured":"F. Karoum, L. W. Chuang, T. Eisler et al: Metabolism of (\u2014)deprenyl to amphetamine and methamphetamine may BEresponsible for deprenyl\u2019s therapeutic benefit: a biochemical assessment. Neurology 32: 503\u2013509, 1982.","journal-title":"Neurology"},{"key":"3_CR788","first-page":"328","volume":"19","author":"J Medlewicz","year":"1983","unstructured":"J. Medlewicz, M. B. H. Youdim: A double-blind placebo study of L-deprenyl in affective disorders. Psychopharmacol Bull 19: 328\u2013332, 1983.","journal-title":"Psychopharmacol Bull"},{"key":"3_CR789","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF01252815","volume":"58","author":"K Baraczka","year":"1983","unstructured":"K. Baraczka, M. I. K. Fekete, B. Kanyicska: Changes in dopamine and 3, 4-dihydroxyphenylacetic acid (DOPAC) levels in human cerebrospinal fluid after L-dopa and deprenyl administration. J Neural Transm 58: 299\u2013304, 1983.","journal-title":"J Neural Transm"},{"key":"3_CR790","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/0006-3223(85)90027-7","volume":"20","author":"MR Liebowitz","year":"1985","unstructured":"M. R. Liebowitz, F. Karoum, F. M. Quitkin, S. O. Davies, D. Schwartz, M. Levitt, M. Linnoila: Biochemical effects of L-deprenyl in atypical depressives. Biol Psychiat 20: 558\u2013565, 1985.","journal-title":"Biol Psychiat"},{"key":"3_CR791","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/0006-3223(85)90105-2","volume":"20","author":"GM Simpson","year":"1985","unstructured":"G. M. Simpson, E. Frederickson, R. Palmer et al: Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: implications for clinical use. Biol Psychiat 20: 684\u2013687, 1985.","journal-title":"Biol Psychiat"},{"key":"3_CR792","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1093\/clinchem\/32.11.2030","volume":"32","author":"G Eisenhofer","year":"1986","unstructured":"G. Eisenhofer, D. S. Goldstein, R. Stull et al: Simultaneous liquid-chromatographic determination of 3, 4-dihydroxyphenylglycol, catecholamines, and 3, 4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 32: 3030\u20133033, 1986.","journal-title":"Clin Chem"},{"key":"3_CR793","first-page":"135","volume":"3","author":"DL Murphy","year":"1987","unstructured":"D. L. Murphy, T. Sunderland, N. A. Garrick, C. S. Aulakh, R. M. Cohen: Selective amine oxidase inhibitors: Basic to clinical studies and back. Psychopharmacol 3: 135\u2013146, 1987.","journal-title":"Psychopharmacol"},{"key":"3_CR794","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF00518180","volume":"91","author":"T Sunderland","year":"1987","unstructured":"T. Sunderland, P. N. Tariot, R. M. Cohen et al: Dose dependent effect of deprenyl on CSF monoamine metabolites in patients with Alzheimer\u2019s disease. Psychopharmacol 91: 293\u2013296, 1987.","journal-title":"Psychopharmacol"},{"key":"3_CR795","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF02248668","volume":"1","author":"DH Lee","year":"1989","unstructured":"D. H. Lee, M. Mendoza, M. T. Dvorozniak, E. Chung, M. H. Van Woert, M. D. Yahr: Platelet monoamine oxidase in Parkinson patients: Effect of L-deprenyl therapy. J Neural Transm Park Dis Dement Sect 1: 189\u2013194, 1989.","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"3_CR796","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF01249283","volume":"54","author":"JD Elsworth","year":"1982","unstructured":"J. D. Elsworth, M. Sandler, A. J. Lees, C. Ward, G. M. Stern: The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties. J Neural Transm 54: 105\u2013110, 1982.","journal-title":"J Neural Transm"},{"key":"3_CR797","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/0278-5846(89)90128-0","volume":"13","author":"GB Baker","year":"1989","unstructured":"G. B. Baker, R. T. Coutts: Metabolism of monoamine oxidase inhibitors. Prog Neuropsychopharmacol Biol Psychiat 13: 395\u2013403, 1989.","journal-title":"Prog Neuropsychopharmacol Biol Psychiat"},{"key":"3_CR798","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/jat\/14.5.330","volume":"14","author":"JE Meeker","year":"1990","unstructured":"J. E. Meeker, P. C. Reynolds: Postmortem tissue methamphetamine concentrations following selegiline administration. J Anal Toxicol 14: 330\u2013331, 1990.","journal-title":"J Anal Toxicol"},{"key":"3_CR799","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1600-0404.1983.tb01524.x","volume":"95","author":"GM Stern","year":"1983","unstructured":"G. M. Stern, A. J. Lees, R. J. Hardie, M. Sandler: Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson\u2019s disease. Acta Neurol Scand Suppl 95: 113\u2013116, 1983.","journal-title":"Acta Neurol Scand Suppl"},{"key":"3_CR800","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.36.2.250","volume":"36","author":"SH Snyder","year":"1986","unstructured":"S. H. Snyder, R. J. d\u2019Amato: A neurotoxin relevant to the pathophysiology of Parkinson\u2019s disease. Neurology 36: 250\u2013258, 1986.","journal-title":"Neurology"},{"key":"3_CR801","first-page":"107","volume":"45","author":"J Knoll","year":"1987","unstructured":"J. Knoll: Critical role in MAO-inhibition in Parkinson\u2019s disease. Adv Neurol 45: 107\u2013110, 1987.","journal-title":"Adv Neurol"},{"key":"3_CR802","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/0006-2952(89)90198-6","volume":"38","author":"M Strolin-Benedetti","year":"1989","unstructured":"M. Strolin-Benedetti, P. Dostert. Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38: 555\u2013561, 1989.","journal-title":"Biochem Pharmacol"},{"key":"3_CR803","first-page":"63","volume":"25","author":"PJ McGrath","year":"1989","unstructured":"P. J. McGrath, J. W. Stewart, W. Harrison, S. Wagner, E. N. Nunes, F. Quitkin: A placebo controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 25: 63\u201367, 1989.","journal-title":"Psychopharmacol Bull"},{"key":"3_CR804","first-page":"998","volume":"35","author":"W Muller-Limmroth","year":"1985","unstructured":"W. Muller-Limmroth\/ Effect of a new antiparkinson drug, selegiline, on psychomotor performance in humans. Arzneim Forsch\/Drug Res 35: 998\u20131002, 1985.","journal-title":"Arzneim Forsch\/Drug Res"},{"key":"3_CR805","first-page":"66","volume":"47","author":"MC Sabelli","year":"1986","unstructured":"M. C. Sabelli, J. Fawcett, F. Gusovsky, J. I. Javaid, P. Wynn, J. Edwar, H. Jeffriess, H. Kravitz: Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylethylamine dietary supplements. J Clin Psychiat 47: 66\u201370, 1986.","journal-title":"J Clin Psychiat"},{"key":"3_CR806","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/BF00307697","volume":"80","author":"S Nakamura","year":"1990","unstructured":"S. Nakamura, T. Kawamata, I. Akiguchi, M. Kameyama, N. Nakamura, H. Kimura: Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80: 419\u2013425, 1990.","journal-title":"Acta Neuropathol"},{"key":"3_CR807","first-page":"203","volume":"32","author":"C Hinze","year":"1990","unstructured":"C. Hinze, D. Harland, M. Zreika, B. Dulery, J.Hardenberg: A double-blind, placebo-controlled study of the tolerability and effects on platelet MAO-B activity of single oral doses of MDL 72.974 A in normal volunteers. J Neural Transm Suppl 32: 203\u2013209, 1990.","journal-title":"J Neural Transm Suppl"},{"key":"3_CR808","volume-title":"Pharmacodynamics of Ro 19\u20136327, a reversible and highly selective MAO-inhibitor","author":"R Zimmer","year":"1988","unstructured":"R. Zimmer, R. Kettler, K. Bauer, M. M. Thiede: Pharmacodynamics of Ro 19\u20136327, a reversible and highly selective MAO-inhibitor. Jerusalem meeting on Parkinson\u2019s disease, June 1988."},{"key":"3_CR809","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1017\/S0317167100032492","volume":"18","author":"M Prada Da","year":"1991","unstructured":"M. Da Prada: New approaches to the treatment of age-related brain disorders. Can J Neurol Sci 18: 384\u2013386, 1991.","journal-title":"Can J Neurol Sci"},{"key":"3_CR810","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF01418415","volume":"40","author":"CJ Bench","year":"1991","unstructured":"C. J. Bench, G. W. Price, A. A. Lammertsma, J. C. Cremer, S. K. Luthra, D. Turton, R. J. Dolan, R. Kettler, J. Dingemanse, M. Da Prada, M. Bizi\u00e8re, G. R. McClelland, V. L. Jamieson, N. B. Wood, R. S. J. Frackowiak: Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19\u20136327. Eur J Clin Pharmacol 40: 169\u2013173, 1991.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Progress in Drug Research \/ Fortschritte der Arzneimittelforschung \/ Progr\u00e8s des recherches pharmaceutiques"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-0348-7141-9_3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:25:18Z","timestamp":1742329518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-0348-7141-9_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992]]},"ISBN":["9783034871433","9783034871419"],"references-count":810,"URL":"https:\/\/doi.org\/10.1007\/978-3-0348-7141-9_3","relation":{},"subject":[],"published":{"date-parts":[[1992]]}}}